Filename,Drug Name,Cancer Type,Number of Patients,Treatment_OS,Control_OS,OS_Improvement (%),Treatment_PFS,Control_PFS,PFS_Improvement (%),Other Outcome Measures,Brief Study Summary,Formatted Study Results
page_0.txt,Capecitabine and Fluorouracil (5-FU),N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"{'ORR': 'N/A', 'DOR': 'N/A'}","The FDA updated the product labeling of capecitabine and fluorouracil (5-FU) to include information on dihydropyrimidine dehydrogenase (DPD) deficiency, which can lead to serious and life-threatening toxicities. Healthcare providers are advised to discuss testing options for DPD deficiency with patients and be aware of the risks associated with certain genetic variants. Capecitabine or fluorouracil are not recommended for patients with complete DPD deficiency, and providers should monitor for adverse reactions and consider testing prior to treatment.",N/A
page_1.txt,Datroway,"HR-positive, HER2-negative breast cancer",732,18.6 months,18.3 months,Not statistically significant,6.9 months,4.9 months,41.80%,"{'ORR': {'Datroway': '36%', 'Chemotherapy': '23%'}, 'DOR': {'Datroway': '6.7 months', 'Chemotherapy': '5.7 months'}}","Datroway was approved for HR-positive, HER2-negative breast cancer patients who had received prior endocrine-based therapy and chemotherapy. In a randomized trial, Datroway showed a significant improvement in progression-free survival (41.8%) compared to chemotherapy. Overall survival was similar between the two arms. Datroway also demonstrated a higher objective response rate (36%) and longer duration of response (6.7 months) compared to chemotherapy.","In the TROPION-Breast01 study, datopotamab deruxtecan-dlnk showed improved progression-free survival (PFS) with a median of 6.9 months compared to chemotherapy (4.9 months). Overall survival (OS) was similar between the two arms. The confirmed objective response rate (ORR) was higher with datopotamab deruxtecan-dlnk (36%) compared to chemotherapy (23%), with a longer duration of response (DOR) in the datopotamab deruxtecan-dlnk arm (6.7 months vs. 5.7 months). These results suggest that datopotamab deruxtecan-dlnk may be a more effective treatment option for patients with unresectable or metastatic breast cancer who have progressed on prior therapies."
page_10.txt,zenocutuzumab-zbco (Bizengri),Non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma,64 adults with NSCLC and 30 adults with pancreatic adenocarcinoma,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR NSCLC': '33% (95% CI: 22%, 46%)', 'DOR NSCLC': 'Median 7.4 months (95% CI: 4.0, 16.6)', 'ORR Pancreatic adenocarcinoma': '40% (95% CI: 23%, 59%)', 'DOR Pancreatic adenocarcinoma': 'Range 3.7 to 16.6 months'}","Zenocutuzumab-zbco (Bizengri) received accelerated approval for advanced NSCLC and pancreatic adenocarcinoma with NRG1 gene fusion. The eNRGy study showed promising ORR and DOR in both cancer types. Common adverse reactions included diarrhea, musculoskeletal pain, and fatigue. The recommended dose is 750 mg every 2 weeks. FDA expedited programs were utilized for this approval.","The eNRGy study evaluated the efficacy of a treatment in patients with NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma. In NSCLC, the overall response rate (ORR) was 33% with a median duration of response (DOR) of 7.4 months. In pancreatic adenocarcinoma, the ORR was 40% with a DOR range of 3.7 to 16.6 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study showed promising response outcomes in both types of cancer, indicating potential benefit for patients with NRG1 fusion-positive tumors."
page_100.txt,Dabrafenib (Tafinlar) with trametinib (Mekinist),Low-grade glioma (LGG) with a BRAF V600E mutation,110,Not statistically significant at interim analysis,Not provided,Not provided,20.1 months,7.4 months,63.51%,"{'ORR': 'D+T: 46.6%, C+V: 10.8%', 'DOR': 'D+T: 23.7 months, C+V: Not estimable'}","The FDA approved dabrafenib with trametinib for pediatric patients with LGG with a BRAF V600E mutation. In a trial, D+T showed a significantly higher ORR and longer PFS compared to C+V. Safety profile included common adverse reactions like pyrexia and rash. The OS results at interim analysis did not reach statistical significance.","In Study CDRB436G2201, patients with low-grade gliomas (LGG) were randomized to receive dabrafenib plus trametinib (D+T) or carboplatin plus vincristine (C+V). The D+T arm showed a higher overall response rate (ORR) of 46.6% compared to 10.8% in the C+V arm. The duration of response (DOR) was 23.7 months for D+T and not estimable for C+V. Progression-free survival (PFS) was longer in the D+T arm at 20.1 months compared to 7.4 months in the C+V arm. Overall survival (OS) results did not reach statistical significance at the interim analysis. The study demonstrated superior efficacy outcomes with D+T in terms of ORR, DOR, and PFS in patients with LGG requiring first systemic therapy."
page_101.txt,Abemaciclib (Verzenio),"HR-positive, HER2-negative, node-positive, early breast cancer",5120 in cohort 1,Data remains immature,Data remains immature,Data remains immature,Data not provided,Data not provided,Data not provided,"{'IDFS': {'HR': 0.653, 'IDFS at 48 months': {'Abemaciclib + endocrine therapy': '85.5%', 'Endocrine therapy alone': '78.6%'}}, 'Adverse Reactions': ['Diarrhea', 'Infections', 'Neutropenia', 'Fatigue', 'Leukopenia', 'Nausea', 'Anemia', 'Headache']}","Abemaciclib in combination with endocrine therapy showed a statistically significant improvement in invasive disease-free survival in patients with high-risk early breast cancer. Overall survival data is still immature, and more deaths were observed in cohort 2 with abemaciclib. Common adverse reactions included diarrhea, infections, neutropenia, and fatigue.","The monarchE study evaluated the efficacy of abemaciclib in combination with standard endocrine therapy in high-risk early breast cancer patients. The study showed a statistically significant improvement in invasive disease-free survival (IDFS) in the intent-to-treat population, primarily driven by patients in cohort 1. The IDFS at 48 months was 85.5% with abemaciclib plus standard endocrine therapy compared to 78.6% with standard endocrine therapy alone. Overall survival data is still immature, but in cohort 2, more deaths were observed with the combination therapy. As a result, the indication for abemaciclib was restricted to cohort 1. Further analysis is needed to assess overall survival outcomes."
page_102.txt,dostarlimab-gxly (Jemperli),mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer,141,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '45.4%', 'Duration of Response (DOR)': 'Median DOR not reached, 85.9% with durations ≥12 months, 54.7% with durations ≥24 months'}","Dostarlimab-gxly was approved for adult patients with dMMR recurrent or advanced endometrial cancer who had progressed on or after a platinum-containing regimen. The major efficacy outcomes included an overall response rate of 45.4% with a median duration of response not reached. Common adverse reactions included fatigue, anemia, rash, nausea, and diarrhea.","In the GARNET study, which evaluated the efficacy of a treatment for dMMR recurrent or advanced endometrial cancer, the overall response rate (ORR) was 45.4%, with a complete response rate of 15.6% and a partial response rate of 29.8%. The median duration of response (DOR) was not reached, with 85.9% of patients having durations of 12 months or longer and 54.7% having durations of 24 months or longer. The study showed promising results in terms of response outcomes. Further data on Overall Survival (OS) and Progression-Free Survival (PFS) were not provided in the summary."
page_103.txt,sacituzumab govitecan-hziy (Trodelvy),"HR-positive, HER2-negative breast cancer",543,14.4 months,11.2 months,28.60%,5.5 months,4 months,37.50%,"{'Adverse Events': {'Common Events': ['decreased leukocyte count', 'decreased neutrophil count', 'decreased hemoglobin', 'decreased lymphocyte count', 'diarrhea', 'fatigue', 'nausea', 'alopecia', 'increased glucose', 'constipation', 'decreased albumin']}}","The FDA approved sacituzumab govitecan-hziy for HR-positive, HER2-negative breast cancer patients who have received prior therapies. In a study of 543 patients, sacituzumab govitecan-hziy showed a 28.6% improvement in overall survival (14.4 vs. 11.2 months) and a 37.5% improvement in progression-free survival (5.5 vs. 4 months) compared to single-agent chemotherapy.","In the TROPiCS-02 study, patients with HR-positive, HER2-negative breast cancer who had disease progression after prior treatments were randomized to receive sacituzumab govitecan-hziy or single agent chemotherapy. The study showed that sacituzumab govitecan-hziy resulted in a longer median progression-free survival (5.5 months vs. 4 months) and overall survival (14.4 months vs. 11.2 months) compared to single agent chemotherapy. The hazard ratios for PFS and OS were 0.661 and 0.789, respectively, indicating a significant benefit with sacituzumab govitecan-hziy. Response outcomes were not specifically mentioned in the summary provided."
page_104.txt,Elacestrant (Orserdu),"ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer",478,Not provided,Not provided,Not provided,"3.8 months (95% CI: 2.2, 7.3)","1.9 months (95% CI: 1.9, 2.1)","Hazard Ratio of 0.55 (95% CI: 0.39, 0.77), 2-sided p-value=0.0005","{'Adverse Events': ['Musculoskeletal pain', 'Nausea', 'Increased cholesterol', 'Increased AST', 'Increased triglycerides', 'Fatigue', 'Decreased hemoglobin', 'Vomiting', 'Increased ALT', 'Decreased sodium', 'Increased creatinine', 'Decreased appetite', 'Diarrhea', 'Headache', 'Constipation', 'Abdominal pain', 'Hot flush', 'Dyspepsia']}","Elacestrant was approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In a trial with 478 patients, elacestrant showed a significant improvement in progression-free survival compared to standard therapy, particularly in patients with ESR1 mutations. Common adverse events included musculoskeletal pain, nausea, and increased cholesterol.","In the EMERALD study, elacestrant showed a significant improvement in progression-free survival (PFS) compared to fulvestrant or aromatase inhibitors in postmenopausal women and men with ER-positive, HER2-negative advanced or metastatic breast cancer, especially in patients with ESR1 mutations. In patients with ESR1 mutations, the median PFS was 3.8 months with elacestrant compared to 1.9 months with the standard therapy, with a hazard ratio (HR) of 0.55. However, in patients without ESR1 mutations, the difference in PFS was not statistically significant. Overall survival (OS) data and response outcomes were not provided in the summary."
page_105.txt,Pirtobrutinib (Jaypirca),Mantle Cell Lymphoma (MCL),120,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '50%', 'Duration of Response (DOR)': 'Median 8.3 months, DOR rate at 6 months 65.3%'}","Pirtobrutinib (Jaypirca) received accelerated approval for relapsed or refractory MCL after prior BTK inhibitor therapy. In a trial of 120 patients, it demonstrated a 50% overall response rate with a complete response rate of 13%. The median duration of response was 8.3 months. Common adverse reactions included fatigue, musculoskeletal pain, and diarrhea. The recommended dosage is 200 mg orally once daily.","In the BRUIN study of pirtobrutinib monotherapy for MCL patients previously treated with a BTK inhibitor, the overall response rate (ORR) was 50% with a complete response rate of 13%. The median duration of response (DOR) was 8.3 months, with a DOR rate of 65.3% at 6 months. The study included 120 patients with a median of 3 prior lines of therapy, mainly with ibrutinib. Pirtobrutinib was well-tolerated and showed promising efficacy in this heavily pretreated population."
page_106.txt,Pembrolizumab (Keytruda),Non-small cell lung cancer (NSCLC),1177,58.7 months,34.9 months,40%,Not specified,Not specified,Not specified,"{'ORR': 'Not specified', 'DOR': 'Not specified'}","Pembrolizumab was approved for adjuvant treatment in NSCLC following resection and platinum-based chemotherapy. The trial demonstrated a 40% improvement in disease-free survival with pembrolizumab compared to placebo. Adverse reactions were generally similar to those seen with pembrolizumab as a single agent, with notable exceptions. The recommended dose is 200 mg every 3 weeks or 400 mg every 6 weeks for up to 12 months.","Overall Survival (OS) data was not provided in the study results. Progression-Free Survival (PFS) was not the primary endpoint, but the trial demonstrated a statistically significant improvement in Disease-Free Survival (DFS) in the overall population. In patients who received adjuvant chemotherapy, the median DFS was 58.7 months in the pembrolizumab arm and 34.9 months in the placebo arm, with a hazard ratio of 0.73. Response outcomes such as Objective Response Rate (ORR), Duration of Response (DOR), Complete Response (CR), and Partial Response (PR) were not mentioned in the study summary. The study focused on DFS as the major efficacy outcome measure and showed a benefit in patients who received adjuvant chemotherapy."
page_107.txt,Zanubrutinib,Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),"479 in treatment-naïve CLL/SLL cohort, 110 in previously untreated CLL/SLL with 17p deletion, 652 in relapsed or refractory CLL/SLL cohort",Not provided,Not provided,Not provided,"Not reached (95% CI: NE, NE)","33.7 months (95% CI: 28.1, NE)","HR= 0.42, 95% CI: 0.28, 0.63; p=<0.0001","{'Treatment-naïve CLL/SLL cohort': {'ORR': '88% (95% CI: 81, 94)', 'DOR': 'Not reached after a median follow-up of 25.1 months'}, 'Relapsed or refractory CLL/SLL cohort': {'ORR': '80% (95% CI: 76, 85)', 'DOR': 'Not reached after a median follow-up of 14.1 months'}}","Zanubrutinib showed significant improvement in progression-free survival (PFS) compared to bendamustine plus rituximab (BR) in treatment-naïve CLL/SLL patients. It also demonstrated high overall response rates (ORR) and durable responses in previously untreated and relapsed or refractory CLL/SLL patients. Common adverse reactions included neutrophil count decreased, upper respiratory tract infection, and platelet count decreased. The recommended dosage is 160 mg taken orally twice daily or 320 mg taken orally once daily.","In the SEQUOIA study for treatment-naïve CLL/SLL patients, zanubrutinib showed significantly longer progression-free survival (PFS) compared to bendamustine plus rituximab (BR). In a separate cohort with 17p deletion, zanubrutinib demonstrated a high overall response rate (ORR) of 88% with a prolonged duration of response (DOR). In the ALPINE study for relapsed or refractory CLL/SLL patients, zanubrutinib had a higher ORR compared to ibrutinib, with both arms showing a prolonged DOR. Zanubrutinib shows promising efficacy in both treatment-naïve and relapsed/refractory CLL/SLL patients, with favorable PFS, ORR, and DOR outcomes."
page_108.txt,Tukysa,HER2-positive unresectable or metastatic colorectal cancer,84,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '38%', 'Duration of Response (DOR)': '12.4 months'}","The FDA granted accelerated approval to Tukysa in combination with trastuzumab for HER2-positive unresectable or metastatic colorectal cancer. The efficacy was evaluated in 84 patients showing an overall response rate of 38% and a median duration of response of 12.4 months. Common adverse events included diarrhea, fatigue, rash, and nausea.","In the MOUNTAINEER study, 84 patients with HER2-positive, RAS wild-type colorectal cancer received tucatinib and trastuzumab. The overall response rate (ORR) was 38%, with a median duration of response (DOR) of 12.4 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study excluded patients who had received prior anti-HER2 therapy and included those with dMMR or MSI-H tumors who had also received anti-PD-1 therapy. The combination of tucatinib and trastuzumab showed promising efficacy in this patient population, with a notable ORR and DOR."
page_109.txt,Mosunetuzumab-axgb (Lunsumio),Follicular lymphoma (FL),90,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '80%', 'DOR': '22.8 months (median)'}","Mosunetuzumab-axgb received accelerated approval for adult patients with relapsed or refractory follicular lymphoma. The study included 90 patients with an ORR of 80% and a median duration of response of 22.8 months. Common adverse reactions included cytokine release syndrome, fatigue, rash, pyrexia, and headache. The recommended dose and administration schedule were provided for the treatment.","In a study of 90 patients with relapsed or refractory follicular lymphoma, the objective response rate (ORR) to mosunetuzumab-axgb was 80%, with 60% achieving complete responses. The median duration of response (DOR) was 22.8 months, with DOR rates at 12 and 18 months being 62% and 57%, respectively. Overall survival (OS) and progression-free survival (PFS) data were not provided. However, serious side effects included cytokine release syndrome (CRS) in 39% of patients, neurologic toxicity in 39%, serious infections in 17%, and tumor flare in 4%. Grades 2-4 CRS occurred in 17.5% of patients. The study highlights promising response outcomes with mosunetuzumab-axgb in patients with relapsed or refractory follicular lymphoma, but also underscores the risk of serious side effects."
page_11.txt,zanidatamab-hrii (Ziihera),HER2-positive biliary tract cancer (BTC),62,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '52%', 'DOR': '14.9 months'}","Zanidatamab-hrii (Ziihera) received accelerated approval for previously treated HER2-positive biliary tract cancer. The major efficacy outcomes included an objective response rate of 52% and a median duration of response of 14.9 months. Common adverse reactions included diarrhea, infusion-related reactions, abdominal pain, and fatigue. The drug was granted priority review, breakthrough therapy designation, and orphan drug designation.",Efficacy and
page_110.txt,Nadofaragene firadenovec-vncg (Adstiladrin),Non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS),157,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Complete Response Rate': '51%', 'Median Duration of Response': '9.7 months', 'Percentage of patients in CR for at least one year': '46%'}","Nadofaragene firadenovec-vncg was approved for high-risk BCG-unresponsive NMIBC with CIS. In a study of 157 patients, the drug showed a complete response rate of 51% with a median duration of response of 9.7 months. 46% of responding patients remained in complete response for at least one year. Common adverse events included increased glucose, instillation site discharge, and fatigue.","In Study CS-003, 157 high-risk NMIBC patients received nadofaragene firadenovec-vncg treatment. 98 BCG-unresponsive CIS patients were evaluated for response. The study showed a 51% complete response rate with a median duration of response of 9.7 months. 46% of responding patients remained in complete response for at least one year. The treatment was well-tolerated with manageable toxicity. Overall survival and progression-free survival data were not provided in the study results."
page_111.txt,Capecitabine tablets (Xeloda),"Stage III colon cancer, locally advanced rectal cancer, metastatic colorectal cancer, advanced or metastatic breast cancer, gastric, esophageal, or gastroesophageal junction cancer, HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,{},"The FDA approved updated labeling for capecitabine tablets (Xeloda) for various cancer types including colon, rectal, colorectal, breast, gastric, esophageal, gastroesophageal junction, and pancreatic adenocarcinoma. The labeling revisions include new indications, dosage regimen updates, removal of contraindications, and additional safety information. The drug is now approved for adjuvant, perioperative, and metastatic treatments in different cancer types, providing healthcare providers with updated information for patient care.",N/A
page_112.txt,Adagrasib (Krazati),Non-small cell lung cancer (NSCLC) with KRAS G12C mutations,112,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '43%', 'DOR': '8.5 months'}","Adagrasib (Krazati) received accelerated approval for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received prior systemic therapy. The approval was based on the KRYSTAL-1 trial, showing a 43% objective response rate and a median duration of response of 8.5 months. Common adverse reactions included diarrhea, nausea, fatigue, and hepatotoxicity.","In a study of 112 patients with advanced cancer who had previously received platinum-based chemotherapy and an immune checkpoint inhibitor, treatment with adagrasib showed promising results. The confirmed objective response rate (ORR) was 43%, with a median duration of response (DOR) of 8.5 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. Adagrasib, given orally twice daily, demonstrated efficacy in patients with disease progression after prior treatments, suggesting it may be a valuable option for this patient population. Further research is needed to fully understand the impact of adagrasib on OS and PFS in this setting."
page_113.txt,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"Study ML39345 evaluated the efficacy of treatment in 49 patients with unresectable or metastatic ASPS. The overall response rate (ORR) was 24%, with 67% of responders having a duration of response (DOR) of 6 months or more, and 42% having a DOR of 12 months or more. The median age of patients was 31 years, with a majority being female and White. The study showed promising outcomes in terms of ORR and DOR in patients with ASPS, indicating potential benefits of the treatment in this population."
page_114.txt,olutasidenib (Rezlidhia),acute myeloid leukemia (AML) with IDH1 mutation,147,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'CR+CRh Rate': '35%', 'Median Time to CR+CRh': '1.9 months', 'Median Duration of CR+CRh': '25.9 months', 'Transfusion Independence Rate': {'Dependent Patients': '34%', 'Independent Patients': '64%'}, 'Common Adverse Reactions': ['nausea', 'fatigue/malaise', 'arthralgia', 'constipation', 'leukocytosis', 'dyspnea', 'fever', 'rash', 'mucositis', 'diarrhea', 'transaminitis'], 'Boxed Warning': 'Differentiation syndrome risk'}","Olutasidenib (Rezlidhia) was approved for adult patients with relapsed or refractory AML with IDH1 mutation. Efficacy was demonstrated by CR+CRh rate of 35%, median time to CR+CRh of 1.9 months, and median duration of CR+CRh of 25.9 months. Adverse reactions included nausea, fatigue, and differentiation syndrome risk.","The study showed a 35% rate of complete remission (CR) plus complete remission with partial hematologic recovery (CRh), with a median duration of 25.9 months. The rate of conversion from transfusion dependence to independence was 34% among patients dependent on transfusions at baseline and 64% among those already independent. The median time to achieve CR+CRh was 1.9 months. Overall survival (OS) and progression-free survival (PFS) were not specifically mentioned in the study results."
page_115.txt,Asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze),Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL),225,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': 'Not provided', 'DOR': 'Not provided'}",FDA approved a new dosing regimen for Rylaze in June 2021 for ALL and LBL patients with hypersensitivity to E. coli-derived asparaginase. Study JZP458-201 evaluated pharmacokinetics and efficacy of Rylaze. The drug demonstrated maintenance of nadir serum asparaginase activity in a high proportion of patients. Common adverse reactions included hematological and nonhematological effects. The study was part of Project Orbis and utilized the RTOR pilot program for streamlined data submission.,"The study evaluated the efficacy of maintaining nadir serum asparaginase activity (NSAA) above 0.1 U/mL in a virtual population. Results showed that with a Monday-Wednesday-Friday dosing regimen of Rylaze, 91.6% of patients maintained NSAA ≥ 0.1 U/mL after the 25 mg/m2 Wednesday dose and 91.4% after the 50 mg/m2 Friday dose. All patients experienced hematological side effects like neutropenia, anemia, or thrombocytopenia. Overall Survival (OS) and Progression-Free Survival (PFS) were not mentioned in the study results. Response outcomes such as Overall Response Rate (ORR), Duration of Response (DOR), Complete Response (CR), or Partial Response (PR) were also not reported."
page_116.txt,Mirvetuximab soravtansine-gynx (Elahere),"Folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer",106,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '31.7%', 'Duration of Response (DOR)': '6.9 months'}","Mirvetuximab soravtansine-gynx received accelerated approval for adult patients with FRα positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Study 0417 included 106 patients with positive outcomes in ORR (31.7%) and median DOR of 6.9 months. Common adverse reactions included vision impairment, fatigue, and gastrointestinal issues. The drug is administered intravenously every three weeks until disease progression or unacceptable toxicity.","Study 0417 evaluated mirvetuximab soravtansine in 106 FRα positive, platinum-resistant ovarian cancer patients. The overall response rate (ORR) was 31.7% with a median duration of response (DOR) of 6.9 months. Progression-free survival (PFS) and overall survival (OS) data were not provided. The study excluded patients with certain eye and lung conditions. The treatment was generally well-tolerated, with manageable toxicity. Further research is needed to assess the impact on PFS and OS in this patient population."
page_117.txt,Tremelimumab (Imjudo) in combination with durvalumab (Imfinzi),Metastatic non-small cell lung cancer (NSCLC),675,14 months,11.7 months,19.66%,6.2 months,4.8 months,29.17%,"{'Overall Response Rate': {'Treatment Arm 1': '39%', 'Treatment Arm 3': '24%'}, 'Median Duration of Response': {'Treatment Arm 1': '9.5 months', 'Treatment Arm 3': '5.1 months'}}","Tremelimumab in combination with durvalumab and platinum-based chemotherapy showed a significant improvement in overall survival (OS) and progression-free survival (PFS) in patients with metastatic NSCLC compared to platinum-based chemotherapy alone. The treatment arm demonstrated a 19.66% improvement in OS and a 29.17% improvement in PFS, with an overall response rate of 39% and a median duration of response of 9.5 months.","In the POSEIDON study, patients with metastatic NSCLC who received tremelimumab, durvalumab, and platinum-based chemotherapy showed a significant improvement in overall survival (OS) compared to those who received platinum-based chemotherapy alone. The median OS was 14 months in the combination treatment group and 11.7 months in the chemotherapy-only group. Progression-free survival (PFS) was also longer in the combination treatment group (6.2 months) compared to the chemotherapy-only group (4.8 months). The overall response rate was higher in the combination treatment group (39%) compared to the chemotherapy-only group (24%), with a longer duration of response in the combination treatment group (9.5 months) compared to the chemotherapy-only group (5.1 months). These results suggest that the combination treatment is more effective in treating metastatic NSCLC."
page_118.txt,Brentuximab vedotin,Classical Hodgkin lymphoma (cHL),600,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Event-free Survival (EFS)': {'Median EFS': 'Not reached', 'Hazard Ratio': 0.41, '95% CI': '0.25, 0.67', 'p-value': 0.0002}, 'Adverse Reactions': {'Grade ≥3': ['Neutropenia', 'Anemia', 'Thrombocytopenia', 'Febrile neutropenia', 'Stomatitis', 'Infection']}}","Brentuximab vedotin in combination with chemotherapy showed a significant improvement in event-free survival for pediatric patients with high-risk classical Hodgkin lymphoma compared to standard treatment. Common Grade ≥3 adverse reactions included neutropenia, anemia, and febrile neutropenia.","In a study comparing brentuximab vedotin plus doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (brentuximab vedotin + AVEPC) to doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) in high-risk lymphoma patients, the brentuximab vedotin + AVEPC arm showed a significantly improved event-free survival (EFS) compared to the ABVE-PC arm (HR=0.41, p=0.0002). Overall survival (OS) and progression-free survival (PFS) data were not provided. The study did not report specific response outcomes such as overall response rate (ORR), duration of response (DOR), complete response (CR), or partial response (PR). The brentuximab vedotin + AVEPC regimen demonstrated promising efficacy in this patient population."
page_119.txt,Cemiplimab-rwlc (Libtayo),Non-small cell lung cancer (NSCLC),466,21.9 months,13.0 months,68.50%,8.2 months,5.0 months,64.00%,"{'Overall Response Rate (ORR)': '43%', 'Duration of Response (DOR)': 'Not provided'}","Cemiplimab-rwlc in combination with platinum-based chemotherapy showed a significant improvement in overall survival (OS) and progression-free survival (PFS) in adult patients with advanced NSCLC compared to placebo plus chemotherapy. The treatment arm demonstrated a 68.5% improvement in OS and a 64.0% improvement in PFS. Additionally, the overall response rate (ORR) was 43%. Common adverse reactions included alopecia, musculoskeletal pain, nausea, fatigue, peripheral neuropathy, and decreased appetite.","In Study 16113, cemiplimab-rwlc plus platinum-based chemotherapy showed a significant improvement in overall survival (OS) compared to placebo plus chemotherapy in advanced NSCLC patients. The median OS was 21.9 months with cemiplimab-rwlc plus chemotherapy versus 13.0 months with placebo plus chemotherapy. Progression-free survival (PFS) was also longer with cemiplimab-rwlc plus chemotherapy (8.2 months) compared to placebo plus chemotherapy (5.0 months). The overall response rate (ORR) was higher with cemiplimab-rwlc plus chemotherapy (43%) than with placebo plus chemotherapy (23%). These results suggest that cemiplimab-rwlc in combination with chemotherapy could be a beneficial treatment option for patients with advanced NSCLC who have not received prior systemic treatment."
page_12.txt,Fludarabine Phosphate Injection,B-cell chronic lymphocytic leukemia (CLL),Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,{},"Fludarabine Phosphate Injection received updated drug labeling for the treatment of adults with B-cell CLL who have not responded to or progressed during treatment with at least one alkylating-agent containing regimen. The dosage regimen was revised, and the boxed warning was removed. This update is part of the Project Renewal initiative to keep older oncology drugs' labeling up to date.",N/A
page_120.txt,Teclistamab-cqyv (Tecvayli),Multiple Myeloma,110,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '61.8%', 'DOR at 6 months': '90.6%', 'DOR at 9 months': '66.5%', 'Adverse Reactions': ['pyrexia', 'CRS', 'musculoskeletal pain', 'injection site reaction', 'fatigue', 'upper respiratory tract infection', 'nausea', 'headache', 'pneumonia', 'diarrhea'], 'Grade 3-4 Laboratory Abnormalities': ['decreased lymphocytes', 'decreased neutrophils', 'decreased white blood cells', 'decreased hemoglobin', 'decreased platelets']}","Teclistamab-cqyv (Tecvayli) received accelerated approval for adult patients with relapsed or refractory multiple myeloma who have received prior lines of therapy. The drug demonstrated an overall response rate of 61.8% and a duration of response rate of 90.6% at 6 months. Common adverse reactions included pyrexia, CRS, and musculoskeletal pain. Grade 3-4 laboratory abnormalities included decreased lymphocytes and neutrophils.","In a study of 110 heavily pretreated patients with multiple myeloma, the overall response rate (ORR) to teclistamab-cqyv was 61.8%. The estimated duration of response (DOR) at 6 months was 90.6% and at 9 months was 66.5%. However, the drug carries a Boxed Warning for life-threatening cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity (ICANS). Among patients, CRS occurred in 72%, neurologic toxicity in 57%, and ICANS in 6%. Grade 3 CRS occurred in 0.6% of patients and Grade 3 or 4 neurologic toxicity in 2.4%. Due to these risks, teclistamab-cqyv is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)."
page_121.txt,"Tremelimumab (Imjudo, AstraZeneca Pharmaceuticals)",Unresectable Hepatocellular Carcinoma (uHCC),782,16.4 months,13.8 months,18.84%,3.8 months,4.1 months,-7.32%,"{'Overall Response Rate (ORR)': {'Tremelimumab + Durvalumab': '20.1%', 'Sorafenib': '5.1%'}}","The study evaluated the efficacy of tremelimumab in combination with durvalumab for patients with unresectable hepatocellular carcinoma. The combination therapy showed a significant improvement in overall survival compared to sorafenib, with a median OS of 16.4 months. Additionally, the treatment arm demonstrated a higher overall response rate of 20.1% compared to 5.1% in the control arm.","In the HIMALAYA study, tremelimumab plus durvalumab showed a significant improvement in overall survival (OS) compared to sorafenib in patients with uHCC. The median OS was 16.4 months with tremelimumab plus durvalumab versus 13.8 months with sorafenib. Progression-free survival (PFS) was similar between the two arms, with median PFS of 3.8 months for tremelimumab plus durvalumab and 4.1 months for sorafenib. The overall response rate (ORR) was higher in the tremelimumab plus durvalumab arm at 20.1% compared to 5.1% with sorafenib. These results support the efficacy of tremelimumab plus durvalumab as a first-line treatment for uHCC patients who have not received prior systemic treatment."
page_122.txt,Futibatinib (Lytgobi),Intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements,103,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '42%', 'Duration of Response (DoR)': 'Median 9.7 months'}","Futibatinib (Lytgobi) received accelerated approval for intrahepatic cholangiocarcinoma with FGFR2 gene fusions. The single-arm trial showed an ORR of 42% with a median DoR of 9.7 months. Common adverse reactions included nail toxicity, musculoskeletal pain, and constipation.","In a study of 103 patients with previously treated intrahepatic cholangiocarcinoma with FGFR2 gene fusion or rearrangement, treatment with futibatinib showed promising results. The overall response rate (ORR) was 42%, with all responders achieving partial responses. The median duration of response (DoR) was 9.7 months. The study demonstrated efficacy in terms of tumor response outcomes. Further, the progression-free survival (PFS) and overall survival (OS) data were not provided in the summary."
page_123.txt,Selpercatinib (Retevmo),Non-small cell lung cancer (NSCLC) with RET gene fusion,316,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Treatment-naïve patients': '84%', 'Previously treated patients': '61%'}, 'DOR': {'Treatment-naïve patients': '20.2 months', 'Previously treated patients': '28.6 months'}}","Selpercatinib was granted regular approval for locally advanced or metastatic NSCLC with RET gene fusion. Efficacy was demonstrated in 316 patients with high ORR and DOR. Common adverse reactions included edema, diarrhea, and fatigue.","In a study of 316 patients with RET fusion-positive NSCLC, selpercatinib showed efficacy with an ORR of 84% and a DOR of 20.2 months in treatment-naïve patients. Among previously treated patients, the ORR was 61% with a DOR of 28.6 months. The median age was 61 years, with 58% female and 97% having metastatic disease. Previously treated patients had received a median of two prior systemic therapies, with 58% having received prior anti PD 1/PD-L1 therapy. Overall survival and progression-free survival data were not provided in the summary."
page_124.txt,Selpercatinib (Retevmo),Solid tumors with RET gene fusion,41,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '44%', 'DOR': '24.5 months', 'Tumor types with responses': ['Pancreatic adenocarcinoma', 'Colorectal', 'Salivary', 'Unknown primary', 'Breast', 'Soft tissue sarcoma', 'Bronchial carcinoid', 'Ovarian', 'Small intestine', 'Cholangiocarcinoma']}","Selpercatinib (Retevmo) was granted accelerated approval for adult patients with solid tumors with RET gene fusion. Efficacy was demonstrated in a trial with 41 patients showing an overall response rate of 44% and a duration of response of 24.5 months. Common adverse reactions included edema, diarrhea, and fatigue.","In the LIBRETTO-001 study, selpercatinib showed efficacy in patients with RET fusion-positive tumors, excluding NSCLC and thyroid cancer, who had disease progression or no satisfactory treatment options. Among 41 patients evaluated, the overall response rate (ORR) was 44% with a duration of response (DOR) of 24.5 months. Tumor types with responses included pancreatic adenocarcinoma, colorectal, salivary, and others. The majority of patients were female, White, and had metastatic disease. Most had received prior systemic therapy, with pancreatic and colorectal cancers being the most common. RET fusion-positive status was detected in almost all patients. Overall, selpercatinib demonstrated promising efficacy in this patient population."
page_125.txt,Pedmark,Solid tumors,239,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Primary Outcome': 'Reduction in hearing loss associated with cisplatin chemotherapy', 'Adverse Reactions': ['vomiting', 'nausea', 'decreased hemoglobin', 'hypernatremia', 'hypokalemia']}","Pedmark, a sodium thiosulfate product, was evaluated in two trials for reducing hearing loss in pediatric patients with solid tumors undergoing cisplatin-based chemotherapy. The incidence of hearing loss was lower in patients receiving sodium thiosulfate along with cisplatin compared to cisplatin alone. Common adverse reactions included vomiting, nausea, and electrolyte imbalances.","In pediatric patients undergoing cisplatin-based chemotherapy for cancer, the addition of sodium thiosulfate resulted in a lower incidence of hearing loss compared to cisplatin alone in both SIOPEL 6 (39% vs. 68%) and COG ACCL0431 (44% vs. 58%). Overall Survival (OS) and Progression-Free Survival (PFS) were not specifically mentioned in the study results. The studies focused on reducing hearing loss as a side effect of cisplatin treatment, with sodium thiosulfate showing potential in preserving hearing function. Response outcomes such as Overall Response Rate (ORR), Duration of Response (DOR), Complete Response (CR), and Partial Response (PR) were not discussed in the study. The primary outcomes were related to hearing loss assessment in pediatric patients with solid tumors undergoing cisplatin-based chemotherapy."
page_126.txt,Durvalumab (Imfinzi),Biliary tract cancer (BTC),685,12.8 months,11.5 months,10.40%,7.2 months,5.7 months,26.30%,"{'Overall Response Rate (ORR)': {'Durvalumab': '27%', 'Placebo': '19%'}}","Durvalumab in combination with gemcitabine and cisplatin showed a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo in patients with locally advanced or metastatic biliary tract cancer. The treatment arm demonstrated a 10.4% improvement in OS and a 26.3% improvement in PFS. Additionally, the overall response rate was higher in the durvalumab arm at 27% compared to 19% in the placebo arm.","In the TOPAZ-1 study, patients with locally advanced unresectable or metastatic BTC who received durvalumab with gemcitabine and cisplatin had a statistically significant improvement in overall survival (OS) compared to those who received placebo with gemcitabine and cisplatin. The median OS was 12.8 months with durvalumab and 11.5 months with placebo. Progression-free survival (PFS) was also longer with durvalumab at 7.2 months compared to 5.7 months with placebo. The overall response rate (ORR) was higher in the durvalumab group at 27% compared to 19% in the placebo group. These results suggest that the addition of durvalumab to standard chemotherapy may benefit patients with BTC in terms of survival and response outcomes."
page_127.txt,Pemazyre,Myeloid/Lymphoid Neoplasms with FGFR1 rearrangement,28,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Complete Response Rate': '78%', 'Common Adverse Reactions': ['Hyperphosphatemia', 'Nail toxicity', 'Alopecia', 'Stomatitis', 'Diarrhea', 'Dry eye', 'Fatigue', 'Rash', 'Abdominal pain', 'Anemia', 'Constipation', 'Dry mouth', 'Epistaxis', 'Serous retinal detachment', 'Extremity pain', 'Decreased appetite', 'Dry skin', 'Dyspepsia', 'Back pain', 'Nausea', 'Blurred vision', 'Peripheral edema', 'Dizziness'], 'Grade 3 or 4 Laboratory Abnormalities': ['Decreased phosphate', 'Decreased lymphocytes', 'Decreased leukocytes', 'Decreased platelets', 'Increased alanine aminotransferase', 'Decreased neutrophils']}","Pemazyre was approved for adults with relapsed or refractory Myeloid/Lymphoid Neoplasms with FGFR1 rearrangement. The efficacy was evaluated in a trial with 28 patients, showing a 78% complete response rate. Common adverse reactions included hyperphosphatemia, nail toxicity, and alopecia. Grade 3 or 4 laboratory abnormalities included decreased phosphate and leukocytes. The recommended dose is 13.5 mg orally once daily.","In the FIGHT-203 study, pemigatinib showed promising efficacy in patients with relapsed or refractory MLNs with FGFR1 rearrangement. The overall survival (OS) and progression-free survival (PFS) data were not specifically mentioned in the summary. However, the study demonstrated high complete response (CR) rates in patients with chronic phase and blast phase MLNs, with a median time-to-CR of 104 days. The median duration of response was not reached, indicating durable responses. The complete cytogenetic response rate was 79% in all patients, including those without evidence of morphologic disease. These results suggest that pemigatinib may be a valuable treatment option for this patient population."
page_128.txt,Ibrutinib (Imbruvica),Chronic Graft Versus Host Disease (cGVHD),47,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '60%', 'Median Duration of Response': '5.3 months', 'Median Time from First Response to Death or New Systemic Therapies': '14.8 months'}","Ibrutinib (Imbruvica) was approved for pediatric patients with chronic graft versus host disease after failure of systemic therapy. The iMAGINE trial showed a 60% overall response rate with a median duration of response of 5.3 months. Common adverse reactions included anemia, musculoskeletal pain, and diarrhea.","The iMAGINE study evaluated the efficacy of ibrutinib in pediatric and young adult patients with moderate or severe cGVHD. The overall response rate (ORR) by Week 25 was 60%, with a median duration of response of 5.3 months. The median time from first response to death or new systemic therapies for cGVHD was 14.8 months. The study included 47 patients with a median age of 13 years, and the majority were male. Progression-Free Survival (PFS) and Overall Survival (OS) data were not provided in the summary. The study showed promising results in terms of response outcomes for this patient population."
page_129.txt,fam-trastuzumab deruxtecan-nxki (Enhertu),non-small cell lung cancer (NSCLC) with activating HER2 mutations,52,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Confirmed Objective Response Rate (ORR)': '58%', 'Median Duration of Response (DOR)': '8.7 months'}","Enhertu received accelerated approval for HER2-mutant NSCLC based on the DESTINY-Lung02 trial, showing a 58% confirmed objective response rate and a median duration of response of 8.7 months in 52 patients. Common adverse reactions include nausea, decreased blood cell counts, and liver enzyme abnormalities.","In a study of patients with HER2-mutant non-squamous NSCLC receiving Enhertu at 5.4 mg/kg every 3 weeks, the confirmed objective response rate (ORR) was 58% with a median duration of response (DOR) of 8.7 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study included 52 patients with a median age of 58 years, majority being female and Asian. The results suggest that Enhertu may be an effective treatment option for patients with HER2-mutant NSCLC who have progressed after prior systemic therapy. Further analysis of OS and PFS outcomes would provide a more comprehensive understanding of the treatment's efficacy."
page_13.txt,Revuforj,Relapsed or refractory acute leukemia with a KMT2A translocation,104,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'CR+CRh Rate': '21.2%', 'Median CR+CRh Duration': '6.4 months', 'Median Time to CR or CRh': '1.9 months', 'Transfusion Independence Rate': '14% for RBC and platelet transfusions, 48% for both RBC and platelet transfusions'}","Revuforj was approved for relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients. The main efficacy outcomes included CR+CRh rate of 21.2% and a median CR+CRh duration of 6.4 months. Adverse reactions were common, and dosing varied by patient weight and concomitant use of CYP3A4 inhibitors. The application was granted priority review and expedited programs due to breakthrough and orphan drug designations.",Efficacy and
page_130.txt,Capmatinib (Tabrecta),Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation,160,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Treatment-naïve patients': '68%', 'Previously treated patients': '44%'}, 'DOR': {'Treatment-naïve patients': '16.6 months', 'Previously treated patients': '9.7 months'}}","Capmatinib (Tabrecta) was granted regular approval for adult patients with metastatic NSCLC with MET exon 14 skipping mutation. Efficacy was demonstrated in 160 patients, showing high ORR in treatment-naïve and previously treated patients. Common adverse reactions included edema, nausea, musculoskeletal pain, and fatigue. The recommended dose is 400 mg orally twice daily. The study conversion to regular approval was based on additional patient data and follow-up time to assess durability of response and clinical benefit.","In a study of 160 patients with metastatic NSCLC and MET exon 14 skipping mutation, treatment with capmatinib showed promising efficacy. Among treatment-naïve patients, the overall response rate (ORR) was 68% with a duration of response (DOR) of 16.6 months. Among previously treated patients, the ORR was 44% with a DOR of 9.7 months. The median age of patients was 71 years, with a majority being female (61%) and White (77%). Most patients had adenocarcinoma (83%) and 16% had CNS metastases. The majority of previously treated patients had received one prior line of systemic therapy (81%) and 86% had received prior platinum-based chemotherapy. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary."
page_131.txt,Darolutamide (Nubeqa),Metastatic hormone-sensitive prostate cancer (mHSPC),1306,Median OS not reached in darolutamide plus docetaxel arm,48.9 months in docetaxel plus placebo arm,Overall survival HR 0.68; p<0.0001,Not provided,Not provided,Time-to-pain progression HR 0.79; p=0.006,{'Time-to-pain progression': 'HR 0.79; p=0.006'},"Darolutamide in combination with docetaxel showed a significant improvement in overall survival compared to docetaxel plus placebo in patients with metastatic hormone-sensitive prostate cancer. The treatment also resulted in a delay in time-to-pain progression. Common adverse reactions included constipation, decreased appetite, rash, hemorrhage, increased weight, and hypertension.","In the ARASENS study, darolutamide plus docetaxel showed improved overall survival (OS) compared to docetaxel plus placebo in patients with mHSPC, with a median OS not reached in the darolutamide arm. The combination also delayed time-to-pain progression significantly. The study included a diverse patient population with a median age of 67 years and various racial/ethnic backgrounds. Response outcomes were not specifically mentioned in the summary provided."
page_132.txt,fam-trastuzumab deruxtecan-nxki (Enhertu),HER2-low breast cancer,557,"{'HR+': {'Median': '23.9 months', '95% CI': '20.8, 24.8'}, 'Overall Population': {'Median': '23.4 months', '95% CI': '20.0, 24.8'}}","{'HR+': {'Median': '17.5 months', '95% CI': '15.2, 22.4'}, 'Overall Population': {'Median': '16.8 months', '95% CI': '14.5, 20.0'}}","{'HR+': '36%', 'Overall Population': '39%'}","{'HR+': {'Median': '10.1 months', '95% CI': '9.5, 11.5'}, 'Overall Population': {'Median': '9.9 months', '95% CI': '9.0, 11.3'}}","{'HR+': {'Median': '5.4 months', '95% CI': '4.4, 7.1'}, 'Overall Population': {'Median': '5.1 months', '95% CI': '4.2, 6.8'}}","{'HR+': '87%', 'Overall Population': '94%'}",{},"Enhertu demonstrated significant improvements in both progression-free survival and overall survival compared to chemotherapy in patients with HER2-low breast cancer. The drug showed a 36% improvement in overall survival in HR+ patients and a 39% improvement in the overall population. Additionally, Enhertu resulted in an 87% and 94% improvement in progression-free survival in HR+ patients and the overall population, respectively.","In the DESTINY-Breast04 study, patients with HER2-low breast cancer treated with Enhertu had significantly longer progression-free survival (PFS) compared to those receiving chemotherapy, both in the hormone receptor-positive (HR+) cohort and overall population. Median PFS was 10.1 months vs. 5.4 months in the HR+ cohort and 9.9 months vs. 5.1 months in the overall population. Overall survival (OS) was also improved with Enhertu, with median OS of 23.9 months vs. 17.5 months in the HR+ cohort and 23.4 months vs. 16.8 months in the overall population. Enhertu showed a higher response rate and longer duration of response compared to chemotherapy, indicating its efficacy in treating HER2-low breast cancer."
page_133.txt,Crizotinib (Xalkori),Inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT),14 pediatric patients and 7 adult patients,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Pediatric Patients': '86% objective response rate', 'Adult Patients': '5 patients with objective responses'}}","Crizotinib (Xalkori) was approved for unresectable, recurrent, or refractory ALK-positive IMT in pediatric and adult patients. The trials showed an 86% objective response rate in pediatric patients and 5 adult patients with objective responses. Common adverse reactions included vomiting, nausea, diarrhea, and vision disorders. Recommended doses vary for adults and pediatric patients. Crizotinib received orphan drug designation.","Overall, the study found that crizotinib showed promising efficacy in both pediatric and adult patients with unresectable, recurrent, or refractory ALK-positive IMT. The objective response rate (ORR) was 86% in pediatric patients and 71% in adult patients. The median duration of response (DOR) was not provided in the summary. The study did not report specific data on overall survival (OS) or progression-free survival (PFS). These results suggest that crizotinib may be a beneficial treatment option for patients with this type of cancer, with a high rate of objective responses observed in both age groups."
page_134.txt,lisocabtagene maraleucel,large B-cell lymphoma (LBCL),184,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Event-Free Survival (EFS)': {'Hazard Ratio': '0.34', '1-year EFS': {'lisocabtagene maraleucel arm': '45%', 'standard therapy arm': '24%'}, 'Median EFS': {'lisocabtagene maraleucel arm': '10.1 months', 'standard therapy arm': '2.3 months'}}, 'Progression-Free Survival (PFS)': {'Hazard Ratio': '0.41'}, 'Complete Response Rate (CR)': '54%', 'Duration of Response (DOR)': {'CR patients': 'Not reached', 'PR patients': '2.1 months'}}","The study evaluated the efficacy of lisocabtagene maraleucel in adult patients with large B-cell lymphoma who had refractory disease or relapse. Results showed significant improvements in event-free survival and progression-free survival compared to standard therapy. Additionally, a high complete response rate was observed in transplant-ineligible patients. However, the treatment is associated with risks of cytokine release syndrome and neurologic toxicities, requiring a Risk Evaluation and Mitigation Strategy.","In the TRANSFORM study, patients with refractory LBCL or relapse within 12 months of CR to first-line therapy were randomized to receive lisocabtagene maraleucel or standard therapy. Lisocabtagene maraleucel showed significantly longer event-free survival (EFS) and progression-free survival compared to standard therapy. In the PILOT study, transplant-ineligible patients with relapsed or refractory LBCL achieved a 54% CR rate with lisocabtagene maraleucel. The median duration of response (DOR) was not reached in CR patients. Overall, 46% of patients achieved CR. FDA approved lisocabtagene maraleucel for LBCL, but with a Risk Evaluation and Mitigation Strategy due to the risk of CRS and neurologic toxicities."
page_135.txt,Dabrafenib (Tafinlar) in combination with trametinib (Mekinist),Solid tumors with BRAF V600E mutation,131 adult patients and 36 pediatric patients,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Adult Patients': '41% with objective response', 'Pediatric Patients': '25% with objective response', 'DOR': {'≥6 months': '78% of pediatric patients', '≥24 months': '44% of pediatric patients'}}}","Accelerated approval granted to dabrafenib in combination with trametinib for the treatment of solid tumors with BRAF V600E mutation in patients who have progressed following prior treatment. Efficacy demonstrated through objective response rates in adult and pediatric patients, with a notable duration of response in pediatric patients. Common adverse reactions reported in both adult and pediatric patients. Recommended dosing provided for both adult and pediatric populations.","In a study evaluating the efficacy of a treatment in adult and pediatric patients with BRAF V600E mutation positive solid tumors, the overall response rate (ORR) was 41% in adult patients and 25% in pediatric patients. The ORR varied among different tumor types, with biliary tract cancer having an ORR of 46%, high grade glioma at 33%, and low grade glioma at 50% in adults. In pediatric patients, the duration of response (DOR) was at least 6 months for 78% of patients and at least 24 months for 44% of patients. Overall survival (OS) and progression-free survival (PFS) outcomes were not specifically mentioned in the summary provided."
page_136.txt,tisagenlecleucel (Kymriah),follicular lymphoma (FL),90 patients in the primary efficacy analysis,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '86%', 'Complete Response (CR) Rate': '68%', 'Duration of Response (DOR)': 'Median DOR not reached, 75% responders still in response at 9 months'}","The FDA granted accelerated approval to tisagenlecleucel for adult patients with relapsed or refractory follicular lymphoma based on the ELARA trial. The trial showed an overall response rate of 86% with a complete response rate of 68%. The median duration of response was not reached, with 75% of responders still in response at 9 months. Common adverse reactions included cytokine release syndrome, infection, fatigue, musculoskeletal pain, headache, and diarrhea.","In this oncology study, the overall response rate (ORR) was 86% with a complete response (CR) rate of 68%. The median duration of response (DOR) was not reached, with 75% of responders still in response at 9 months. Among all patients who underwent leukapheresis, the ORR was 86% with a CR rate of 67%. These results suggest a high level of efficacy in terms of response outcomes. Further analysis showed promising results in terms of progression-free survival (PFS) and overall survival (OS), indicating potential benefits for patients in terms of survival outcomes."
page_137.txt,Nivolumab (Opdivo),Esophageal squamous cell carcinoma (ESCC),970,"{'nivolumab, fluorouracil, and cisplatin': '13.2 months', 'nivolumab and ipilimumab': '12.8 months'}",10.7 months,"{'nivolumab, fluorouracil, and cisplatin vs. chemotherapy': '26%', 'nivolumab and ipilimumab vs. chemotherapy': '22%'}",{},{},{},"{'Adverse Reactions (nivolumab and fluoropyrimidine- and platinum-containing chemotherapy)': ['nausea', 'decreased appetite', 'fatigue', 'constipation', 'stomatitis', 'diarrhea', 'vomiting'], 'Adverse Reactions (nivolumab and ipilimumab)': ['rash', 'fatigue', 'pyrexia', 'nausea', 'diarrhea', 'constipation']}","Nivolumab in combination with chemotherapy or ipilimumab showed significant improvements in overall survival for patients with advanced or metastatic esophageal squamous cell carcinoma compared to chemotherapy alone. Common adverse reactions included nausea, fatigue, and diarrhea.","In the CHECKMATE-648 study, which included 970 patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC), significant improvements in overall survival (OS) were observed with nivolumab-containing regimens compared to chemotherapy. The hazard ratios (HR) for OS were 0.74 for nivolumab, fluorouracil, and cisplatin vs. chemotherapy, and 0.78 for nivolumab and ipilimumab vs. chemotherapy. In the intention-to-treat (ITT) population, median OS was 13.2 months with nivolumab, fluorouracil, and cisplatin, 12.8 months with nivolumab and ipilimumab, and 10.7 months with fluorouracil and cisplatin. In the subgroup with tumor cell PD-L1 ≥1%, the HRs for OS were 0.54 for nivolumab, fluorouracil, and cisplatin vs. chemotherapy, and 0.64 for nivolumab and ipilimumab vs. chemotherapy. These results demonstrate the efficacy of nivolumab-containing regimens in improving OS in patients with ESCC."
page_138.txt,Ivosidenib (Tibsovo),Acute myeloid leukemia (AML) with IDH1 mutation,146,24.0 months,7.9 months,67.09%,Not provided,Not provided,Not provided,"{'EFS': 'HR 0.35; 95% CI: 0.17, 0.72, p=0.0038', 'CR': '47% in treatment arm, 15% in control arm', 'Duration of CR': 'NE in treatment arm, 11.2 months in control arm', 'Adverse Reactions': ['Diarrhea', 'Fatigue', 'Edema', 'Nausea', 'Vomiting', 'Decreased appetite', 'Leukocytosis', 'Arthralgia', 'Dyspnea', 'Abdominal pain', 'Mucositis', 'Rash', 'Electrocardiogram QT prolonged', 'Differentiation syndrome', 'Myalgia']}","Ivosidenib in combination with azacitidine showed a significant improvement in overall survival (OS) for newly diagnosed AML patients with IDH1 mutation, with a 67.09% increase in OS compared to the control arm. The treatment also demonstrated a higher complete remission rate and longer duration of complete remission. Common adverse reactions include diarrhea, fatigue, and differentiation syndrome.","In this study, the combination of ivosidenib plus azacitidine showed significant improvements in event-free survival (EFS), overall survival (OS), and complete remission (CR) rates compared to placebo plus azacitidine in patients. The EFS events occurred less frequently in the ivosidenib plus azacitidine arm (65% vs. 84% in the placebo arm). Median OS was longer in the ivosidenib plus azacitidine arm (24.0 months vs. 7.9 months in the placebo arm). The CR rate was higher in the ivosidenib plus azacitidine arm (47% vs. 15% in the placebo arm), with a longer median duration of CR in the ivosidenib plus azacitidine arm. These results suggest that the combination therapy is more effective in improving survival outcomes and achieving complete remission in patients."
page_139.txt,Azacitidine (Vidaza),Juvenile Myelomonocytic Leukemia (JMML),18,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Clinical Complete Remission (cCR)': '3 patients', 'Clinical Partial Remission (cPR)': '6 patients', 'Proportion of patients undergoing HSCT': '94%', 'Median time to response': '1.2 months', 'Most common adverse reactions': ['Pyrexia', 'Rash', 'Upper respiratory tract infection', 'Anemia']}","Azacitidine (Vidaza) was approved for pediatric patients with newly diagnosed JMML. The study evaluated the efficacy of azacitidine prior to HSCT in 18 pediatric patients, with 50% showing clinical responses. Most common adverse reactions included pyrexia, rash, upper respiratory tract infection, and anemia.","Efficacy was evaluated in AZA-JMML-001 (NCT02447666), an international, multicenter, open-label study to evaluate the pharmacokinetics, pharmacodynamics,"
page_14.txt,Obecabtagene autoleucel (Aucatzyl),B-cell precursor acute lymphoblastic leukemia (ALL),65,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Rate and duration of complete remission (CR) achieved within 3 months after infusion': '42% achieved CR within 3 months, median duration of CR achieved within 3 months was 14.1 months', 'Rate and duration of overall complete remission': 'Not provided', 'Adverse reactions': 'Common adverse reactions included CRS, infections, musculoskeletal pain, viral infections, fever, nausea, bacterial infections, diarrhea, febrile neutropenia, ICANS, hypotension, pain, fatigue, headache, encephalopathy, and hemorrhage'}",Obecabtagene autoleucel (Aucatzyl) was approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Efficacy was evaluated in a trial where 42% of patients achieved complete remission within 3 months. Adverse reactions included cytokine release syndrome and neurologic toxicities. The recommended dose is 410 X 106 CD19 CAR-positive viable T cells administered as split dose infusion.,Efficacy and
page_140.txt,fam-trastuzumab deruxtecan-nxki (Enhertu),HER2-positive breast cancer,524,OS not mature at the time of analysis,OS not mature at the time of analysis,OS not mature at the time of analysis,"PFS not reached (95% CI: 18.5, not estimable)","6.8 months (95% CI: 5.6, 8.2)","Hazard ratio 0.28 (95% CI: 0.22, 0.37; p-value<0.0001)","{'ORR': {'Enhertu arm': '82.7% (95% CI: 77.4, 87.2)', 'Ado-trastuzumab emtansine arm': '36.1% (95% CI: 30.0, 42.5)'}}","The study evaluated fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with HER2-positive breast cancer who had received prior anti-HER2-based regimens. The trial showed a significant improvement in progression-free survival with Enhertu compared to ado-trastuzumab emtansine. Overall survival data was not mature at the time of analysis. Enhertu also demonstrated a higher objective response rate compared to the control arm. Common adverse reactions included nausea, fatigue, and vomiting.","In the DESTINY-Breast03 study, patients with HER2-positive metastatic breast cancer treated with Enhertu had a significantly longer median progression-free survival (PFS) compared to those receiving ado-trastuzumab emtansine (not reached vs. 6.8 months). The hazard ratio for PFS was 0.28, indicating a significant benefit with Enhertu. Overall survival (OS) data was immature at the time of the analysis. The confirmed objective response rate (ORR) was higher in the Enhertu arm (82.7%) compared to the ado-trastuzumab emtansine arm (36.1%). These results suggest that Enhertu may be a more effective treatment option for patients with HER2-positive metastatic breast cancer who have received prior trastuzumab and taxane therapy."
page_141.txt,Alpelisib (Vijoice),PIK3CA-related overgrowth spectrum (PROS),37,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Radiological Response at Week 24': '27% (95% CI: 14, 44)', 'Duration of Response': '60% had a response lasting 12 months or longer', 'Common Adverse Reactions': ['Diarrhea', 'Stomatitis', 'Hyperglycemia']}","Alpelisib (Vijoice) received accelerated approval for patients with severe manifestations of PIK3CA-related overgrowth spectrum (PROS). Efficacy was evaluated in 37 patients, with 27% showing a radiological response at Week 24. Common adverse reactions included diarrhea, stomatitis, and hyperglycemia.","In the study evaluating the efficacy of alpelisib in patients with PROS, 27% of patients had a radiological response at week 24, with 60% of responders having a response lasting 12 months or longer. The study included 37 patients with severe or life-threatening manifestations of PROS and documented PIK3CA gene mutations. Progression-Free Survival (PFS) and Overall Survival (OS) data were not provided in the summary."
page_142.txt,axicabtagene ciloleucel,large B-cell lymphoma (LBCL),359,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Event-free Survival (EFS)': {'Hazard Ratio': 0.4, '18-month EFS Rate (axicabtagene ciloleucel arm)': '41.5%', '18-month EFS Rate (standard therapy arm)': '17.0%', 'Median EFS (axicabtagene ciloleucel arm)': '8.3 months', 'Median EFS (standard therapy arm)': '2.0 months'}, 'Objective Response Rate (ORR)': {'Axicabtagene ciloleucel arm': '83%', 'Standard therapy arm': '50%'}, 'Adverse Reactions': ['Cytokine release syndrome (CRS)', 'Neurologic toxicities', 'Fever', 'Hypotension', 'Encephalopathy', 'Fatigue', 'Tachycardia', 'Headache', 'Nausea', 'Febrile neutropenia', 'Diarrhea', 'Musculoskeletal pain', 'Infections with pathogen unspecified', 'Chills', 'Decreased appetite']}","The study evaluated the efficacy of axicabtagene ciloleucel in adult patients with refractory large B-cell lymphoma. Axicabtagene ciloleucel demonstrated significantly longer event-free survival compared to standard therapy, with higher objective response rates. Adverse reactions included cytokine release syndrome and neurologic toxicities. The study highlighted the potential of axicabtagene ciloleucel as a treatment option for this patient population.","In a study comparing axicabtagene ciloleucel to standard therapy, axicabtagene ciloleucel showed significantly longer event-free survival (EFS) with a hazard ratio of 0.40. The 18-month EFS rate was 41.5% in the axicabtagene ciloleucel arm compared to 17.0% in the standard therapy arm. The median EFS was 8.3 months for axicabtagene ciloleucel and 2.0 months for standard therapy. The objective response rate was higher in the axicabtagene ciloleucel arm at 83% compared to 50% in the standard therapy arm. However, axicabtagene ciloleucel comes with a boxed warning for cytokine release syndrome (CRS) and neurologic toxicities, with CRS occurring in 90% of patients and neurologic toxicities in 78% of patients."
page_143.txt,Pluvicto,Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC),551,15.3 months,11.3 months,35.40%,not specified,not specified,not specified,"{'ORR': 'not specified', 'DOR': 'not specified'}","Pluvicto was approved for the treatment of adult patients with PSMA-positive mCRPC who have been previously treated with AR pathway inhibition and taxane-based chemotherapy. In a trial of 551 patients, Pluvicto plus BSoC showed a statistically significant improvement in OS compared to BSoC alone, with a 35.4% increase in median OS. Common adverse reactions included fatigue, dry mouth, and nausea.","In the VISION study, Pluvicto plus best standard of care (BSoC) showed a significant improvement in overall survival (OS) and radiographic progression-free survival (rPFS) compared to BSoC alone in men with PSMA-positive mCRPC. The hazard ratio (HR) for OS was 0.62, with a median OS of 15.3 months in the Pluvicto plus BSoC arm versus 11.3 months in the BSoC arm. The trial also demonstrated a limited interpretation of the rPFS effect due to high censoring in the control arm. Overall, the combination of Pluvicto and BSoC showed promising results in improving survival outcomes for patients with metastatic castration-resistant prostate cancer."
page_144.txt,Pembrolizumab (Keytruda),Endometrial carcinoma,90,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '46%', 'DOR': 'Median not reached, 68% with response durations ≥12 months, 44% with response durations ≥24 months'}","Pembrolizumab was approved for patients with advanced endometrial carcinoma that is MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation. Efficacy was evaluated in a trial with 90 patients, showing an ORR of 46% and a median duration of response not reached, with a significant proportion having response durations ≥12 and ≥24 months.","In the KEYNOTE-158 study of 90 patients with unresectable or metastatic MSI-H or dMMR endometrial carcinoma, pembrolizumab showed promising efficacy. The objective response rate (ORR) was 46%, with a median duration of response (DoR) not reached. 68% of patients had response durations of at least 12 months, and 44% had response durations of at least 24 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study demonstrated encouraging response outcomes in this patient population, supporting the use of pembrolizumab in this setting."
page_145.txt,Opdualag (nivolumab and relatlimab),Metastatic or unresectable Stage III or IV melanoma,714,NR,34.1 months,Not statistically significant,10.1 months,4.6 months,"HR=0.75; 95% CI: 0.62, 0.92; p-value=0.0055","{'Adverse Reactions': ['musculoskeletal pain', 'fatigue', 'rash', 'pruritus', 'diarrhea'], 'Common Laboratory Abnormalities': ['decreased hemoglobin', 'decreased lymphocytes', 'increased AST', 'increased ALT', 'decreased sodium']}","Opdualag (nivolumab and relatlimab) showed a statistically significant improvement in progression-free survival compared to nivolumab in patients with metastatic or unresectable melanoma. However, the overall survival difference was not statistically significant. Common adverse reactions included musculoskeletal pain, fatigue, rash, pruritus, and diarrhea.","In the RELATIVITY-047 study, Opdualag (nivolumab and relatlimab) showed a significant improvement in progression-free survival (PFS) compared to nivolumab alone, with a median PFS of 10.1 months vs. 4.6 months. However, the overall survival (OS) results were not statistically significant, with a median OS not reached in the Opdualag arm and 34.1 months in the nivolumab arm. Response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not specifically mentioned in the summary provided."
page_146.txt,Olaparib (Lynparza),High-risk early breast cancer with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative,1836,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'IDFS': {'HR': '0.58', '95% CI': '0.46, 0.74', 'p-value': '<0.0001', '3-year IDFS': {'Olaparib': '86%', 'Placebo': '77%'}}, 'Overall Survival': {'HR': '0.68', '95% CI': '0.50, 0.91', 'p-value': '0.0091'}, 'Adverse Reactions': ['Nausea', 'Fatigue', 'Anemia', 'Vomiting', 'Headache', 'Diarrhea', 'Leukopenia', 'Neutropenia', 'Decreased appetite', 'Dysgeusia', 'Dizziness', 'Stomatitis']}","The FDA approved olaparib for the adjuvant treatment of high-risk early breast cancer patients with gBRCAm HER2-negative mutations. The OlympiA study showed a significant improvement in invasive disease-free survival and overall survival with olaparib compared to placebo. Common adverse reactions included nausea, fatigue, anemia, and vomiting. Olaparib demonstrated efficacy in reducing the risk of recurrence and death in this patient population.","The study showed that patients receiving olaparib had a significantly higher invasive disease-free survival (IDFS) rate compared to those receiving a placebo, with a hazard ratio (HR) of 0.58 and a 3-year IDFS of 86% vs. 77%. Overall survival (OS) was also improved in the olaparib arm, with a HR of 0.68 and fewer deaths (8% vs. 12%) compared to the placebo arm. The study demonstrated a statistically significant improvement in both IDFS and OS for patients receiving olaparib (Lynparza) compared to those receiving a placebo. Additional response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not specifically mentioned in the provided text."
page_147.txt,Nivolumab (Opdivo),Non-small cell lung cancer (NSCLC),358,"31.6 months (95% CI: 30.2, not reached)","20.8 months (95% CI: 14.0, 26.7)","Hazard ratio 0.63 (97.38% CI: 0.43, 0.91; p=0.0052)",Not provided,Not provided,Not provided,"{'Event-free Survival (EFS)': 'Median EFS 31.6 months in treatment arm vs 20.8 months in control arm', 'Pathologic Complete Response (pCR)': 'pCR rate 24% in treatment arm vs 2.2% in control arm', 'Adverse Reactions': 'Nausea, constipation, fatigue, decreased appetite, rash'}","FDA approved nivolumab with platinum-doublet chemotherapy for resectable NSCLC in the neoadjuvant setting, showing significant improvement in overall survival and pathologic complete response rates compared to chemotherapy alone.","In the CHECKMATE-816 study, patients with resectable NSCLC were randomized to receive nivolumab plus chemotherapy or chemotherapy alone. The study showed a significant improvement in event-free survival (EFS) with a median of 31.6 months in the nivolumab plus chemotherapy arm compared to 20.8 months in the chemotherapy alone arm. The hazard ratio was 0.63, indicating a lower risk of events in the nivolumab group. Additionally, the pathologic complete response (pCR) rate was higher in the nivolumab plus chemotherapy arm at 24% compared to 2.2% in the chemotherapy alone arm. These results suggest that the combination of nivolumab and chemotherapy may improve outcomes in patients with resectable NSCLC."
page_148.txt,Ciltacabtagene autoleucel (CARVYKTI),Multiple Myeloma,97,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '97.9%', 'Duration of Response (DOR)': '21.8 months'}","Ciltacabtagene autoleucel was approved for adult patients with relapsed or refractory multiple myeloma after multiple prior lines of therapy. The CARTITUDE-1 trial showed a high overall response rate of 97.9% with a median duration of response of 21.8 months. Adverse reactions included cytokine release syndrome and nervous system toxicities, leading to a boxed warning on the label.","The CARTITUDE-1 study evaluated ciltacabtagene autoleucel in 97 patients with relapsed or refractory multiple myeloma. The overall response rate (ORR) was 97.9%, with a median duration of response (DOR) of 21.8 months. The study showed promising efficacy in patients who had received at least three prior lines of therapy, including a PI, an IMiD, and an anti-CD38 monoclonal antibody. The study also found that the most common adverse events were cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Parkinsonism, Guillain-Barré syndrome, and cytopenia. These adverse events can be fatal or life-threatening."
page_149.txt,tebentafusp-tebn (Kimmtrak),metastatic uveal melanoma,378,21.7 months,16 months,51%,3.3 months,2.9 months,73%,"{'Adverse Reactions': ['cytokine release syndrome', 'rash', 'pyrexia', 'pruritus', 'fatigue', 'nausea', 'chills', 'abdominal pain', 'edema', 'hypotension', 'dry skin', 'headache', 'vomiting'], 'Laboratory Abnormalities': ['decreased lymphocyte count', 'increased creatinine', 'increased glucose', 'increased aspartate aminotransferase', 'increased alanine aminotransferase', 'decreased hemoglobin', 'decreased phosphate']}",The study evaluated the efficacy of tebentafusp-tebn in patients with metastatic uveal melanoma. Patients treated with tebentafusp-tebn showed a significant improvement in overall survival (OS) with a median OS of 21.7 months compared to 16 months in the control arm. Progression-free survival (PFS) was also improved in the treatment arm with a median PFS of 3.3 months compared to 2.9 months in the control arm. Common adverse reactions and laboratory abnormalities were reported.,"In a study of 378 patients with metastatic uveal melanoma, tebentafusp-tebn showed improved overall survival (OS) with a median of 21.7 months compared to 16 months in the investigator's choice arm. Progression-free survival (PFS) was also longer with tebentafusp-tebn at 3.3 months compared to 2.9 months in the investigator's choice arm. The response outcomes were not specifically mentioned in the summary provided. The study demonstrated a significant benefit in OS and PFS for patients treated with tebentafusp-tebn compared to standard treatment options like pembrolizumab, ipilimumab, or dacarbazine."
page_15.txt,asciminib (Scemblix),Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP),405,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Main Efficacy Outcome Measure': 'Major molecular response (MMR) rate at 48 weeks', 'MMR Rate at 48 weeks - Asciminib arm': '68%', 'MMR Rate at 48 weeks - IS-TKIs arm': '49%', 'Common Adverse Reactions': ['musculoskeletal pain', 'rash', 'fatigue', 'upper respiratory tract infection', 'headache', 'abdominal pain', 'diarrhea'], 'Common Laboratory Abnormalities': ['decreased lymphocyte count', 'decreased leukocyte count', 'decreased platelet count', 'decreased neutrophil count', 'decreased calcium corrected']}","Asciminib (Scemblix) received accelerated approval for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. The ASC4FIRST trial showed a significant improvement in major molecular response rate at 48 weeks with asciminib compared to investigator-selected tyrosine kinase inhibitors. Common adverse reactions included musculoskeletal pain, rash, and fatigue. The recommended dosage is 80 mg once daily or 40 mg twice daily.",Efficacy and
page_150.txt,Abatacept (Orencia),Acute Graft Versus Host Disease (aGVHD),N/A,97% OS rate at Day 180 after HSCT,84% OS rate at Day 180 after HSCT,13%,N/A,N/A,N/A,"{'Severe aGVHD-free survival': 'HR 0.55; 95% CI 0.26, 1.18', 'Moderate-severe aGVHD-free survival': 'HR 0.54; 95% CI 0.35, 0.83'}","Abatacept (Orencia) was approved for the prophylaxis of aGVHD in combination with a CNI and MTX for patients undergoing HSCT. The OS rate at Day 180 after HSCT was significantly higher in patients receiving abatacept compared to placebo, with a 13% improvement in OS. Additional evidence from a registry-based study also showed improved OS with abatacept. Common adverse reactions include anemia, hypertension, and infections. The drug received priority review, breakthrough designation, and orphan drug designation.","Overall, the use of abatacept in combination with a CNI and MTX in patients undergoing HSCT showed improved overall survival rates at Day 180 compared to placebo or CNI and MTX alone. In GVHD-1, patients receiving abatacept had a higher OS rate of 97% compared to 84% with placebo. In GVHD-2, patients treated with abatacept had an OS rate of 98% compared to 75% with CNI and MTX alone. While severe aGVHD-free survival was not significantly improved with abatacept, moderate-severe aGVHD-free survival was better with abatacept in both studies. These results suggest that abatacept may be effective in improving overall survival outcomes in patients undergoing HSCT from matched or 1 allele-mismatched unrelated donors."
page_151.txt,"Pembrolizumab (Keytruda, Merck)",Stage IIB or IIC melanoma,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,{'Recurrence-free survival (RFS)': 'Statistically significant improvement in RFS with hazard ratio of 0.65'},"Pembrolizumab was approved for adjuvant treatment of stage IIB or IIC melanoma following complete resection. The KEYNOTE-716 trial showed a significant improvement in recurrence-free survival with pembrolizumab compared to placebo. Common adverse reactions included fatigue, diarrhea, pruritus, and arthralgia.","In the KEYNOTE-716 study, patients with completely resected stage IIB or IIC melanoma were randomized to receive pembrolizumab or placebo. The trial showed a significant improvement in recurrence-free survival (RFS) with pembrolizumab compared to placebo, with a hazard ratio of 0.65. The median RFS was not reached in either arm at the time of the first interim analysis. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. Additional response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not mentioned in the study results."
page_152.txt,Rituximab,"Diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL)",328,Not provided,Not provided,64% (HR 0.36),Not provided,Not provided,Not provided,"{'EFS': 'HR 0.32; 90% CI: 0.17, 0.58; p=0.0012'}","Rituximab in combination with chemotherapy showed a 64% improvement in overall survival (HR 0.36) in pediatric patients with previously untreated advanced stage DLBCL, BL, BLL, or B-AL. The study demonstrated a significant reduction in event-free survival events in the rituximab group compared to chemotherapy alone.","In the Inter-B-NHL Ritux 2010 study, patients with previously untreated advanced stage CD20-positive DLBCL/BL/BLL/B-AL were randomized to receive LMB chemotherapy alone or in combination with rituximab. The interim analysis showed a significant improvement in event-free survival (EFS) with rituximab-LMB compared to LMB alone (HR 0.32). Overall survival (OS) also favored the rituximab-LMB group, with a HR of 0.36. Response outcomes were not specifically mentioned in the summary, but the addition of rituximab to chemotherapy showed promising results in terms of EFS and OS in this patient population."
page_153.txt,Darzalex Faspro + Kyprolis + Dexamethasone,Multiple Myeloma,66,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '84.8%', 'DOR': 'Median duration of response not reached', 'Maintained Response (6 months)': '85.2%', 'Maintained Response (9 months)': '82.5%'}","The study evaluated the efficacy of Darzalex Faspro, Kyprolis, and dexamethasone in 66 patients with relapsed or refractory multiple myeloma. The overall response rate was 84.8%, with a median duration of response not reached. A high percentage of patients maintained response for at least 6 and 9 months. Common adverse reactions included upper respiratory tract infections, fatigue, and hypertension.","In the PLEIADES study, a cohort of 66 relapsed or refractory multiple myeloma patients received Darzalex Faspro, Kyprolis, and dexamethasone. The overall response rate (ORR) was 84.8%, with a median duration of response not reached at 9.2 months. 85.2% maintained response for at least 6 months, and 82.5% maintained response for at least 9 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary."
page_154.txt,Pafolacianine (Cytalux),Ovarian cancer,178,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': 'Not provided', 'DOR': 'Not provided'}","Pafolacianine was approved for adult patients with ovarian cancer for intraoperative identification of malignant lesions. Efficacy was evaluated in a study of 178 women, showing improved detection of ovarian cancer lesions with pafolacianine. Common adverse reactions included nausea, vomiting, and abdominal pain. The recommended dose is 0.025 mg/kg administered intravenously before surgery.","In a study of 178 women with ovarian cancer or high suspicion, pafolacianine was used for fluorescence imaging during surgery. 26.9% of patients had ovarian cancer lesions detected with pafolacianine that were missed by standard inspection. The false positive rate of pafolacianine was 20.2%. Overall Survival (OS) and Progression-Free Survival (PFS) outcomes were not reported."
page_155.txt,Sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro),Locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa),31,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '39% (95% CI: 22%, 58%)', 'Duration of Response (DOR)': 'Median DOR not reached (95% CI: 6.5 months, not estimable)', 'Response lasting >12 months': '67%', 'Response lasting >24 months': '58%'}","Sirolimus protein-bound particles were approved for adult patients with locally advanced unresectable or metastatic malignant PEComa. Efficacy was evaluated in a clinical trial with 31 patients, showing a 39% overall response rate and a median duration of response not reached. Common adverse reactions included stomatitis, fatigue, rash, and others. The recommended dosage is 100 mg/m2 administered on specific days of each cycle.","The AMPECT study evaluated the efficacy of sirolimus protein-bound particles in 31 patients with malignant PEComa. The overall response rate (ORR) was 39%, with 2 patients achieving complete responses. The median duration of response (DOR) was not reached, with 67% of responders having a response lasting over 12 months and 58% lasting over 24 months. The study showed promising outcomes in terms of response outcomes. The progression-free survival (PFS) and overall survival (OS) data were not provided in the summary."
page_156.txt,Pembrolizumab (Keytruda),Renal cell carcinoma (RCC),994,Not mature at the time of the study,Not mature at the time of the study,Not applicable,Not provided in the study,Not provided in the study,Not applicable,"{'DFS': 'Hazard Ratio (HR) 0.68; 95% CI: 0.53, 0.87; p=0.0010', 'Adverse Reactions': ['Musculoskeletal pain', 'Fatigue', 'Rash', 'Diarrhea', 'Pruritus', 'Hypothyroidism']}","Pembrolizumab was approved for adjuvant treatment of RCC patients at intermediate-high or high risk of recurrence. The KEYNOTE-564 trial showed a statistically significant improvement in disease-free survival with pembrolizumab compared to placebo. Overall survival data were not mature at the time of the study. Common adverse reactions included musculoskeletal pain, fatigue, rash, diarrhea, pruritus, and hypothyroidism.","In the KEYNOTE-564 study, pembrolizumab showed a significant improvement in disease-free survival (DFS) compared to placebo in patients with intermediate-high or high risk of recurrence of renal cell carcinoma (RCC). The median DFS was not reached in either arm, but the pembrolizumab group had a lower risk of recurrence, metastasis, or death. Overall survival (OS) data were not mature at the time of the analysis. The study demonstrated a statistically significant difference in DFS with a hazard ratio of 0.68. Further data on OS and response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not fully reported in the summary."
page_157.txt,asciminib (Scemblix),Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP),233,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'MMR at 24 weeks': {'asciminib': '25%', 'bosutinib': '13%'}, 'MMR at 96 weeks': {'asciminib': '49%'}, 'Common Adverse Reactions': ['upper respiratory tract infections', 'musculoskeletal pain', 'fatigue', 'nausea', 'rash', 'diarrhea'], 'Common Laboratory Abnormalities': ['decreased platelet counts', 'increased triglycerides', 'decreased neutrophil counts', 'decreased hemoglobin', 'increased creatine kinase', 'increased alanine aminotransferase', 'increased lipase', 'increased amylase']}","Asciminib (Scemblix) has shown promising results in patients with Ph+ CML in CP, previously treated with two or more TKIs, and in patients with the T315I mutation. The MMR rates were higher with asciminib compared to bosutinib, and the drug demonstrated manageable adverse reactions and laboratory abnormalities. The recommended doses for different patient populations were provided, and the FDA expedited programs facilitated the approval process.","In the oncology study evaluating asciminib in patients with Ph+ CML in CP with the T315I mutation, the major molecular response (MMR) rate at 24 weeks was 25%. The median duration of MMR has not been reached after a follow-up of 20 months. In patients with the T315I mutation, MMR was achieved by 42% at 24 weeks and 49% at 96 weeks. The median duration of treatment was 108 weeks. Overall survival (OS) and progression-free survival (PFS) data were not provided in the study results. Asciminib showed a higher MMR rate compared to bosutinib in this patient population."
page_158.txt,Atezolizumab (Tecentriq),Non-small cell lung cancer (NSCLC),1005,Not reached,35.3 months,34%,Not provided,Not provided,Not provided,"{'Adverse Reactions': ['Increased aspartate aminotransferase', 'Blood creatinine', 'Alanine aminotransferase', 'Hyperkalemia', 'Rash', 'Cough', 'Hypothyroidism', 'Pyrexia', 'Fatigue/asthenia', 'Musculoskeletal pain', 'Peripheral neuropathy', 'Arthralgia', 'Pruritus'], 'Recommended Dose': ['840 mg every 2 weeks', '1200 mg every 3 weeks', '1680 mg every 4 weeks for up to 1 year']}","Atezolizumab was approved for adjuvant treatment in NSCLC patients with PD-L1 expression on ≥1% of tumor cells following resection and platinum-based chemotherapy. In a randomized trial, atezolizumab showed a 34% improvement in overall survival compared to best supportive care. Common adverse reactions included increased liver enzymes, rash, and fatigue. The recommended dose is 840-1680 mg every 2-4 weeks for up to 1 year.","The IMpower010 study showed that in patients with stage II-IIIA NSCLC with PD-L1 expression on ≥1% of tumor cells, atezolizumab significantly improved disease-free survival (DFS) compared to best supportive care (BSC). Median DFS was not reached in the atezolizumab arm versus 35.3 months in the BSC arm, with a hazard ratio (HR) of 0.66. In patients with PD-L1 TC ≥ 50%, the DFS HR was 0.43. Atezolizumab demonstrated efficacy in this population, with a favorable safety profile. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary."
page_159.txt,Pembrolizumab (Keytruda),Cervical cancer,617,"Not reached (95% CI: 19.8, NR)","16.3 months (95% CI: 14.5, 19.4)","HR 0.64; 95% CI: 0.50, 0.81; 1-sided p-value = 0.0001","10.4 months (95% CI: 9.7, 12.3)","8.2 months (95% CI: 6.3, 8.5)","HR 0.62; 95% CI: 0.50, 0.77; 1-sided p-value < 0.0001","{'ORR': '68% (pembrolizumab) vs. 50% (placebo)', 'DOR': '18.0 months (pembrolizumab) vs. 10.4 months (placebo)'}","Pembrolizumab in combination with chemotherapy showed significant improvement in overall survival and progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer. The treatment arm demonstrated better objective response rates and longer duration of response compared to the control arm.","In a study focusing on patients with tumors expressing PD-L1, pembrolizumab showed significant improvements in overall survival (OS) with a median not reached compared to 16.3 months in the placebo arm. Progression-free survival (PFS) was also longer in the pembrolizumab arm at 10.4 months compared to 8.2 months in the placebo arm. The objective response rates were higher with pembrolizumab at 68% compared to 50% with placebo, and the median duration of response (DoR) was longer at 18.0 months with pembrolizumab compared to 10.4 months with placebo. These results suggest that pembrolizumab is effective in improving OS, PFS, and response outcomes in patients with PD-L1 expressing tumors."
page_16.txt,Zolbetuximab-clzb (Vyloy),Locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma,"{'SPOTLIGHT': 565, 'GLOW': 507}","{'SPOTLIGHT': '18.2 months', 'GLOW': '14.4 months'}","{'SPOTLIGHT': '15.5 months', 'GLOW': '12.2 months'}","{'SPOTLIGHT': '17.4%', 'GLOW': '18.0%'}","{'SPOTLIGHT': '10.6 months', 'GLOW': '8.2 months'}","{'SPOTLIGHT': '8.7 months', 'GLOW': '6.8 months'}","{'SPOTLIGHT': '22.5%', 'GLOW': '20.6%'}",{},"Zolbetuximab-clzb in combination with chemotherapy showed significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to placebo in patients with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma. The treatment demonstrated a PFS improvement of 22.5% in SPOTLIGHT and 20.6% in GLOW, with OS improvements of 17.4% and 18.0% respectively.",Efficacy and
page_160.txt,Abemaciclib (Verzenio),"HR-positive, HER2-negative, node-positive, early breast cancer",2003,Data not mature,Data not mature,Data not available,Data not available,Data not available,Data not available,"{'Major Efficacy Outcome Measure': 'Invasive Disease-Free Survival (IDFS)', 'Common Adverse Reactions': ['Diarrhea', 'Infections', 'Neutropenia', 'Fatigue', 'Leukopenia', 'Nausea', 'Anemia', 'Headache'], 'Recommended Abemaciclib Starting Dose': '150 mg taken twice daily in combination with tamoxifen or an aromatase inhibitor'}","Abemaciclib in combination with endocrine therapy showed a statistically significant improvement in invasive disease-free survival in patients with high-risk early breast cancer. Overall survival data were not mature at the time of analysis. Common adverse reactions included diarrhea, infections, and fatigue. The recommended starting dose of abemaciclib is 150 mg twice daily with endocrine therapy.","In the monarchE study, patients with high-risk early breast cancer showed a significant improvement in invasive disease-free survival (IDFS) when treated with 2 years of abemaciclib plus standard endocrine therapy compared to standard endocrine therapy alone. The IDFS at 36 months was 86.1% for the abemaciclib group and 79.0% for the standard therapy group. Overall survival data were not yet mature. The study focused on patients with HR-positive, HER2-negative, node-positive breast cancer with a high risk of recurrence and Ki-67 Score ≥20%. Response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not specifically mentioned in the summary provided."
page_161.txt,,,,,,,,,,{},The FDA recognized a portion of the OncoKB database as a valid source of scientific evidence for clinical and potential clinical significance biomarkers in tumor profiling tests. The database contains detailed information on alterations in 682 cancer genes curated from various sources worldwide. This recognition allows test developers to use the data to support the clinical validity of tumor profiling tests in premarket submissions.,N/A
page_162.txt,brexucabtagene autoleucel (Tecartus),B-cell precursor acute lymphoblastic leukemia (ALL),54,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Complete Response Rate (CR)': '52%', 'Duration of CR': 'Median duration not reached; estimated to exceed 12 months for more than half the patients', 'Adverse Reactions': ['Cytokine release syndrome (CRS)', 'Neurologic toxicities', 'Fever', 'Hypotension', 'Encephalopathy', 'Tachycardias', 'Nausea', 'Chills', 'Headache', 'Fatigue', 'Febrile neutropenia', 'Diarrhea', 'Musculoskeletal pain', 'Hypoxia', 'Rash', 'Edema', 'Tremor', 'Infection with pathogen unspecified', 'Constipation', 'Decreased appetite', 'Vomiting']}","Brexucabtagene autoleucel showed a 52% complete response rate in adult patients with relapsed or refractory B-cell precursor ALL. The median duration of complete response was not reached, with an estimated duration exceeding 12 months for more than half the patients. Adverse reactions included cytokine release syndrome, neurologic toxicities, and common non-laboratory adverse events. The recommended dose is a single intravenous infusion preceded by lymphodepleting chemotherapy.","In the ZUMA-3 study, brexucabtagene autoleucel showed promising efficacy in adults with relapsed or refractory B-cell precursor ALL. 52% of patients achieved a complete response (CR) within 3 months of infusion, with a median duration of CR not reached at a median follow-up of 7.1 months. The duration of CR was estimated to exceed 12 months for over half of the patients. However, the therapy comes with risks, as 92% of patients experienced cytokine release syndrome (CRS) and 87% experienced neurologic toxicities. Grade ≥3 CRS was seen in 26% of patients, while Grade ≥3 neurologic toxicities were seen in 35% of patients."
page_163.txt,Ruxolitinib (Jakafi),Chronic graft-versus-host disease (cGVHD),329,"25 months (95% CI 16.8, NE)","5.6 months (95% CI 4.1, 7.8)",N/A,"4.2 months (95% CI 3.2, 6.7)","2.1 months (95% CI 1.6, 3.2)",N/A,"{'Overall Response Rate (ORR)': {'Ruxolitinib Arm': '70% (95% CI 63%, 77%)', 'BAT Arm': '57% (95% CI 49%, 65%)', 'Difference in Response Rate': '13% (95% CI 3%, 23%)'}, 'Median Durations of Response': {'Ruxolitinib Arm': '4.2 months (95% CI 3.2, 6.7)', 'BAT Arm': '2.1 months (95% CI 1.6, 3.2)'}}","Ruxolitinib was approved for the treatment of chronic graft-versus-host disease in patients who failed one or two lines of systemic therapy. In a clinical trial, ruxolitinib showed a higher overall response rate (70%) compared to best available therapy (57%). The median overall survival was significantly longer in the ruxolitinib arm (25 months) compared to the control arm (5.6 months). Adverse reactions included anemia, thrombocytopenia, infections, and viral infections.","The REACH-3 study compared ruxolitinib to best available therapy for corticosteroid-refractory chronic GVHD after stem cell transplantation. The overall response rate (ORR) was 70% for ruxolitinib and 57% for BAT, with a difference of 13%. The median duration of response was 4.2 months for ruxolitinib and 2.1 months for BAT. The median time from first response to death or new therapies was 25 months for ruxolitinib and 5.6 months for BAT. Ruxolitinib showed superior efficacy in terms of ORR and duration of response compared to BAT in this study."
page_164.txt,tisotumab vedotin-tftv (Tivdak),recurrent or metastatic cervical cancer,101,not provided,not provided,not provided,not provided,not provided,not provided,"{'ORR': '24%', 'DOR': '8.3 months'}","Accelerated approval was granted to tisotumab vedotin-tftv for adult patients with recurrent or metastatic cervical cancer based on the innovaTV 204 trial. The study included 101 patients with a 24% objective response rate and a median response duration of 8.3 months. Common adverse reactions included hemoglobin decreased, fatigue, and peripheral neuropathy.","In a study of 101 patients with recurrent or metastatic cervical cancer, tisotumab vedotin-tftv showed an objective response rate (ORR) of 24% and a median response duration of 8.3 months. Overall survival (OS) and progression-free survival (PFS) data were not provided. Sixty-nine percent of patients had previously received bevacizumab. The study focused on patients who had received no more than two prior systemic regimens, including at least one platinum-based chemotherapy regimen. The results suggest that tisotumab vedotin-tftv may be a potential treatment option for patients with recurrent or metastatic cervical cancer."
page_165.txt,Cabometyx (cabozantinib),Differentiated Thyroid Cancer (DTC),Not specified,Not specified,Not specified,Not specified,11.0 months,1.9 months,478.95%,"{'ORR': '18%', 'DOR': 'Not specified'}","Cabometyx (cabozantinib) was approved for locally advanced or metastatic DTC patients who had progressed following VEGFR-targeted therapy and were ineligible or refractory to radioactive iodine. In a clinical trial, Cabometyx significantly improved progression-free survival with a median PFS of 11.0 months compared to 1.9 months in the placebo arm. The overall response rate was 18% in the Cabometyx arm. Common adverse reactions included diarrhea, PPE, fatigue, hypertension, and stomatitis.","In the COSMIC-311 study, cabozantinib showed significant efficacy in patients with locally advanced or metastatic differentiated thyroid cancer (DTC) who had previously received VEGFR-targeted therapy and were ineligible for radioactive iodine. Cabozantinib demonstrated a median progression-free survival (PFS) of 11.0 months compared to 1.9 months with placebo, reducing the risk of disease progression or death. The overall response rate (ORR) was 18% with cabozantinib and 0% with placebo. These results indicate that cabozantinib is effective in improving PFS and ORR in this patient population."
page_166.txt,Mobocertinib (Exkivity),Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations,114,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '28%', 'Response Duration': 'Median of 17.5 months'}","Mobocertinib (Exkivity) was granted accelerated approval by the FDA for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The approval was based on Study 101, which showed an overall response rate of 28% and a median response duration of 17.5 months in 114 patients. Common adverse reactions included diarrhea, rash, nausea, and others. The recommended dose is 160 mg orally daily until disease progression or intolerable toxicity.","In a study of 114 patients with advanced cancer who had previously received platinum-based chemotherapy, treatment with mobocertinib resulted in an overall response rate (ORR) of 28%. The median response duration was 17.5 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study focused on evaluating response outcomes such as complete response (CR) and partial response (PR) according to RECIST 1.1 criteria. The results suggest that mobocertinib shows promising efficacy in this patient population, with a notable ORR and durable response duration."
page_167.txt,Zanubrutinib (Brukinsa),Marginal Zone Lymphoma (MZL),86,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Trial 1': {'Overall Response Rate': '56%', 'Complete Response Rate': '20%'}, 'Trial 2': {'Overall Response Rate': '80%', 'Complete Response Rate': '20%'}}, 'DOR': {'Median Duration of Response': 'Not estimable', '1-year DoR Rate': {'Trial 1': '85%', 'Trial 2': '72%'}}, 'Adverse Reactions': {'Common Reactions': ['Decreased neutrophil count', 'Upper respiratory tract infection', 'Decreased platelet count', 'Hemorrhage', 'Decreased lymphocyte count', 'Rash', 'Musculoskeletal pain'], 'Serious Reactions': '40% of patients experienced serious adverse reactions, most commonly pyrexia and pneumonia'}}","Zanubrutinib (Brukinsa) received accelerated approval for adult patients with relapsed or refractory MZL based on two trials showing promising overall response rates and duration of response. Common adverse reactions were reported, with serious reactions occurring in 40% of patients. The recommended dosage is 160 mg orally twice daily or 320 mg orally once daily. Continued approval may be contingent upon further clinical benefit confirmation in a confirmatory trial.","efficacy measures were overall response rate (ORR) and duration of response (DoR), as assessed by an independent review committee using the 2014 Lugano criteria. In the first trial, the CT-based ORR was 56% (95% CI: 43%, 68%), with 20% achieving complete responses (CR). In the second trial, the ORR was 80% (95% CI: 56%, 94%), with a CR rate of 20%. The median DoR was not estimable; the estimated 1-year rate of DoR was 85% (95% CI: 67, 93) and 72% (95% CI: 40, 88), respectively.
The most common"
page_168.txt,Zanubrutinib,Waldenström’s macroglobulinemia,201,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Response Rate': '77.5% in zanubrutinib arm', 'Duration of Response at 12 months': '94.4% in zanubrutinib arm', 'Response Rate in Cohort 2': '50% in zanubrutinib arm'}","Zanubrutinib was approved for adult patients with Waldenström’s macroglobulinemia based on the ASPEN trial, showing a response rate of 77.5% and a duration of response at 12 months of 94.4% in the zanubrutinib arm. Common adverse reactions include neutrophil count decreased, upper respiratory tract infection, and rash.","The study on zanubrutinib in Waldenström’s Macroglobulinemia showed a response rate of 77.5% in the zanubrutinib arm, with a duration of response at 12 months of 94.4%. In Cohort 2, a response was seen in 50% of patients. The efficacy outcomes were based on response rate (CR+VGPR+PR) and duration of response (DOR). The study results support the approval of zanubrutinib for this indication."
page_169.txt,Ivosidenib (Tibsovo),Cholangiocarcinoma,185,Not significant,Not significant,N/A,"HR 0.37; 95% CI: 0.25, 0.54; p<0.0001",N/A,N/A,"{'Adverse Reactions': ['Fatigue', 'Nausea', 'Abdominal pain', 'Diarrhea', 'Cough', 'Decreased appetite', 'Ascites', 'Vomiting', 'Anemia', 'Rash']}","Ivosidenib was approved for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. A clinical trial showed a significant improvement in progression-free survival with ivosidenib treatment. Overall survival analysis was not significant, likely impacted by patients crossing over to receive ivosidenib after disease progression. Common adverse reactions included fatigue, nausea, and abdominal pain.","efficacy endpoint was progression-free survival (PFS) as determined by independent review committee according to RECIST 1.1. The trial demonstrated a statistically significant improvement in PFS for patients randomized to ivosidenib (HR 0.37; 95% CI: 0.25, 0.54; p<0.0001). The analysis of OS was not significant (0.79; 95% CI: 0.56, 1.12; p=0.093); 70% of patients randomized to placebo had crossed over to receive ivosidenib after radiographic disease progression.
The most common"
page_17.txt,"Inavolisib (Itovebi, Genentech, Inc.) with palbociclib and fulvestrant","Endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer",325,Not provided,Not provided,Not provided,15.0 months,7.3 months,51.40%,"{'ORR': '58% in treatment arm, 25% in control arm', 'DOR': '18.4 months in treatment arm, 9.6 months in control arm'}","Inavolisib with palbociclib and fulvestrant showed a significant improvement in progression-free survival (PFS) compared to placebo in patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative breast cancer. The treatment arm demonstrated a 51.4% improvement in PFS, along with higher objective response rate (ORR) and longer duration of response (DOR) compared to the control arm.",Efficacy and
page_170.txt,Nivolumab (Opdivo),Urothelial Carcinoma (UC),Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"{'Primary Efficacy Endpoint': 'Investigator-assessed disease-free survival (DFS)', 'Common Adverse Reactions': ['Rash', 'Fatigue', 'Diarrhea', 'Pruritus', 'Musculoskeletal pain', 'Urinary tract infection']}","Nivolumab was approved for adjuvant treatment of high-risk UC patients post-radical resection. CHECKMATE-274 trial showed significant improvement in disease-free survival with nivolumab vs. placebo. Common adverse reactions included rash, fatigue, and diarrhea.","The study showed a statistically significant improvement in disease-free survival (DFS) with nivolumab compared to placebo in patients with tumors expressing PD-L1 ≥1%. The median DFS was 20.8 months with nivolumab versus 10.8 months with placebo in the intent-to-treat (ITT) population. For patients with PD-L1 ≥1%, the median DFS was not reached with nivolumab compared to 8.4 months with placebo. In patients with PD-L1-negative tumors, the DFS hazard ratio estimate was 0.83. Overall survival (OS) data is still immature, with 33% of deaths in the randomized population. In the UTUC subpopulation, there were 20 deaths in the nivolumab arm and 17 in the placebo arm. Further analysis is needed to fully assess the impact of nivolumab on OS and response outcomes."
page_171.txt,dostarlimab-gxly (Jemperli),mismatch repair deficient (dMMR) recurrent or advanced solid tumors,209,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '41.6%', 'Duration of Response (DoR)': 'Median 34.7 months, 95.4% with duration ≥6 months'}","The FDA granted accelerated approval to dostarlimab-gxly for adult patients with dMMR recurrent or advanced solid tumors who have progressed on prior treatment. The GARNET Trial showed an overall response rate of 41.6% with a median duration of response of 34.7 months. Common adverse reactions include fatigue, anemia, diarrhea, and nausea. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials.","The GARNET Trial evaluated the efficacy of dostarlimab in 209 patients with dMMR recurrent or advanced solid tumors. The study found an overall response rate (ORR) of 41.6%, with a complete response rate of 9.1% and a partial response rate of 32.5%. The median duration of response (DoR) was 34.7 months, with 95.4% of patients having a response lasting at least 6 months. These results suggest that dostarlimab shows promising efficacy in patients who progressed following systemic therapy with no satisfactory alternative treatment options."
page_172.txt,Belzutifan (Welireg),"Von Hippel-Lindau (VHL) disease associated with renal cell carcinoma (RCC), CNS hemangioblastomas, or pancreatic neuroendocrine tumors (pNET)",61,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR (Overall Response Rate) in VHL-RCC': '49%', 'ORR in CNS hemangioblastomas': '63%', 'ORR in pNET': '83%', 'Duration of Response (DoR) in responders': '≥12 months', 'Time-to-Response (TTR)': 'Median 8 months'}","Belzutifan (Welireg) was approved for adult patients with VHL disease associated with RCC, CNS hemangioblastomas, or pNET. In a study of 61 patients, significant response rates were observed in VHL-RCC, CNS hemangioblastomas, and pNET. Common adverse reactions included anemia, fatigue, and increased creatinine. Belzutifan dosage is 120 mg once daily. The FDA expedited the review process, granting priority review for this indication.","Overall, the study showed promising results in patients with VHL-associated RCC, with an overall response rate (ORR) of 49%. The median duration of response (DoR) was not reached, with 56% of responders having a DoR of at least 12 months. In patients with other VHL-associated non-RCC tumors, such as CNS hemangioblastomas and pNET, the ORR was 63% and 83% respectively. The median DoR was also not reached for these patients, with a significant percentage having response durations of at least 12 months. These findings suggest that the treatment was effective in these patient populations, with durable responses and high response rates."
page_173.txt,Lenvatinib plus pembrolizumab,Renal cell carcinoma (RCC),355 (Lenvatinib plus pembrolizumab) and 357 (Sunitinib),Not reached,Not reached,"HR 0.66; 95% CI: 0.49, 0.88; p=0.0049","23.9 months (95% CI: 20.8, 27.7)","9.2 months (95% CI: 6.0, 11.0)","HR 0.39; 95% CI: 0.32, 0.49; p<0.0001","{'Objective Response Rate': '71% (combination) vs. 36% (sunitinib)', 'Complete Response Rate': '16% (combination) vs. 4% (sunitinib)', 'Adverse Reactions': ['Fatigue', 'Diarrhea', 'Musculoskeletal pain', 'Hypothyroidism', 'Hypertension', 'Stomatitis', 'Decreased appetite', 'Rash', 'Nausea', 'Decreased weight', 'Dysphonia', 'Proteinuria', 'Palmar-plantar erythrodysesthesia syndrome', 'Abdominal pain', 'Hemorrhagic events', 'Vomiting', 'Constipation', 'Hepatotoxicity', 'Headache', 'Acute kidney injury', 'Arterial thrombotic events (5% of patients)']}","The combination of lenvatinib plus pembrolizumab showed significant improvements in progression-free survival and overall survival compared to single-agent sunitinib in patients with advanced RCC. Adverse reactions were reported, including arterial thrombotic events. The FDA expedited the review process and granted priority review and breakthrough therapy designation for this indication.","In the CLEAR study, the combination of lenvatinib and pembrolizumab showed significant efficacy in patients with advanced RCC. Patients on this combination had a median PFS of 23.9 months compared to 9.2 months with sunitinib. The median OS was not reached in either arm, but the combination showed a significant improvement with a HR of 0.66. The objective response rate was 71% with the combination compared to 36% with sunitinib, with complete response rates of 16% and 4% respectively. Overall, the lenvatinib plus pembrolizumab combination demonstrated superior PFS, OS, and response outcomes compared to single-agent sunitinib in the first-line setting for advanced RCC patients."
page_174.txt,Pembrolizumab (Keytruda),Triple-negative breast cancer (TNBC),1174,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'pCR Rate': '63% with pembrolizumab + chemotherapy vs. 56% with chemotherapy alone', 'Event Free Survival (EFS) HR': '0.63 (p=0.00031)'}","Pembrolizumab in combination with chemotherapy showed a higher pathological complete response rate and improved event-free survival in patients with high-risk early-stage TNBC. Common adverse reactions were reported, and the drug received accelerated approval for this indication.","In the KEYNOTE-522 study, pembrolizumab in combination with neoadjuvant chemotherapy followed by surgery and adjuvant pembrolizumab showed improved outcomes in patients with high-risk early-stage TNBC. The study found a higher pathological complete response (pCR) rate of 63% with pembrolizumab plus chemotherapy compared to 56% with chemotherapy alone. The event-free survival (EFS) was also better with pembrolizumab, with a lower number of patients experiencing EFS events (16% vs. 24%). Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study included patients regardless of tumor PD-L1 expression. These results suggest that pembrolizumab in combination with chemotherapy may be a promising treatment option for this patient population."
page_175.txt,Pembrolizumab (Keytruda) in combination with Lenvatinib (Lenvima),Advanced endometrial carcinoma,827,17.4 months,12.0 months,31%,6.6 months,3.8 months,74%,"{'ORR': '30%', 'DOR': '9.2 months'}",Pembrolizumab in combination with Lenvatinib showed significant improvement in overall survival (31% improvement) and progression-free survival (74% improvement) compared to standard chemotherapy in patients with advanced endometrial carcinoma. The treatment also demonstrated a higher objective response rate of 30% and a longer duration of response of 9.2 months.,"In patients with advanced endometrial cancer not MSI-H or dMMR, the combination of pembrolizumab and lenvatinib showed improved outcomes compared to standard chemotherapy. The pembrolizumab and lenvatinib group had a longer median progression-free survival (6.6 vs. 3.8 months), overall survival (17.4 vs. 12.0 months), higher objective response rate (30% vs. 15%), and longer duration of response (9.2 vs. 5.7 months). These results suggest that the pembrolizumab and lenvatinib combination may be a more effective treatment option for this patient population."
page_176.txt,Belumosudil (Rezurock),Chronic graft-versus-host disease (chronic GVHD),65,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '75%', 'Complete Response (CR)': '6%', 'Partial Response (PR)': '69%', 'Median Time to First Response': '1.8 months', 'Median Duration of Response': '1.9 months', 'Percentage of patients with no death or new systemic therapy initiation for at least 12 months since response': '62%'}","Belumosudil (Rezurock) was approved for adult and pediatric patients with chronic GVHD after failure of at least two prior lines of systemic therapy. The main efficacy outcome measure was an overall response rate of 75%, with a median time to first response of 1.8 months. The most common adverse reactions included infections, asthenia, nausea, and diarrhea.","In the study, patients with chronic GVHD treated with belumosudil 200 mg once daily had an overall response rate (ORR) of 75%, with 6% achieving a complete response (CR) and 69% achieving a partial response (PR). The median time to first response was 1.8 months, and the median duration of response was 1.9 months. 62% of patients who achieved a response did not experience death or require new systemic therapy initiation for at least 12 months since response. Overall survival (OS) and progression-free survival (PFS) data were not specifically mentioned in the study results."
page_177.txt,Darzalex Faspro,Multiple Myeloma,304,Not provided,Not provided,Not provided,12.4 months,6.9 months,37%,"{'Adverse Reactions': ['fatigue', 'pneumonia', 'upper respiratory tract infection', 'diarrhea']}","The FDA approved Darzalex Faspro in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received prior therapy. In the APOLLO trial, the combination showed a significant improvement in progression-free survival compared to pomalidomide and dexamethasone alone, with a 37% reduction in the risk of disease progression or death.","In the APOLLO study, Darzalex Faspro with pomalidomide and dexamethasone (Pd) showed improved efficacy compared to Pd alone in patients with multiple myeloma. The median progression-free survival (PFS) was 12.4 months with Darzalex Faspro-Pd versus 6.9 months with Pd alone, representing a 37% reduction in the risk of disease progression or death. Overall survival (OS) data was not provided. The study also reported positive response outcomes, although specific details were not mentioned. Darzalex Faspro-Pd combination therapy demonstrated significant benefit in terms of PFS compared to Pd alone in this patient population."
page_178.txt,Enfortumab vedotin-ejfv (Padcev),Locally advanced or metastatic urothelial cancer,608,12.9 months,9.0 months,30%,5.6 months,3.7 months,51.40%,"{'ORR': '40.6%', 'DOR': '13.8 months'}",Enfortumab vedotin-ejfv showed significant improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy in patients with locally advanced or metastatic urothelial cancer who had previously received PD-1 or PD-L1 inhibitors and platinum-based chemotherapy. The drug also demonstrated a high overall response rate (ORR) of 40.6% and a median response duration of 13.8 months.,"In a study comparing EV arm to chemotherapy in urothelial cancer patients, the EV arm showed a longer median OS of 12.9 months compared to 9.0 months with chemotherapy. The median PFS was also longer at 5.6 months for the EV arm versus 3.7 months for chemotherapy. The ORR was significantly higher in the EV arm at 40.6% compared to 17.9% with chemotherapy. In patients ineligible for cisplatin-containing chemotherapy, the EV treatment showed a confirmed ORR of 51% with 22% complete responses, and a median response duration of 13.8 months. These results suggest that EV treatment may provide better overall survival, progression-free survival, and response outcomes compared to chemotherapy in urothelial cancer patients."
page_179.txt,Asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze),Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL),102,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Main Efficacy Outcome Measure': 'Achievement and maintenance of nadir serum asparaginase activity (NSAA) above 0.1 U/mL', 'Common Adverse Reactions': ['Abnormal liver test', 'Nausea', 'Musculoskeletal pain', 'Fatigue', 'Infection', 'Headache', 'Pyrexia', 'Drug hypersensitivity', 'Febrile neutropenia', 'Decreased appetite', 'Stomatitis', 'Bleeding', 'Hyperglycemia']}","Asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) was approved for the treatment of ALL and LBL in patients with hypersensitivity to E. coli-derived asparaginase. The efficacy was evaluated in a trial with 102 patients, showing a high proportion of patients maintaining NSAA levels. Common adverse reactions were reported. The drug received fast track and orphan drug designation, and the FDA approval was expedited through the RTOR pilot program.","In Study JZP458-201, Rylaze showed high efficacy in 102 patients with ALL or LBL who were hypersensitive to E. coli-derived asparaginase. The main outcome measure was maintaining nadir serum asparaginase activity (NSAA) above 0.1 U/mL. Results indicated that a dosage of 25 mg/m2 administered every 48 hours resulted in 93.6% of patients maintaining NSAA ≥ 0.1 U/mL. Overall Survival (OS) and Progression-Free Survival (PFS) data were not provided. Response outcomes such as Overall Response Rate (ORR), Duration of Response (DOR), Complete Response (CR), and Partial Response (PR) were also not reported in the study."
page_18.txt,Nivolumab (Opdivo),Non-small cell lung cancer (NSCLC),461,Not formally tested for statistical significance,Not provided,Not provided,Not provided,Not provided,Not provided,"{'EFS': 'Event-free survival (EFS) by blinded independent central review', 'Adverse Reactions': 'Similar to those in other clinical trials of nivolumab with chemotherapy'}","Nivolumab with platinum-doublet chemotherapy as neoadjuvant and adjuvant treatment for resectable NSCLC showed promising results in terms of event-free survival. Overall survival was not formally tested for statistical significance, but no detriment was observed. Adverse reactions were manageable, with a small percentage of patients experiencing delays in surgery or being unable to undergo surgery due to adverse reactions.",Efficacy and
page_180.txt,Avapritinib (Ayvakit™),Advanced systemic mastocytosis (AdvSM),53,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': 'Overall response rate of 57%', 'DOR': 'Median duration of response was 38.3 months', 'Time to Response': 'Median time to response was 2.1 months'}","Avapritinib was approved for adult patients with AdvSM, showing an overall response rate of 57% with a median duration of response of 38.3 months. The most common adverse reactions were edema, diarrhea, nausea, and fatigue/asthenia.","In the EXPLORER and PATHFINDER trials for AdvSM patients, treatment with avapritinib showed promising efficacy outcomes. The overall response rate (ORR) was 57%, with 28% achieving complete remissions and 28% achieving partial remissions. The median duration of response was 38.3 months, and the median time to response was 2.1 months. These results suggest that avapritinib may be effective in treating AdvSM, with a significant proportion of patients experiencing a positive response to treatment."
page_181.txt,Infigratinib (Truseltiq),Cholangiocarcinoma,108,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '23%', 'Duration of Response (DoR)': 'Median 5 months', 'Complete Response': 1, 'Partial Responses': 24, 'Patients with response maintained for 6 months or more': 8}","Infigratinib (Truseltiq) showed an overall response rate of 23% in patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. The median duration of response was 5 months, with 8 patients maintaining response for 6 months or more. Common adverse reactions included hyperphosphatemia, increased creatinine, nail toxicity, and stomatitis.","In the study CBGJ398X2204, infigratinib showed efficacy in patients with previously treated cholangiocarcinoma with FGFR2 fusion or rearrangement. The overall response rate (ORR) was 23%, with 1 complete response and 24 partial responses. The median duration of response (DoR) was 5 months, with 8 patients maintaining response for 6 months or more. The study demonstrated promising outcomes in terms of response outcomes."
page_182.txt,Sotorasib (Lumakras™),Non-small cell lung cancer (NSCLC) with KRAS G12C mutations,124,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '36%', 'DOR': 'Median response duration of 10 months'}","Sotorasib (Lumakras™) received accelerated approval for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy. The approval was based on the CodeBreaK 100 trial, showing an objective response rate of 36% with a median response duration of 10 months. Common adverse reactions included diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough.","In a study of 124 patients with advanced cancer who had previously received systemic therapy, treatment with sotorasib at 960 mg daily showed promising results. The objective response rate (ORR) was 36%, with a median response duration of 10 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study demonstrated potential efficacy of sotorasib in this patient population, with a notable proportion of patients experiencing a positive response to treatment. Further research is needed to fully understand the impact of sotorasib on OS and PFS in this setting."
page_183.txt,amivantamab-vmjw (Rybrevant),non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations,81,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '40%', 'Response Duration': 'Median of 11.1 months'}","The FDA granted accelerated approval to amivantamab-vmjw for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. The approval was based on the CHRYSALIS trial, which showed an overall response rate of 40% with a median response duration of 11.1 months. Common adverse reactions included rash, infusion-related reactions, and musculoskeletal pain.","In a study of 81 patients with advanced NSCLC and EGFR exon 20 insertion mutations, treatment with amivantamab-vmjw showed promising efficacy. The overall response rate (ORR) was 40%, with a median response duration of 11.1 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study focused on patients whose disease had progressed after platinum-based chemotherapy. Amivantamab-vmjw was administered once weekly for 4 weeks, then every 2 weeks until disease progression or unacceptable toxicity. The results suggest that amivantamab-vmjw may be a potential treatment option for this specific patient population."
page_184.txt,Nivolumab (Opdivo),Esophageal or Gastroesophageal Junction (GEJ) cancer,794,22.4 months (median DFS),11 months (median DFS),51.40%,Not provided,Not provided,Not provided,"{'Main Efficacy Outcome Measure': 'Disease-free survival (DFS)', 'Common Adverse Reactions': ['Fatigue', 'Rash', 'Musculoskeletal pain', 'Pruritus', 'Diarrhea', 'Nausea', 'Asthenia', 'Cough', 'Dyspnea', 'Constipation', 'Decreased appetite', 'Back pain', 'Arthralgia', 'Upper respiratory tract infection', 'Pyrexia', 'Headache', 'Abdominal pain', 'Vomiting']}","Nivolumab demonstrated a significant improvement in disease-free survival (DFS) for patients with completely resected esophageal or GEJ cancer with residual pathologic disease who received neoadjuvant chemoradiotherapy. The median DFS was 22.4 months for nivolumab-treated patients compared to 11 months for those on placebo, representing a 51.4% improvement in DFS. Common adverse reactions to nivolumab included fatigue, rash, musculoskeletal pain, and gastrointestinal symptoms.","In the CHECKMATE-577 study, patients with resected esophageal or GEJ cancers who received nivolumab showed a significant improvement in disease-free survival (DFS) compared to those on placebo. The median DFS was 22.4 months with nivolumab versus 11 months with placebo. Overall Survival (OS) and Progression-Free Survival (PFS) data were not provided in the summary. Response outcomes such as Objective Response Rate (ORR), Duration of Response (DOR), Complete Response (CR), and Partial Response (PR) were not mentioned in the study results. The study demonstrated a benefit in DFS regardless of tumor PD-L1 expression and histology."
page_185.txt,Pembrolizumab (Keytruda),HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma,264,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': {'Pembrolizumab Arm': '74%', 'Placebo Arm': '52%'}, 'Duration of Response (DoR)': {'Pembrolizumab Arm': '10.6 months', 'Placebo Arm': '9.5 months'}}",Pembrolizumab in combination with trastuzumab and chemotherapy showed a statistically significant improvement in overall response rate compared to placebo in patients with HER2 positive gastric or GEJ adenocarcinoma. The median duration of response was slightly longer in the pembrolizumab arm. Adverse reactions were consistent with the known safety profile of pembrolizumab.,"efficacy measure for this analysis was overall response rate (ORR) assessed by blinded independent review committee. The ORR was 74% (95% CI 66, 82) in the pembrolizumab arm and 52% (95% CI 43, 61) in the placebo arm (one-sided p-value< 0.0001, statistically significant).
The median duration of response (DoR) was 10.6 months (range 1.1+, 16.5+) for patients treated with pembrolizumab and 9.5 months (range 1.4+, 15.4+) for those in the placebo arm.
The"
page_186.txt,Loncastuximab tesirine-lpyl (Zynlonta),"Relapsed or refractory large B-cell lymphoma, including DLBCL",145,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': 'Overall response rate of 48.3%', 'DOR': 'Median response duration of 10.3 months'}","Loncastuximab tesirine-lpyl received accelerated approval for adult patients with relapsed or refractory large B-cell lymphoma based on the LOTIS-2 trial. The drug demonstrated an overall response rate of 48.3% with a median response duration of 10.3 months. Common adverse reactions included thrombocytopenia, neutropenia, and fatigue. Further confirmatory trials may be required for continued approval.","efficacy outcome measure was overall response rate (ORR), as assessed by an independent review committee using Lugano 2014 criteria. The ORR was 48.3% (95% CI: 39.9, 56.7) with a complete response rate of 24.1% (95% CI: 17.4, 31.9). After a median follow-up of 7.3 months, median response duration  was 10.3 months (95% CI: 6.9, NE). Of the 70 patients who achieved objective responses, 36% were censored for response duration prior to 3 months.
Most common (≥20%)"
page_187.txt,dostarlimab-gxly (Jemperli),mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer,71,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '42.3%', 'Duration of Response (DOR)': 'Median not reached, 93.3% with durations ≥6 months', 'Adverse Reactions': {'Serious': '34% of patients', 'Common (≥20%)': ['fatigue/asthenia', 'nausea', 'diarrhea', 'anemia', 'constipation'], 'Common Grade 3 or 4 (≥2%)': ['anemia', 'transaminases increased'], 'Immune-mediated': ['pneumonitis', 'colitis', 'hepatitis', 'endocrinopathies', 'nephritis']}}","Dostarlimab-gxly was granted accelerated approval for dMMR recurrent or advanced endometrial cancer based on the GARNET Trial. The study included 71 patients with a confirmed ORR of 42.3% and a median duration of response not reached. Adverse reactions were reported in 34% of patients, with common ones being fatigue, nausea, and diarrhea. Immune-mediated adverse reactions were also observed. The recommended dosing schedule was provided for the drug.","In the GARNET Trial, patients with dMMR recurrent or advanced endometrial cancer who received dostarlimab-gxly showed a confirmed overall response rate (ORR) of 42.3%, with a complete response rate of 12.7% and a partial response rate of 29.6%. The median duration of response (DOR) was not reached, with 93.3% of patients having response durations of at least 6 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study demonstrated promising efficacy outcomes in this patient population, with a significant proportion of patients achieving durable responses to dostarlimab-gxly treatment."
page_188.txt,Nivolumab (Opdivo),"Gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma","1,581",14.4 months,11.1 months,29.70%,7.7 months,6.0 months,28.30%,{},"Nivolumab in combination with chemotherapy showed significant improvement in overall survival (OS) and progression-free survival (PFS) in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma. The study demonstrated a 29.7% improvement in OS and a 28.3% improvement in PFS compared to chemotherapy alone.","In the CHECKMATE-649 study, patients with previously untreated advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma who received nivolumab in combination with chemotherapy had significantly improved outcomes compared to those who received chemotherapy alone. For patients with PD-L1 CPS ≥5, the nivolumab plus chemotherapy group showed a median overall survival (OS) of 14.4 months vs. 11.1 months in the chemotherapy alone group, and a median progression-free survival (PFS) of 7.7 months vs. 6.0 months, respectively. The study also demonstrated a statistically significant improvement in OS for all randomized patients, with a median OS of 13.8 months in the nivolumab plus chemotherapy group vs. 11.6 months in the chemotherapy alone group."
page_189.txt,Sacituzumab govitecan (Trodelvy),Locally advanced or metastatic urothelial cancer (mUC),112,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '27.7%', 'DOR': '7.2 months'}","The FDA granted accelerated approval to sacituzumab govitecan for patients with locally advanced or metastatic urothelial cancer who previously received specific chemotherapy and immunotherapy. The study showed an objective response rate of 27.7% with a median duration of response of 7.2 months. Common adverse reactions included neutropenia, nausea, and diarrhea.",Efficacy and
page_19.txt,Selpercatinib,Medullary Thyroid Cancer (MTC) with a RET mutation,Not specified,Not specified,Not specified,Not specified,PFS not reached in selpercatinib arm,16.8 months in cabozantinib/vandetanib arm,Hazard Ratio 0.280,"{'Adverse Reactions': ['Hypertension', 'Edema', 'Dry mouth', 'Fatigue', 'Diarrhea'], 'Grade 3 or 4 Laboratory Abnormalities': ['Decreased lymphocytes', 'Increased ALT', 'Decreased neutrophils', 'Increased ALP', 'Increased blood creatinine', 'Decreased calcium', 'Increased AST']}","Selpercatinib was granted traditional approval for advanced or metastatic MTC with a RET mutation. In a randomized study, selpercatinib showed improved progression-free survival compared to cabozantinib/vandetanib. Patients on selpercatinib reported less severe side effects. Common adverse reactions included hypertension, edema, dry mouth, fatigue, and diarrhea. Recommended dosing varies by age group. The drug received priority review, breakthrough designation, and orphan drug designation.","In the LIBRETTO-531 study, selpercatinib showed superior efficacy compared to cabozantinib or vandetanib in patients with advanced or metastatic RET-mutant MTC. Selpercatinib demonstrated a significantly longer progression-free survival (PFS) with a median not reached, compared to 16.8 months in the control arm. The hazard ratio for PFS was 0.280, indicating a strong benefit with selpercatinib. Additionally, patients on selpercatinib reported less severe side effects compared to those on cabozantinib or vandetanib. Overall survival (OS) data and response outcomes were not specifically mentioned in the summary provided."
page_190.txt,sacituzumab govitecan (Trodelvy),triple-negative breast cancer (mTNBC),529,11.8 months,6.9 months,41%,4.8 months,1.7 months,65%,"{'Adverse Reactions': ['nausea', 'neutropenia', 'diarrhea', 'fatigue', 'alopecia', 'anemia', 'vomiting', 'constipation', 'rash', 'decreased appetite', 'abdominal pain']}","The study evaluated sacituzumab govitecan in patients with unresectable locally advanced or metastatic triple-negative breast cancer who had relapsed after at least two prior chemotherapies. The treatment arm showed a significant improvement in both progression-free survival (PFS) and overall survival (OS) compared to the control arm, with a 41% improvement in OS and a 65% improvement in PFS.",Efficacy and
page_191.txt,Cetuximab,Colorectal cancer (mCRC) or squamous cell carcinoma of the head and neck (SCCHN),Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"{'Adverse Reactions': 'Cutaneous adverse reactions, headache, diarrhea, infection'}","The FDA approved a new dosage regimen of 500 mg/m2 cetuximab for patients with K-Ras wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck. The approval was based on population PK modeling analyses and pooled analyses of overall response rates, progression-free survival, and overall survival from published literature. The most common adverse reactions to cetuximab are cutaneous adverse reactions, headache, diarrhea, and infection.","efficacy results were consistent across dosage regimens and supported the results of the population PK modeling analyses.
The most common"
page_192.txt,Isatuximab-irfc,Multiple Myeloma,302,Not provided,Not provided,Not provided,Not reached,20.27 months,45%,"{'Adverse Reactions': ['Upper respiratory tract infection', 'Infusion-related reactions', 'Fatigue', 'Hypertension', 'Diarrhea', 'Pneumonia', 'Dyspnea', 'Insomnia', 'Bronchitis', 'Cough', 'Back pain'], 'Hematology Laboratory Abnormalities': ['Decreased hemoglobin', 'Decreased lymphocytes', 'Decreased platelets']}","Isatuximab-irfc in combination with carfilzomib and dexamethasone showed a significant 45% reduction in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma compared to carfilzomib and dexamethasone alone. Common adverse reactions included upper respiratory tract infection, infusion-related reactions, and fatigue.",efficacy and
page_193.txt,Idecabtagene vicleucel,Multiple Myeloma,127,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '72%', 'CR Rate': '28%', 'DOR': '65% of patients in CR for at least 12 months'}","Idecabtagene vicleucel was approved by the FDA for adult patients with relapsed or refractory multiple myeloma after multiple prior lines of therapy. The therapy showed an overall response rate of 72% and a complete response rate of 28%. A significant percentage of patients who achieved complete response remained in remission for at least 12 months. Common side effects include cytokine release syndrome, infections, fatigue, musculoskeletal pain, and hypogammaglobulinemia.","In a study of 127 patients with relapsed and refractory multiple myeloma, efficacy of idecabtagene vicleucel was evaluated. The overall response rate (ORR) was 72%, with a complete response (CR) rate of 28%. 65% of patients who achieved CR remained in CR for at least 12 months. The study also found that idecabtagene vicleucel had a boxed warning for cytokine release syndrome (CRS), neurologic toxicities, hemophagocytic lymphohistiocytosis/ macrophage activation syndrome, and prolonged cytopenias. Common side effects included CRS, infections, fatigue, musculoskeletal pain, and hypogammaglobulinemia. The therapy is approved with a risk evaluation and mitigation strategy requiring specially certified healthcare facilities to recognize and manage CRS and nervous system toxicities."
page_194.txt,Pembrolizumab (Keytruda),Metastatic or locally advanced esophageal or gastroesophageal (GEJ) carcinoma,749,12.4 months,9.8 months,26.50%,6.3 months,5.8 months,8.60%,"{'Adverse Reactions': ['nausea', 'constipation', 'diarrhea', 'vomiting', 'stomatitis', 'fatigue/asthenia', 'decreased appetite', 'weight loss'], 'Recommended Dose': '200 mg every 3 weeks or 400 mg every 6 weeks'}",The FDA approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma who are not candidates for surgical resection or definitive chemoradiation. The KEYNOTE-590 trial showed a significant improvement in overall survival (OS) and progression-free survival (PFS) with pembrolizumab compared to chemotherapy alone.,"In the KEYNOTE-590 study, pembrolizumab in combination with cisplatin and fluorouracil showed a significant improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo with chemotherapy in patients with esophageal or gastroesophageal junction carcinoma. The median OS was 12.4 months with pembrolizumab versus 9.8 months with chemotherapy, and the median PFS was 6.3 months versus 5.8 months, respectively. The trial also demonstrated a statistically significant increase in response outcomes with pembrolizumab, indicating better outcomes for patients receiving this combination therapy."
page_195.txt,Tivozanib,Renal Cell Carcinoma,175,16.4 months,19.2 months,-14.58%,5.6 months,3.9 months,43.59%,"{'ORR': {'Tivozanib Arm': '18%', 'Sorafenib Arm': '8%'}}","Tivozanib, a kinase inhibitor, was approved for adult patients with relapsed or refractory advanced renal cell carcinoma. In a trial comparing tivozanib to sorafenib, tivozanib showed a median OS of 16.4 months compared to 19.2 months for sorafenib. The median PFS was 5.6 months for tivozanib and 3.9 months for sorafenib, with a significant improvement in PFS. The ORR was 18% for tivozanib and 8% for sorafenib. Common adverse reactions included fatigue, hypertension, and diarrhea.","In the TIVO-3 study comparing tivozanib to sorafenib in advanced RCC patients, tivozanib showed a longer median PFS of 5.6 months compared to 3.9 months with sorafenib. However, there was no significant difference in median OS between the two arms. The ORR was higher with tivozanib at 18% compared to 8% with sorafenib. Overall, tivozanib demonstrated superior PFS and ORR outcomes in this patient population."
page_196.txt,axicabtagene ciloleucel,follicular lymphoma,81,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '91%', 'DOR': 'Not reached', 'CR Rate': '60%', 'Median Time-to-Response': '1 month', '1-year Rate of Continued Remission': '76.2%'}","Axicabtagene ciloleucel received accelerated approval for adult patients with relapsed or refractory follicular lymphoma. The ZUMA-5 trial showed an objective response rate of 91% with a complete remission rate of 60%. The median duration of response was not reached, and the 1-year rate of continued remission was 76.2%.","In a study of 81 patients, the objective response rate (ORR) was 91% with a complete remission (CR) rate of 60% and a median time-to-response of 1 month. The median duration of response (DOR) was not reached, and the 1-year rate of continued remission was 76.2%. Among all leukapheresed patients in the trial (n=123), the ORR was 89% with a CR rate of 62%. Axicabtagene ciloleucel showed promising efficacy in non-Hodgkin’s lymphoma, but had notable side effects including cytokine release syndrome (CRS) in 88% of patients (Grade ≥3, 10%) and neurologic toxicities in 81% of patients (Grade ≥3, 26%)."
page_197.txt,Lorbrena,Non-small cell lung cancer (NSCLC) with ALK-positive tumors,296,Data immature at the time of analysis,Data immature at the time of analysis,Data immature at the time of analysis,Median not estimable for lorlatinib arm,9.3 months,72%,"{'ORR': {'Intracranial': {'Lorlatinib arm': '82%', 'Crizotinib arm': '23%'}}, 'DOR': {'Intracranial': {'≥ 12 months': {'Lorlatinib arm': '79%', 'Crizotinib arm': '0%'}}}, 'Adverse Reactions': ['Edema', 'Peripheral neuropathy', 'Weight gain', 'Cognitive effects', 'Fatigue', 'Dyspnea', 'Arthralgia', 'Diarrhea', 'Mood effects', 'Hypercholesterolemia', 'Hypertriglyceridemia', 'Cough']}","Lorbrena (lorlatinib) received regular approval for ALK-positive NSCLC based on Study B7461006, showing a 72% improvement in PFS compared to crizotinib. The intracranial ORR was 82% in the lorlatinib arm and 23% in the crizotinib arm. Adverse reactions included edema, neuropathy, weight gain, and cognitive effects.",N/A
page_198.txt,Melphalan flufenamide (Pepaxto),Multiple Myeloma,97,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '23.7%', 'Duration of Response (DOR)': '4.2 months'}",The FDA granted accelerated approval to melphalan flufenamide in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. The main efficacy outcome measures were an overall response rate of 23.7% and a median duration of response of 4.2 months. Safety data showed common adverse reactions and laboratory abnormalities. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.,"In the HORIZON study, patients with relapsed refractory multiple myeloma who received melphalan flufenamide and dexamethasone showed an overall response rate (ORR) of 23.7% and a median duration of response (DOR) of 4.2 months. The study included patients who had received four or more prior lines of therapy and were refractory to specific agents. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The treatment regimen demonstrated some efficacy in this heavily pretreated patient population, but further research may be needed to improve outcomes."
page_199.txt,Cemiplimab-rwlc (Libtayo),Non-small cell lung cancer (NSCLC),710,22.1 months,14.3 months,34%,6.2 months,5.6 months,10%,"{'Overall Response Rate (ORR)': {'Cemiplimab-rwlc arm': '37%', 'Chemotherapy arm': '21%'}}","Cemiplimab-rwlc demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) compared to platinum-based chemotherapy in patients with advanced NSCLC. The median OS was 22.1 months with cemiplimab-rwlc versus 14.3 months with chemotherapy, showing a 34% improvement. The median PFS was 6.2 months with cemiplimab-rwlc and 5.6 months with chemotherapy, indicating a 10% improvement. Additionally, the overall response rate was 37% in the cemiplimab-rwlc arm and 21% in the chemotherapy arm.","Study 1624 showed that cemiplimab-rwlc improved overall survival (OS) and progression-free survival (PFS) in patients with locally advanced or metastatic NSCLC compared to platinum-based chemotherapy. Median OS was 22.1 months with cemiplimab-rwlc versus 14.3 months with chemotherapy, and median PFS was 6.2 months versus 5.6 months, respectively. The overall response rate (ORR) was 37% with cemiplimab-rwlc and 21% with chemotherapy. These results indicate that cemiplimab-rwlc is a more effective treatment option for NSCLC patients who are not candidates for surgery or definitive chemoradiation."
page_2.txt,Sotorasib (Lumakras) with Panitumumab (Vectibix),KRAS G12C-mutated metastatic colorectal cancer (mCRC),160,Not statistically powered for OS,Not statistically powered for OS,Not applicable,5.6 months,2 months,64%,"{'Overall Response Rate (ORR)': '26%', 'Duration of Response (DOR)': '4.4 months'}",Sotorasib with Panitumumab showed a significant improvement in progression-free survival (PFS) compared to standard of care in patients with KRAS G12C-mutated mCRC. The treatment arm demonstrated a 64% improvement in PFS with a median PFS of 5.6 months. Overall response rate (ORR) was 26% and median duration of response (DOR) was 4.4 months.,Efficacy and
page_20.txt,Osimertinib (Tagrisso),"Locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations",216,Not available,Not available,Not available,39.1 months,5.6 months,Not available,"{'Adverse Reactions': ['lymphopenia', 'leukopenia', 'interstitial lung disease/pneumonitis', 'thrombocytopenia', 'neutropenia', 'rash', 'diarrhea', 'nail toxicity', 'musculoskeletal pain', 'cough', 'COVID-19 infection']}","Osimertinib (Tagrisso) was approved for locally advanced, unresectable non-small cell lung cancer with specific mutations. In a trial of 216 patients, osimertinib showed a significant improvement in progression-free survival compared to placebo. Overall survival results were immature at the time of analysis. Common adverse reactions included lymphopenia, leukopenia, and interstitial lung disease. The recommended dose is 80 mg once daily until disease progression or unacceptable toxicity.",Efficacy and
page_200.txt,cemiplimab-rwlc (Libtayo),locally advanced basal cell carcinoma (laBCC) and metastatic basal cell carcinoma (mBCC),84 patients with laBCC and 28 patients with mBCC,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Confirmed Objective Response Rate (ORR) laBCC': '29%', 'Confirmed Objective Response Rate (ORR) mBCC': '21%', 'Median Duration of Response (DOR) laBCC': 'Not reached (range: 2.1 to 21.4+ months)', 'Median Duration of Response (DOR) mBCC': 'Not reached (range: 9 to 23.0+ months)', 'Percentage of Responders maintaining response for at least 6 months': '79% for laBCC, 100% for mBCC'}","The study evaluated the efficacy of cemiplimab-rwlc in patients with locally advanced and metastatic basal cell carcinoma who had progressed on hedgehog pathway inhibitor therapy. The confirmed objective response rates were 29% for laBCC and 21% for mBCC, with a median duration of response not reached for both groups. A high percentage of responders maintained their response for at least 6 months. Common adverse reactions included fatigue, musculoskeletal pain, diarrhea, rash, and pruritis.","Study 1620 evaluated cemiplimab-rwlc in advanced BCC patients who had failed HHI therapy. In patients with laBCC, the confirmed ORR was 29% with a median DOR not reached, and 79% maintained response for at least 6 months. In mBCC patients, the confirmed ORR was 21% with a median DOR not reached, and all responders maintained their responses for at least 6 months. Overall survival data was not provided. The study showed promising response outcomes in both laBCC and mBCC patients, with a significant proportion maintaining responses for an extended period."
page_201.txt,lisocabtagene maraleucel,R/R large B-cell lymphoma,192,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '73%', 'CR Rate': '54%', 'Median DOR (CR)': 'Not reached', 'Median DOR (partial response)': '1.4 months', 'CR Remission lasting at least 6 months': '65%', 'CR Remission lasting at least 9 months': '62%', 'CRS Grade 3 or higher': '4%', 'Neurologic toxicity Grade 3 or higher': '12%', 'Infections Grade 3 or higher': '19%', 'Prolonged cytopenias Grade 3 or higher': '31%'}",Lisocabtagene maraleucel was approved for the treatment of adult patients with R/R large B-cell lymphoma after two or more lines of therapy. The overall response rate was 73% with a complete response rate of 54%. The median duration of response was not reached for patients achieving a complete response. Adverse reactions included cytokine release syndrome and neurologic toxicity.,"The TRANSCEND study evaluated lisocabtagene maraleucel in R/R large B-cell lymphoma patients. The ORR was 73% with a CR rate of 54%. Median time to first response was one month. 65% of patients with CR had remission lasting at least 6 months. Median DOR was not reached for CR patients. CRS occurred in 46% (Grade 3 or higher, 4%) and neurologic toxicity in 35% (Grade 3 or higher, 12%). Three patients had fatal neurologic toxicity. PFS and OS data were not provided in the summary."
page_202.txt,Umbralisib (Ukoniq),Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL),69 patients with MZL and 117 patients with FL,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'MZL': '49%', 'FL': '43%'}, 'DOR': {'MZL': 'Median not reached', 'FL': 'Median 11.1 months'}}","Umbralisib (Ukoniq) received accelerated approval for relapsed or refractory MZL and FL based on ORR and DOR in a trial with 69 MZL and 117 FL patients. Common adverse reactions included diarrhea-colitis, fatigue, and neutropenia. Continued approval may require confirmatory trials. Healthcare professionals should report adverse events to the FDA.","In patients with Marginal Zone Lymphoma (MZL), the study showed an Overall Response Rate (ORR) of 49% with 16% achieving complete responses. The Median Duration of Response (DOR) was not reached. For patients with Follicular Lymphoma (FL), the ORR was 43% with 3% achieving complete responses. The Median DOR was 11.1 months. These results suggest promising efficacy in terms of response outcomes for both MZL and FL patients in the study."
page_203.txt,Tepotinib (Tepmetko),Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations,152,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Treatment Naive Patients': {'ORR': '43%', 'Median Response Duration': '10.8 months'}, 'Previously Treated Patients': {'ORR': '43%', 'Median Response Duration': '11.1 months'}}, 'Adverse Reactions': ['Edema', 'Fatigue', 'Nausea', 'Diarrhea', 'Musculoskeletal pain', 'Dyspnea'], 'Potential Side Effects': ['Interstitial lung disease', 'Hepatotoxicity', 'Embryo-fetal toxicity']}","Tepotinib (Tepmetko) received accelerated approval for adult patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations. The VISION trial demonstrated an overall response rate of 43% with a median response duration of around 11 months in both treatment-naive and previously treated patients. Common adverse reactions included edema, fatigue, nausea, diarrhea, musculoskeletal pain, and dyspnea. Tepotinib is recommended at a dose of 450 mg orally once daily with food.","In the VISION trial for advanced or metastatic NSCLC with MET exon 14 skipping alterations, tepotinib showed efficacy. The overall response rate (ORR) was 43% for both treatment-naïve and previously treated patients, with a median response duration of around 10-11 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study demonstrated promising outcomes in terms of response outcomes, indicating the potential benefit of tepotinib in this patient population."
page_204.txt,Nivolumab (Opdivo) and Cabozantinib (Cabometyx),Renal Cell Carcinoma (RCC),651,Not reached,Not reached,"HR 0.60 (95% CI: 0.40, 0.89)",16.6 months,8.3 months,"HR 0.51 (95% CI: 0.41, 0.64)","{'Confirmed ORR': {'Nivolumab + Cabozantinib': '55.7%', 'Sunitinib': '27.1%'}}","The combination of nivolumab and cabozantinib showed significant improvements in progression-free survival, overall survival, and confirmed overall response rate for patients with advanced RCC compared to sunitinib. Common adverse reactions included diarrhea, fatigue, and hepatotoxicity. The FDA expedited review programs were utilized, leading to the approval of this first-line treatment ahead of schedule.","In the CHECKMATE-9ER study, patients with previously untreated advanced RCC who received nivolumab plus cabozantinib had significantly improved outcomes compared to those who received sunitinib. The combination therapy showed a median progression-free survival (PFS) of 16.6 months versus 8.3 months with a hazard ratio (HR) of 0.51. Overall survival (OS) was not reached in either arm, but the HR was 0.60. The confirmed overall response rate (ORR) was 55.7% for nivolumab plus cabozantinib and 27.1% for sunitinib. These results indicate that the combination therapy led to better PFS, OS, and ORR outcomes in patients with advanced RCC."
page_205.txt,Darzalex Faspro,Light chain (AL) amyloidosis,388,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Hematologic Complete Response Rate': {'D-VCd arm': '42.1%', 'VCd arm': '13.5%', 'Odds Ratio': '4.8', 'p-value': '<0.0001'}, 'Adverse Reactions': ['Upper respiratory tract infection', 'Diarrhea', 'Peripheral edema', 'Constipation', 'Peripheral sensory neuropathy', 'Fatigue', 'Nausea', 'Insomnia', 'Dyspnea', 'Cough']}","Darzalex Faspro in combination with bortezomib, cyclophosphamide, and dexamethasone showed a significantly higher hematologic complete response rate in patients with newly diagnosed AL amyloidosis compared to the VCd arm. Adverse reactions were common, including upper respiratory tract infection, diarrhea, and peripheral edema.","In the ANDROMEDA study, patients with newly diagnosed AL amyloidosis were randomized to receive either bortezomib, cyclophosphamide, and dexamethasone (VCd arm) or Darzalex Faspro with VCd (D-VCd arm). The D-VCd arm showed a significantly higher hematologic complete response rate of 42.1% compared to 13.5% in the VCd arm. The odds ratio was 4.8 with a p-value of <0.0001. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study demonstrated improved response outcomes with the addition of Darzalex Faspro to the treatment regimen for AL amyloidosis patients."
page_206.txt,fam-trastuzumab deruxtecan-nxki,HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma,188,12.5 months,8.4 months,48.80%,5.6 months,3.5 months,60.00%,"{'ORR': {'Treatment Arm': '40.5%', 'Control Arm': '11.3%'}, 'DOR': {'Treatment Arm': '11.3 months', 'Control Arm': '3.9 months'}}","The study evaluated fam-trastuzumab deruxtecan-nxki in patients with HER2-positive gastric or GEJ adenocarcinoma who had progressed on prior regimens. The treatment arm showed significant improvements in overall survival (OS) and progression-free survival (PFS) compared to the control arm, with a notable increase in objective response rate (ORR) and duration of response (DOR). Common adverse reactions were reported, and the drug received breakthrough therapy designation and orphan drug designation in gastric cancer.","In the DESTINY-Gastric01 study, patients with HER2-positive gastric or GEJ adenocarcinoma who had progressed on prior treatments showed improved outcomes with fam-trastuzumab deruxtecan-nxki compared to irinotecan or paclitaxel. The fam-trastuzumab deruxtecan-nxki arm had a longer overall survival (OS) of 12.5 months vs 8.4 months, a higher objective response rate (ORR) of 40.5% vs 11.3%, a longer progression-free survival (PFS) of 5.6 months vs 3.5 months, and a longer duration of response (DOR) of 11.3 months vs 3.9 months. These results suggest that fam-trastuzumab deruxtecan-nxki may be a more effective treatment option for this patient population."
page_207.txt,Crizotinib (Xalkori),Systemic Anaplastic Large Cell Lymphoma (ALK-positive),26,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '88%', 'DOR': '39% maintained response for at least 6 months, 22% maintained response for at least 12 months', 'Adverse Reactions': {'Ocular Toxicity': '65%', 'Gastrointestinal Toxicity': '92%', 'Serious Adverse Reactions': '35%', 'Common Adverse Reactions': ['Diarrhea', 'Vomiting', 'Nausea', 'Vision disorder', 'Headache', 'Musculoskeletal pain', 'Stomatitis', 'Fatigue', 'Decreased appetite', 'Pyrexia', 'Abdominal pain', 'Cough', 'Pruritus'], 'Grade 3-4 Laboratory Abnormalities': ['Neutropenia', 'Lymphopenia', 'Thrombocytopenia']}}","Crizotinib was approved for pediatric and young adult patients with relapsed or refractory, systemic ALK-positive ALCL. The study showed an ORR of 88%, with a complete remission rate of 81%. Adverse reactions included ocular and gastrointestinal toxicity, with common reactions being diarrhea, vomiting, and vision disorders. The recommended dosage is 280 mg/m2 orally twice daily. Ophthalmologic evaluations are recommended due to the risk of visual loss.","In a study of crizotinib in patients aged 1 to 21 with relapsed or refractory ALK-positive ALCL, the overall response rate (ORR) was 88%, with a complete remission rate of 81%. 39% of responders maintained their response for at least 6 months, and 22% for at least 12 months. The study did not establish efficacy in older adults. Ocular toxicity (Grade 1 or 2 visual disorders) occurred in 65% of patients, while gastrointestinal toxicity occurred in 92%. The study showed promising results in terms of ORR and duration of response in pediatric patients with relapsed or refractory ALK-positive ALCL."
page_208.txt,Osimertinib (TAGRISSO),Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations,682,Median DFS not reached in the osimertinib arm,Median DFS of 19.6 months in the placebo arm,"HR 0.17 (95% CI: 0.12, 0.23; <0.0001)",Not provided,Not provided,Not provided,"{'Adverse Reactions': 'Common adverse reactions included lymphopenia, leukopenia, thrombocytopenia, diarrhea, anemia, rash, musculoskeletal pain, nail toxicity, neutropenia, dry skin, stomatitis, fatigue, and cough.'}","Osimertinib was approved for adjuvant therapy in NSCLC patients with specific mutations after tumor resection. The ADAURA trial showed a significant improvement in disease-free survival with osimertinib compared to placebo, leading to the FDA approval of the drug for this indication.","In the ADAURA study, patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC who underwent complete tumor resection were randomized to receive osimertinib or placebo. Osimertinib significantly improved disease-free survival (DFS) compared to placebo in patients with stage II - IIIA NSCLC. The median DFS was not reached in the osimertinib arm versus 19.6 months in the placebo arm. Overall survival (OS) data is not provided in the summary. Osimertinib is recommended at a dose of 80 mg orally once daily for up to 3 years. Response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not mentioned in the summary."
page_209.txt,Relugolix,Prostate cancer,934,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Medical castration rate': '96.7% (95% CI: 94.9%, 97.9%)', 'Common adverse reactions': ['hot flush', 'musculoskeletal pain', 'fatigue', 'diarrhea', 'constipation'], 'Common laboratory abnormalities': ['increased glucose', 'triglycerides', 'alanine aminotransferase', 'aspartate aminotransferase', 'decreased hemoglobin']}","The FDA approved relugolix for adult patients with advanced prostate cancer based on the results of the HERO trial. The study showed a medical castration rate of 96.7% in the relugolix arm. Common adverse reactions included hot flush, musculoskeletal pain, fatigue, diarrhea, and constipation. The recommended dose is a loading dose of 360 mg followed by a daily oral dose of 120 mg.","In the HERO study, relugolix demonstrated a medical castration rate of 96.7% in men with prostate cancer, compared to leuprolide acetate. Overall Survival (OS) and Progression-Free Survival (PFS) data were not provided in the summary. Response outcomes such as Objective Response Rate (ORR), Duration of Response (DOR), Complete Response (CR), and Partial Response (PR) were also not mentioned in the summary."
page_21.txt,Isatuximab-irfc (Sarclisa),Multiple Myeloma,446,Not provided,Not provided,Not provided,Not reached (NR),54.3 months,40%,"{'Adverse Reactions': ['Upper respiratory tract infection', 'Diarrhea', 'Fatigue', 'Peripheral sensory neuropathy', 'Pneumonia', 'Musculoskeletal pain', 'Cataract', 'Constipation', 'Peripheral edema', 'Rash', 'Infusion-related reaction', 'Insomnia', 'COVID-19 infection']}","Isatuximab-irfc in combination with bortezomib, lenalidomide, and dexamethasone showed a 40% reduction in the risk of disease progression or death compared to the standard treatment in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplant. Common adverse reactions included upper respiratory tract infection, diarrhea, and fatigue.",Efficacy and
page_210.txt,selinexor (XPOVIO),multiple myeloma,not specified,not specified,not specified,not specified,13.9 months,9.5 months,31.60%,"{'Common Adverse Reactions': ['nausea', 'fatigue', 'decreased appetite', 'diarrhea', 'peripheral neuropathy', 'upper respiratory tract infection', 'decreased weight', 'cataract', 'vomiting'], 'Grade 3-4 Laboratory Abnormalities': ['thrombocytopenia', 'lymphopenia', 'hypophosphatemia', 'anemia', 'hyponatremia', 'neutropenia'], 'Recommended Dose': '100 mg orally once weekly on day 1 of each week of a 35-day cycle in combination with bortezomib and dexamethasone'}","Selinexor in combination with bortezomib and dexamethasone showed a significant improvement in progression-free survival (PFS) compared to the standard treatment in patients with relapsed or refractory multiple myeloma. Common adverse reactions include nausea, fatigue, and peripheral neuropathy. The recommended dose is 100 mg orally once weekly.","The BOSTON Trial evaluated the efficacy of selinexor in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. The study showed that the combination therapy (SVd) significantly improved progression-free survival (PFS) compared to the standard therapy (Vd), with a median PFS of 13.9 months vs. 9.5 months, respectively. The estimated hazard ratio for PFS was 0.70, indicating a 30% reduction in the risk of disease progression or death with SVd. Overall survival data is not provided in the summary. Response outcomes such as overall response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not mentioned in the summary."
page_211.txt,margetuximab-cmkb (MARGENZA),metastatic HER2-positive breast cancer,536,Not provided,Not provided,Not provided,5.8 months,4.9 months,17.30%,"{'ORR': '22%', 'DOR': '6.1 months'}","Margetuximab-cmkb in combination with chemotherapy was approved for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. In a randomized trial, margetuximab showed a 17.3% improvement in progression-free survival compared to the control arm. Additionally, the treatment arm demonstrated a 22% objective response rate with a median duration of response of 6.1 months.","In the SOPHIA study, margetuximab plus chemotherapy showed improved progression-free survival (PFS) compared to trastuzumab plus chemotherapy in patients with HER2+ metastatic breast cancer. The median PFS was 5.8 months with margetuximab versus 4.9 months with trastuzumab. The objective response rate (ORR) was 22% with margetuximab and 16% with trastuzumab, with a median duration of response (DOR) of 6.1 months and 6.0 months, respectively. Overall survival (OS) data was not provided in the summary. These results suggest that margetuximab may be a promising treatment option for patients with HER2+ metastatic breast cancer who have received prior anti-HER2 therapies."
page_212.txt,pralsetinib (GAVRETO),RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer,"55 patients with RET-mutant MTC who received prior cabozantinib or vandetanib, 29 patients with RET-mutant MTC who did not receive prior cabozantinib or vandetanib, and 9 patients with RET fusion-positive thyroid cancer",Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': {'RET-mutant MTC (prior cabozantinib or vandetanib)': '60%', 'RET-mutant MTC (no prior cabozantinib or vandetanib)': '66%', 'RET fusion-positive thyroid cancer': '89%'}, 'Response Duration': {'RET-mutant MTC (prior cabozantinib or vandetanib)': '79% lasting 6 months or longer', 'RET-mutant MTC (no prior cabozantinib or vandetanib)': '84% lasting 6 months or longer', 'RET fusion-positive thyroid cancer': '100% lasting 6 months or longer'}}","Pralsetinib (GAVRETO) was approved for RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer based on a multicenter clinical trial showing high overall response rates and durable responses in patients. Common adverse reactions included constipation, hypertension, and fatigue. The recommended dose is 400 mg orally once daily. The FDA granted accelerated approval, priority review, breakthrough therapy, and orphan drug designation for this indication.","The ARROW study evaluated the efficacy of treatments in patients with RET gene alterations. In patients with advanced or metastatic RET-mutant MTC who had prior cabozantinib or vandetanib, the overall response rate (ORR) was 60%, with 79% of responders having responses lasting 6 months or longer. In patients with RET-mutant MTC who did not receive prior cabozantinib or vandetanib, the ORR was 66%, with 84% having responses lasting 6 months or longer. For patients with RET fusion-positive thyroid cancer who were radioactive iodine-refractory, the ORR was 89%, with all responders having responses lasting 6 months or longer. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary."
page_213.txt,Sonalleve MR-HIFU system,Osteoid osteoma in the extremities,9,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,Not applicable,"{'Pain scores decrease within 4 weeks of treatment': 'Statistically significant', 'Pain medication usage after 4 weeks': '8 out of 9 patients achieved no pain medication usage'}",The Sonalleve MR-HIFU system was approved for the treatment of osteoid osteoma in the extremities. Clinical results showed a probable benefit with a statistically significant decrease in pain scores within 4 weeks of treatment. 8 out of 9 patients achieved no pain medication usage after 4 weeks. No technical difficulties or serious adverse events were reported in the study.,"Efficacy was evaluated in a study of nine patients treated with MR-HIFU, without technical difficulties or serious"
page_214.txt,Naxitamab (DANYELZA),High-risk neuroblastoma in the bone or bone marrow,"22 in Study 201, 38 in Study 12-230",Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Study 201': '45%', 'Study 12-230': '34%'}, 'DOR': {'Study 201': '30% responders with DOR ≥6 months', 'Study 12-230': '23% patients with DOR ≥6 months'}}","Naxitamab in combination with GM-CSF showed promising overall response rates in patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow, with some patients experiencing durable responses lasting 6 months or more. Adverse reactions were manageable with premedication and monitoring. Further confirmatory trials are needed for continued approval.","In two trials evaluating naxitamab in patients with relapsed or refractory neuroblastoma, the overall response rate (ORR) was 45% in Study 201 and 34% in Study 12-230. The duration of response (DOR) was at least 6 months in 30% of responders in Study 201 and 23% in Study 12-230. Responses were seen in the bone, bone marrow, or both. Overall survival (OS) and progression-free survival (PFS) data were not provided. Naxitamab treatment was associated with serious infusion-related reactions and neurotoxicity, including neuropathic pain and reversible posterior leukoencephalopathy syndrome. Patients should receive premedication and close monitoring during and after infusions to mitigate these risks."
page_215.txt,Pembrolizumab (KEYTRUDA),Triple-negative breast cancer (TNBC),Not specified,Not specified,Not specified,Not specified,9.7 months,5.6 months,42.90%,"{'Adverse Reactions': ['fatigue', 'nausea', 'diarrhea', 'constipation', 'vomiting', 'alopecia', 'rash', 'cough', 'decreased appetite', 'headache'], 'Laboratory Abnormalities': ['anemia', 'leukopenia', 'neutropenia', 'lymphopenia', 'thrombocytopenia', 'elevated ALT and AST', 'hyperglycemia', 'hypoalbuminemia', 'increased alkaline phosphatase', 'hypocalcemia', 'hyponatremia', 'hypophosphatemia', 'hypokalemia'], 'Recommended Dose': '200 mg every 3 weeks or 400 mg every 6 weeks administered prior to chemotherapy until disease progression, unacceptable toxicity, or up to 24 months'}","Pembrolizumab in combination with chemotherapy showed a significant improvement in progression-free survival (PFS) in patients with locally recurrent unresectable or metastatic TNBC expressing PD-L1 (CPS ≥10). The median PFS was 9.7 months with pembrolizumab plus chemotherapy compared to 5.6 months with placebo, representing a 42.9% improvement. Common adverse reactions and laboratory abnormalities were reported, and the recommended dose for adult patients was provided.","efficacy outcome measure was progression-free survival (PFS) as assessed by blinded independent review according to RECIST 1.1, tested in the subgroup of patients with CPS ≥10. Median PFS was 9.7 months (95% CI: 7.6, 11.3) in the pembrolizumab plus chemotherapy arm and 5.6 months (95% CI:5.3, 7.5) in the placebo arm (HR 0.65; 95% CI: 0.49, 0.86; one-sided p-value=0.0012).
The most common"
page_216.txt,"Rucaparib, Alpelisib, Alectinib, Olaparib","Ovarian, Non-small cell lung, Breast, Metastatic castration resistance prostate cancer",Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"{'Companion diagnostic indications': {'1': 'Identify mutations in BRCA1 and BRCA2 genes in ovarian cancer for rucaparib', '2': 'Identify ALK rearrangements in NSCLC for alectinib', '3': 'Identify mutations in PIK3CA gene in breast cancer for alpelisib', '4': 'Identify mutations in BRCA1, BRCA2, and ATM genes in mCRPC for olaparib'}, 'Efficacy': 'Efficacy for the mentioned drugs was shown to be maintained in patients with specific gene alterations', 'Approval Basis': 'Retrospective testing with FoundationOne Liquid CDx of plasma samples from patients in clinical trials'}","The FoundationOne Liquid CDx test was approved as a companion diagnostic device for multiple biomarkers in various cancers, allowing for personalized treatment based on genetic alterations. Efficacy of rucaparib, alpelisib, alectinib, and olaparib was confirmed in patients with specific gene alterations detected by the test.","The study found that the efficacy of rucaparib, alpelisib, alectinib, and olaparib was maintained in patients with confirmed BRCA1 and/or BRCA2 gene alterations, PIK3CA mutations, ALK rearrangement, and BRCA1, BRCA2, and/or ATM gene alterations. Overall survival (OS) and progression-free survival (PFS) were favorable in these patients. Response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were also positive. FoundationOne Liquid CDx was used to identify these mutations and alterations in the blood, but if not detected, a tumor biopsy was recommended for further evaluation."
page_217.txt,Larotrectinib,Solid tumors with NTRK gene fusion,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"{'Overall Response Rate (ORR)': 'Not specified', 'Response Duration': 'Not specified'}","The study focused on the approval of Larotrectinib for solid tumors with NTRK gene fusion, based on data from three clinical trials. The FoundationOne CDx test was approved as a companion diagnostic for Larotrectinib. Efficacy was maintained in patients with confirmed NTRK fusion positive results. The major efficacy outcome measures included ORR and response duration.","The study evaluated larotrectinib's efficacy in patients with confirmed NTRK fusion positive results using the FoundationOne CDx assay. Overall response rate (ORR) and response duration were key outcome measures, with efficacy shown to be maintained in these patients. The FoundationOne CDx assay was approved as a companion diagnostic for larotrectinib based on retrospective testing of tumor tissue samples from patients in three clinical trials. The assay, a next-generation sequencing (NGS) based device, can detect various mutations in addition to NTRK gene fusions. Overall survival (OS) and progression-free survival (PFS) outcomes were not specifically mentioned in the study results."
page_218.txt,Venetoclax,Acute Myeloid Leukemia (AML),"{'VIALE-A': {'Venetoclax + Azacitidine': 286, 'Placebo + Azacitidine': 145}, 'VIALE-C': {'Venetoclax + LDAC': 143, 'Placebo + LDAC': 68}}","{'VIALE-A': '14.7 months', 'VIALE-C': 'Not significantly improved'}","{'VIALE-A': '9.6 months', 'VIALE-C': 'Not significantly improved'}","{'VIALE-A': '34%', 'VIALE-C': 'Not significant'}","{'VIALE-A': 'Data not provided', 'VIALE-C': 'Data not provided'}","{'VIALE-A': 'Data not provided', 'VIALE-C': 'Data not provided'}","{'VIALE-A': 'Data not provided', 'VIALE-C': 'Data not provided'}","{'VIALE-A': {'CR Rate': {'Venetoclax + Azacitidine': '37%', 'Placebo + Azacitidine': '18%'}}, 'VIALE-C': {'CR Rate': {'Venetoclax + LDAC': '27%', 'Placebo + LDAC': '7.4%'}, 'Duration of CR': {'Venetoclax + LDAC': '11.1 months', 'Placebo + LDAC': '8.3 months'}}}","Venetoclax in combination with azacitidine showed a significant improvement in overall survival (OS) and complete remission (CR) rate in patients with newly-diagnosed AML. However, the combination with LDAC did not significantly improve OS. Common adverse reactions were nausea, diarrhea, and thrombocytopenia.","In the VIALE-A trial, venetoclax plus azacitidine showed improved overall survival (OS) with a median of 14.7 months compared to 9.6 months with placebo plus azacitidine. The complete remission (CR) rate was also higher at 37% versus 18%.
In the VIALE-C trial, venetoclax plus LDAC had a CR rate of 27% with a median duration of 11.1 months, while placebo plus LDAC had a CR rate of 7.4% with a median duration of 8.3 months. However, there was no significant difference in OS between the two groups."
page_219.txt,Pembrolizumab (KEYTRUDA®),Classical Hodgkin lymphoma (cHL),304,Not provided,Not provided,Not provided,13.2 months,8.3 months,37.35%,"{'Serious Adverse Reactions': '30% of patients with pneumonitis, pneumonia, pyrexia, myocarditis, acute kidney injury, febrile neutropenia, sepsis', 'Common Adverse Reactions': 'Upper respiratory tract infection, musculoskeletal pain, diarrhea, cough, pyrexia, fatigue, rash', 'Adverse Reactions Requiring Systemic Corticosteroids': '38% of patients, including pneumonitis in 11%'}","The study extended the approval of pembrolizumab for adult and pediatric patients with relapsed or refractory classical Hodgkin lymphoma. In a phase 3 trial, pembrolizumab showed a statistically significant improvement in progression-free survival compared to brentuximab vedotin. Serious adverse reactions were reported in 30% of patients, with pneumonitis being a common adverse event. The recommended dose for patients with lymphoma is 200 mg every 3 weeks or 400 mg every 6 weeks for adults, and 2 mg/kg every 3 weeks for pediatric patients, for up to 2 years.","Efficacy was based on progression-free survival (PFS) per blinded independent central review assessment. PFS was statistically significantly longer in the pembrolizumab arm. The median PFS was 13.2 months (95% CI: 10.9, 19.4) in the pembrolizumab arm and 8.3 months (95% CI: 5.7, 8.8) in the BV arm, with a hazard ratio of 0.65 (95% CI: 0.48, 0.88; p=0.0027).
Serious"
page_22.txt,Amivantamab-vmjw (Rybrevant),Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations,657,Data not provided,Data not provided,Data not provided,"6.3 months (95% CI: 5.6, 8.4)","4.2 months (95% CI: 4.0, 4.4)","Hazard ratio 0.48 [95% CI: 0.36, 0.64], p-value<0.0001","{'Overall Response Rate (ORR)': '53% in treatment arm, 29% in control arm', 'Overall Survival (OS)': 'No statistically significant difference observed', 'Adverse Reactions': 'Common adverse reactions included rash, infusion-related reactions, fatigue, nail toxicity, nausea, constipation, edema, stomatitis, decreased appetite, musculoskeletal pain, vomiting, and COVID-19 infection'}","Amivantamab-vmjw in combination with carboplatin and pemetrexed showed a significant improvement in progression-free survival compared to carboplatin and pemetrexed alone in patients with NSCLC with specific mutations. However, no statistically significant difference was observed in overall survival between the treatment and control arms. Common adverse reactions were manageable. Further regulatory reviews are ongoing internationally.",Efficacy and
page_220.txt,Nivolumab (OPDIVO) plus ipilimumab (YERVOY),Unresectable malignant pleural mesothelioma,303 (nivolumab plus ipilimumab arm) and 302 (chemotherapy arm),Median OS of 18.1 months,Median OS of 14.1 months,"HR 0.74; 95% CI: 0.61, 0.89; p=0.002",Median PFS of 6.8 months,Median PFS of 7.2 months,"HR 1.0; 95% CI 0.82, 1.21","{'Confirmed Overall Response Rate': '40% (nivolumab plus ipilimumab) and 43% (chemotherapy)', 'Median Response Duration': '11.0 months (nivolumab plus ipilimumab) and 6.7 months (chemotherapy)'}","The combination of nivolumab plus ipilimumab showed a statistically significant improvement in overall survival compared to chemotherapy in patients with unresectable malignant pleural mesothelioma. The treatment arm demonstrated a median OS of 18.1 months and a median PFS of 6.8 months, with a confirmed overall response rate of 40%.","In the CHECKMATE-743 study, patients with unresectable malignant pleural mesothelioma who received nivolumab and ipilimumab had a significantly improved overall survival compared to those who received chemotherapy (18.1 vs. 14.1 months). However, there was no significant difference in progression-free survival between the two treatment arms. The overall response rate was similar between nivolumab plus ipilimumab and chemotherapy (40% vs. 43%), with a longer median response duration in the nivolumab plus ipilimumab arm (11.0 vs. 6.7 months). These results suggest that nivolumab plus ipilimumab may be a more effective treatment option for patients with unresectable malignant pleural mesothelioma compared to chemotherapy."
page_221.txt,Atezolizumab (Tecentriq),Triple Negative Breast Cancer (mTNBC),Not specified,Not effective,Favored paclitaxel + placebo,Not effective,Not effective,Not effective,Not effective,{},The clinical trial studying atezolizumab and paclitaxel in patients with mTNBC did not show significant reduction in cancer progression and death compared to placebo and paclitaxel. Interim overall survival results favored paclitaxel + placebo over paclitaxel + atezolizumab in both PD-L1-positive and total population. FDA will review the findings and communicate any changes. Health care professionals should not replace paclitaxel protein-bound with paclitaxel in clinical practice.,N/A
page_222.txt,pralsetinib (GAVRETO),RET fusion-positive non-small cell lung cancer (NSCLC),87 patients previously treated with platinum chemotherapy and 27 patients who never received systemic treatment,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '57% in previously treated patients, 70% in treatment-naive patients', 'Response Duration': '80% of responding patients in previously treated group had responses lasting 6 months or longer, 58% in treatment-naive group'}","Pralsetinib (GAVRETO) was granted accelerated approval for adult patients with metastatic RET fusion-positive NSCLC. Efficacy was demonstrated in a multicenter clinical trial with high overall response rates and durable responses in both previously treated and treatment-naive patients. Common adverse reactions were reported, and the recommended dose and administration instructions were provided.","In a study of patients with RET fusion-positive NSCLC, the overall response rate (ORR) was 57% in those previously treated with platinum chemotherapy and 70% in treatment-naive patients. The response duration was 6 months or longer in 80% of responding previously treated patients and 58% of treatment-naive patients. The study showed promising efficacy outcomes in terms of ORR and response duration for patients with RET alterations, indicating potential benefits for this patient population in terms of overall survival (OS) and progression-free survival (PFS)."
page_223.txt,ONUREG,Acute Myeloid Leukemia,472,24.7 months,14.8 months,40.54%,not provided,not provided,not provided,"{'Adverse Reactions': ['nausea', 'vomiting', 'diarrhea', 'fatigue/asthenia', 'constipation', 'pneumonia', 'abdominal pain', 'arthralgia', 'decreased appetite', 'febrile neutropenia', 'dizziness', 'pain in extremity'], 'Recommended Dose': '300 mg orally once daily with or without food on days 1 through 14 of each 28-day cycle'}","The study investigated the efficacy of ONUREG in patients with acute myeloid leukemia who achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy. The median overall survival was 24.7 months in the ONUREG arm compared to 14.8 months in the placebo arm, showing a 40.54% improvement in overall survival. Adverse reactions included nausea, vomiting, diarrhea, and fatigue/asthenia.","In the QUAZAR study, patients who achieved CR or CRi with intensive induction chemotherapy were randomized to receive Onureg or placebo. The study showed a significant improvement in overall survival (OS) with a median OS of 24.7 months in the Onureg arm compared to 14.8 months in the placebo arm. The hazard ratio (HR) was 0.69, indicating a 31% reduction in the risk of death with Onureg. Subgroup analysis confirmed the OS benefit for patients in either CR or CRi. Progression-free survival (PFS) and response outcomes were not specifically mentioned in the summary provided."
page_224.txt,Guardant360 CDx,not specified,not specified,not specified,not specified,not specified,not specified,not specified,not specified,{},The study outcomes related to the Guardant360 CDx were not provided in the text.,N/A
page_225.txt,Carfilzomib (KYPROLIS) and Daratumumab (DARZALEX),Multiple Myeloma,"466 in CANDOR trial, 85 in EQUULEUS trial",Not provided,Not provided,Not provided,Not reached in DKd arm,15.8 months in Kd arm,37% improvement in PFS (HR 0.63),"{'ORR': '81%', 'DOR': '27.5 months'}","Carfilzomib and daratumumab in combination with dexamethasone showed a 37% improvement in progression-free survival compared to carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma. The overall response rate was 81% with a duration of response of 27.5 months. Common adverse reactions included infusion related reactions, anemia, diarrhea, and fatigue.","The combination of carfilzomib and daratumumab with dexamethasone showed promising results in two clinical trials. In the CANDOR trial, the DKd arm had a median PFS that was not reached, compared to 15.8 months in the Kd arm. The EQUULEUS trial showed an ORR of 81% in patients with relapsed or refractory multiple myeloma, with a duration of response of 27.5 months. These results suggest that the combination therapy may be effective in improving PFS and ORR in patients with multiple myeloma who have received prior lines of therapy."
page_226.txt,Belantamab mafodotin-blmf,Multiple myeloma,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"{'ORR': '31%', 'DOR': '73% of responders had response durations ≥6 months'}","Belantamab mafodotin-blmf was granted accelerated approval for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies. The drug showed an overall response rate of 31%, with 73% of responders having response durations of at least 6 months. However, the confirmatory trial did not meet its primary endpoint for superior progression-free survival, leading to the FDA's withdrawal of the biologics license.","In a study evaluating belantamab mafodotin-blmf in patients with multiple myeloma, the overall response rate (ORR) was 31%, with 73% of responders having response durations ≥6 months. The recommended dose of 2.5 mg/kg was associated with these response outcomes. However, the drug carries a Boxed Warning for ocular toxicity, including severe vision loss and corneal ulcer. Ophthalmic exams are recommended at baseline, prior to each dose, and for worsening symptoms. Due to these risks, belantamab mafodotin-blmf is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BLENREP REMS."
page_227.txt,tafasitamab-cxix (MONJUVI),Diffuse large B-cell lymphoma (DLBCL),81,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Best ORR': '55% (complete responses in 37% and partial responses in 18% of patients)', 'Median Response Duration': '21.7 months'}","Tafasitamab-cxix in combination with lenalidomide showed a best overall response rate of 55% in patients with relapsed or refractory DLBCL. The most common adverse reactions were neutropenia, fatigue, anemia, and diarrhea. The study was based on an open-label, multicenter single-arm trial in 81 patients.","In the L-MIND study, tafasitamab-cxix with lenalidomide showed promising efficacy in 71 DLBCL patients. The best overall response rate (ORR) was 55%, with 37% achieving complete responses and 18% achieving partial responses. The median response duration was 21.7 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary."
page_228.txt,Atezolizumab (Tecentriq),BRAF V600 mutation-positive unresectable or metastatic melanoma,514,Not provided,Not provided,Not provided,15.1 months,10.6 months,42.45%,"{'Adverse Reactions': ['rash', 'musculoskeletal pain', 'nausea', 'fatigue', 'hepatotoxicity', 'pyrexia', 'pruritus', 'edema', 'stomatitis', 'hypothyroidism', 'photosensitivity reaction']}","Atezolizumab in combination with cobimetinib and vemurafenib showed a significant improvement in progression-free survival (PFS) compared to placebo in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. The most common adverse reactions included rash, musculoskeletal pain, and nausea.","The study evaluated the efficacy of cobimetinib and vemurafenib in combination with atezolizumab in 514 patients with promising results. The median progression-free survival (PFS) was 15.1 months in the atezolizumab arm compared to 10.6 months in the placebo arm. The hazard ratio (HR) for PFS was 0.78, indicating a significant improvement in PFS with the combination therapy. Overall survival (OS) data was not provided in the summary. Response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not mentioned in the summary. The study demonstrated a benefit in PFS with the addition of atezolizumab to cobimetinib and vemurafenib in patients with the specified cancer type."
page_229.txt,brexucabtagene autoleucel (TECARTUS),mantle cell lymphoma (MCL),74,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '87%', 'DOR': 'Not provided'}","Brexucabtagene autoleucel received accelerated approval for the treatment of adult patients with relapsed or refractory mantle cell lymphoma based on the ZUMA-2 trial. The study showed an objective response rate of 87% with a complete remission rate of 62%. The most common Grade 3 or higher reactions included anemia, neutropenia, and thrombocytopenia. The recommended dose is a single intravenous infusion preceded by lymphodepleting chemotherapy.","The study evaluated brexucabtagene autoleucel in patients with refractory large B-cell lymphoma. The overall response rate (ORR) was 87%, with a complete remission (CR) rate of 62%. The median duration of response was not reached. Grade 3 or higher reactions included anemia, neutropenia, and cytokine release syndrome. The FDA approved brexucabtagene autoleucel with a Risk Evaluation and Mitigation Strategy due to potential toxicities. The recommended dose is a single infusion preceded by lymphodepleting chemotherapy. The approval was based on ORR and durability of response, with continued approval contingent on confirmatory trials. Brexucabtagene autoleucel received orphan drug designation, breakthrough therapy designation, and priority review from the FDA. Healthcare professionals should report all serious reactions."
page_23.txt,Pembrolizumab (Keytruda),Malignant Pleural Mesothelioma (MPM),"440 (222 in treatment arm, 218 in control arm)",17.3 months,16.1 months,7.50%,7.1 months,7.1 months,0%,"{'ORR': {'Treatment Arm': '52%', 'Control Arm': '29%'}, 'DOR': {'Treatment Arm': '6.9 months', 'Control Arm': '6.8 months'}}","Pembrolizumab in combination with chemotherapy showed a statistically significant improvement in overall survival for patients with unresectable advanced or metastatic MPM compared to chemotherapy alone. The treatment arm demonstrated a median OS of 17.3 months, a 7.5% improvement over the control arm. Additionally, the treatment arm had a higher objective response rate of 52% and a similar progression-free survival compared to the control arm.",Efficacy and
page_230.txt,Inqovi,"Myelodysplastic syndromes (MDS) including refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia (CMML)","80 in trial ASTX727-01-B, 133 in trial ASTX727-02",Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Complete Response Rate': '18% in trial ASTX727-01-B, 21% in trial ASTX727-02', 'Median Duration of Complete Response': '8.7 months in trial ASTX727-01-B, 7.5 months in trial ASTX727-02', 'Transfusion Independence Rate': '49% in trial ASTX727-01-B, 53% in trial ASTX727-02'}","Inqovi, an oral combination of decitabine and cedazuridine, was approved for adult patients with MDS. Trials demonstrated significant complete response rates and transfusion independence in patients. Common adverse reactions were reported, and the safety profile was similar to IV decitabine. Inqovi showed efficacy in treating MDS and CMML.","The study showed that 21% of patients achieved a complete response (CR) with a median duration of 7.5 months. Among patients dependent on transfusions at baseline, 53% became transfusion-independent, while 63% of those already independent remained so. Overall survival (OS) and progression-free survival (PFS) data were not provided. These results suggest a significant proportion of patients achieved a CR and were able to reduce or eliminate the need for transfusions, indicating a positive response to treatment."
page_231.txt,avelumab (BAVENCIO),urothelial carcinoma,700,21.4 months,14.3 months,33%,not provided,not provided,not provided,"{'Adverse Reactions': 'fatigue, musculoskeletal pain, urinary tract infection, rash', 'Serious Adverse Reactions': '28% of patients', 'Recommended Dose': '800 mg every 2 weeks'}","Avelumab was approved for maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy. In the JAVELIN Bladder 100 trial, avelumab showed a significant improvement in overall survival compared to best supportive care alone, with a 33% reduction in the risk of death. Common adverse reactions included fatigue, musculoskeletal pain, urinary tract infection, and rash.","The JAVELIN Bladder 100 trial investigated the efficacy of avelumab for maintenance treatment of urothelial carcinoma. Overall survival (OS) was significantly longer in patients receiving avelumab compared to best supportive care (BSC) alone, with a median OS of 21.4 months vs. 14.3 months. Patients with PD-L1-positive tumors had a greater benefit in OS with a HR of 0.56. Progression-free survival (PFS) data was not provided. Response outcomes were not detailed in the summary. Avelumab showed promising results as a maintenance treatment for urothelial carcinoma, particularly in patients with PD-L1-positive tumors."
page_232.txt,Pembrolizumab (KEYTRUDA),Colorectal cancer,307,Data not mature,Data not mature,Data not available,16.5 months,8.2 months,50%,"{'Adverse Reactions': ['fatigue', 'musculoskeletal pain', 'decreased appetite', 'pruritus', 'diarrhea', 'nausea', 'rash', 'pyrexia', 'cough', 'dyspnea', 'constipation', 'pain', 'abdominal pain'], 'Recommended Dose': '200 mg every 3 weeks or 400 mg every 6 weeks'}",Pembrolizumab was approved for first-line treatment of unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer based on the KEYNOTE‑177 trial. The study showed a 50% improvement in progression-free survival with a median PFS of 16.5 months in the pembrolizumab arm compared to 8.2 months in the chemotherapy arm.,"efficacy outcome measures were progression-free survival (PFS) and overall survival (OS). Median PFS was 16.5 months (95% Confidence Interval [CI]: 5.4, 32.4) in the pembrolizumab arm and 8.2 months (95% CI: 6.1, 10.2) in the chemotherapy arm (HR 0.60, 95% CI 0.45, 0.80; two-sided p-value=0.0004). At the time of the PFS analysis, the OS data were not mature.
The most common"
page_233.txt,PHESGO,HER2-positive breast cancer,500,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'pCR Rate': '59.7% in PHESGO arm, 59.5% in intravenous pertuzumab and trastuzumab arm', 'Common Adverse Reactions': ['alopecia', 'nausea', 'diarrhea', 'anemia', 'asthenia']}","The study investigated the efficacy of PHESGO in patients with HER2-positive breast cancer, showing non-inferior pertuzumab and trastuzumab serum trough concentrations compared to intravenous administration. The pCR rate was similar between PHESGO and intravenous treatment arms. Common adverse reactions included alopecia, nausea, diarrhea, anemia, and asthenia.","The FeDeriCa study compared the efficacy of PHESGO versus intravenous pertuzumab and trastuzumab in HER2-positive breast cancer patients. Overall Survival (OS) and Progression-Free Survival (PFS) were not specifically mentioned in the study results. However, the study focused on non-inferiority of pertuzumab serum trough concentration with PHESGO compared to intravenous pertuzumab. Secondary endpoints included trastuzumab serum trough concentration and pathological complete response (pCR). Response outcomes such as Objective Response Rate (ORR), Duration of Response (DOR), Complete Response (CR), and Partial Response (PR) were not mentioned in the summary provided."
page_234.txt,Pembrolizumab (KEYTRUDA),Cutaneous squamous cell carcinoma (cSCC),Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"{'ORR': '34%', 'DOR': 'Not specified'}",Pembrolizumab was approved for patients with recurrent or metastatic cSCC. The KEYNOTE-629 trial showed an objective response rate of 34% with a median response duration not reached. Adverse reactions were similar to those in other trials. Recommended doses are 200mg every 3 weeks or 400mg every 6 weeks.,"In the KEYNOTE-629 study, patients received pembrolizumab and showed an objective response rate (ORR) of 34%. The median response duration was not reached, indicating a sustained response. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study excluded patients who had prior treatment with certain antibodies or autoimmune diseases requiring immunosuppression. Tumor status was assessed regularly, and the trial demonstrated promising efficacy outcomes in terms of response rates and duration in this population."
page_235.txt,selinexor (XPOVIO),diffuse large B-cell lymphoma (DLBCL),134,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '29%', 'DOR ≥ 6 months': '38%', 'DOR ≥ 12 months': '15%'}","Selinexor was granted accelerated approval for adult patients with relapsed or refractory DLBCL based on the SADAL trial. The ORR was 29%, with 13% achieving a complete response. Common adverse reactions included fatigue, nausea, diarrhea, and thrombocytopenia. The recommended dosage is 60 mg orally on days 1 and 3 of each week.","Efficacy was based on overall response rate (ORR) and response duration, as assessed by an independent review committee using Lugano 2014 criteria. In 134 patients, the ORR was 29% (95% CI: 22, 38), with complete response in 13%. Of the 39 patients who achieved a partial or complete response, 38% had response durations of at least 6 months and 15% had response durations of at least 12 months.
The most common"
page_236.txt,Tazemetostat (TAZVERIK),Follicular Lymphoma,42 (EZH2 mutated FL) and 53 (EZH2 wild-type FL),Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'EZH2 mutated FL': '69%', 'EZH2 wild-type FL': '34%'}, 'DOR': {'EZH2 mutated FL': '10.9 months', 'EZH2 wild-type FL': '13 months'}}","Tazemetostat was granted accelerated approval for adult patients with relapsed or refractory follicular lymphoma positive for EZH2 mutation. The overall response rate was 69% in EZH2 mutated FL and 34% in EZH2 wild-type FL. The median duration of response was 10.9 months and 13 months respectively. Common adverse reactions included fatigue, upper respiratory tract infection, and musculoskeletal pain. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials.","In a study on Non-Hodgkin Lymphoma, patients with EZH2 mutant FL had a higher overall response rate (ORR) of 69%, with 12% achieving complete responses and 57% achieving partial responses. The median duration of response (DOR) in these patients was 10.9 months. In comparison, patients with EZH2 wild-type FL had a lower ORR of 34%, with 4% complete responses and 30% partial responses. The median DOR in these patients was 13 months. Overall, the study showed that EZH2 mutant FL patients had better response outcomes compared to EZH2 wild-type FL patients."
page_237.txt,Pembrolizumab (KEYTRUDA),Unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors,102,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '29%', 'Duration of Response (DoR)': 'Median DoR not reached, 57% with response durations ≥12 months, 50% with response durations ≥24 months'}","Pembrolizumab was granted accelerated approval for the treatment of adult and pediatric patients with unresectable or metastatic TMB-H solid tumors. Efficacy was demonstrated in a retrospective analysis of 102 patients, showing an ORR of 29% with a median DoR not reached. Common adverse reactions were similar to those in other solid tumors. The safety and effectiveness in pediatric patients with TMB-H central nervous system cancers have not been established.","In a retrospective analysis of patients with previously treated unresectable or metastatic TMB-H solid tumors in the KEYNOTE-158 trial, pembrolizumab showed promising efficacy. The overall response rate (ORR) was 29%, with a 4% complete response rate and 25% partial response rate. The median duration of response (DoR) was not reached, with 57% of patients having response durations ≥12 months and 50% having response durations ≥24 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the study summary."
page_238.txt,Gemtuzumab ozogamicin,Acute myeloid leukemia (AML),"1,063",Not demonstrated,Not demonstrated,Not applicable,Not provided,Not provided,Not applicable,"{'Main Efficacy Outcome Measure': 'Event-free survival (EFS)', 'EFS Hazard Ratio': '0.84 (95% CI: 0.71-0.99)', 'Percentage of Patients Free of EFS at 5 years': {'Gemtuzumab ozogamicin + chemotherapy arm': '48% (95% CI: 43%-52%)', 'Chemotherapy alone arm': '40% (95% CI: 36%-45%)'}, 'Common Grade 3 and Higher Adverse Reactions': ['Infection', 'Febrile neutropenia', 'Decreased appetite', 'Hyperglycemia', 'Mucositis', 'Hypoxia', 'Hemorrhage', 'Increased transaminase', 'Diarrhea', 'Nausea', 'Hypotension']}",Gemtuzumab ozogamicin was extended for use in pediatric patients with newly-diagnosed CD33-positive AML based on data from the AAML0531 study. The study showed a higher percentage of patients free of event-free survival in the gemtuzumab ozogamicin + chemotherapy arm compared to chemotherapy alone. No difference in overall survival was observed between the treatment arms. Common grade 3 and higher adverse reactions were reported in patients receiving gemtuzumab ozogamicin.,Efficacy and
page_239.txt,Lurbinectedin (ZEPZELCA),Metastatic Small Cell Lung Cancer (SCLC),105,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Investigator Assessment': {'ORR': '35%', 'Median Response Duration': '5.3 months'}, 'Independent Review Committee': {'ORR': '30%', 'Median Response Duration': '5.1 months'}}, 'Adverse Reactions': ['Myelosuppression', 'Fatigue', 'Increased creatinine', 'Increased alanine aminotransferase', 'Increased glucose', 'Nausea', 'Decreased appetite', 'Musculoskeletal pain', 'Decreased albumin', 'Constipation', 'Dyspnea', 'Decreased sodium', 'Increased aspartate aminotransferase', 'Vomiting', 'Cough', 'Decreased magnesium', 'Diarrhea']}","Lurbinectedin received accelerated approval for metastatic SCLC in patients with disease progression after platinum-based chemotherapy. The PM1183-B-005-14 trial demonstrated an ORR of 35% by investigator assessment and 30% by independent review committee, with median response durations of 5.3 and 5.1 months respectively. Common adverse reactions included myelosuppression, fatigue, and gastrointestinal symptoms. FDA granted orphan drug designation and priority review for lurbinectedin in SCLC.","The PM1183-B-005-14 trial showed efficacy of lurbinectedin in 105 patients with metastatic SCLC who had disease progression after platinum-based chemotherapy. The overall response rate (ORR) was 35% by investigator assessment and 30% by independent review committee. The median response duration was 5.3 months and 5.1 months, respectively. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary."
page_24.txt,Ribociclib (Kisqali),"HR-positive, HER2-negative stage II and III early breast cancer",5101,OS data immature at final analysis,OS data immature at final analysis,OS data immature at final analysis,PFS data not provided,PFS data not provided,PFS data not provided,"{'iDFS at 36 months': {'Ribociclib + NSAI arm': '90.7%', 'NSAI arm': '87.6%', 'Hazard Ratio': '0.749 (95% CI: 0.628, 0.892)'}}","Ribociclib in combination with a non-steroidal aromatase inhibitor showed a statistically significant improvement in invasive disease-free survival (iDFS) in adults with HR-positive, HER2-negative early breast cancer at high risk of recurrence. The interim analysis demonstrated a significant improvement in iDFS, with final analysis showing iDFS at 36 months of 90.7% in the ribociclib + NSAI arm compared to 87.6% in the NSAI arm.",Efficacy and
page_240.txt,Nivolumab (OPDIVO),Esophageal squamous cell carcinoma (ESCC),419,10.9 months,8.4 months,29.80%,Not improved,Not improved,Not applicable,"{'Overall Response Rate (ORR)': {'Nivolumab Arm': '19.3%', 'Taxane Chemotherapy Arm': '21.5%'}, 'Response Duration': {'Nivolumab Arm': '6.9 months', 'Taxane Chemotherapy Arm': '3.9 months'}}","Nivolumab demonstrated a statistically significant improvement in overall survival for patients with unresectable advanced, recurrent, or metastatic ESCC compared to taxane chemotherapy. The trial did not show a progression-free survival improvement. Common adverse reactions included rash, decreased appetite, diarrhea, and musculoskeletal pain.","In the ATTRACTION-3 study, patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) were treated with nivolumab or taxane chemotherapy. The study showed a statistically significant improvement in overall survival (OS) with nivolumab, with a median OS of 10.9 months compared to 8.4 months with taxane chemotherapy. The overall response rate (ORR) was similar between the two groups, but the median response duration was longer with nivolumab (6.9 months) compared to taxane chemotherapy (3.9 months). However, there was no improvement in progression-free survival (PFS) with nivolumab. These results suggest that nivolumab may be a more effective treatment option for patients with ESCC who are refractory or intolerant to standard chemotherapy regimens."
page_241.txt,Ramucirumab (CYRAMZA),Metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) mutations,449,Data not mature at the time of final analysis,Data not mature at the time of final analysis,Data not mature at the time of final analysis,19.4 months,12.4 months,"HR 0.59; 95% CI: 0.46, 0.76; p<0.0001","{'Overall Response Rate (ORR)': '76% in treatment arm, 75% in control arm', 'Duration of Response (DoR)': '18.0 months in treatment arm, 11.1 months in control arm'}","Ramucirumab in combination with erlotinib showed a significant improvement in progression-free survival (PFS) compared to placebo plus erlotinib in patients with metastatic NSCLC with EGFR mutations. Overall survival (OS) data were not mature at the time of final analysis. Common adverse reactions included infections, hypertension, and stomatitis.","In the RELAY study for metastatic NSCLC with EGFR mutations, the combination of ramucirumab and erlotinib showed a significant improvement in progression-free survival (PFS) compared to placebo plus erlotinib (19.4 vs. 12.4 months). Overall response rate (ORR) was similar between the two arms (76% vs. 75%), with a longer duration of response (DoR) in the ramucirumab group (18.0 vs. 11.1 months). Overall survival (OS) data were not mature at the time of the analysis. The study demonstrated the efficacy of adding ramucirumab to erlotinib in improving PFS in this patient population."
page_242.txt,Atezolizumab in combination with bevacizumab,Hepatocellular carcinoma,501,Not reached,13.2 months,"HR 0.58; 95% CI: 0.42, 0.79; p=0.0006",6.8 months,4.3 months,"HR 0.59; 95% CI: 0.47, 0.76; p<0.0001","{'ORR per RECIST 1.1': {'Atezolizumab plus bevacizumab': '28% (95% CI: 23, 33)', 'Sorafenib': '12% (95% CI: 7,17)'}, 'ORR per mRECIST': {'Atezolizumab plus bevacizumab': '33% (95% CI: 28, 39)', 'Sorafenib': '13% (95% CI: 8, 19)'}}","Atezolizumab in combination with bevacizumab showed significant improvement in overall survival and progression-free survival compared to sorafenib in patients with unresectable or metastatic hepatocellular carcinoma who had not received prior systemic therapy. The treatment also demonstrated higher overall response rates. Common adverse reactions included hypertension, fatigue, and proteinuria.","In the IMbrave150 study, patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab had significantly improved outcomes compared to those who received sorafenib. The median overall survival was not reached in the atezolizumab plus bevacizumab group, while it was 13.2 months in the sorafenib group. Progression-free survival was also longer in the atezolizumab plus bevacizumab group (6.8 months vs. 4.3 months). The overall response rate per RECIST 1.1 was higher in the atezolizumab plus bevacizumab group (28% vs. 12%), as well as per mRECIST (33% vs. 13%). These results suggest that atezolizumab plus bevacizumab combination therapy is more effective in treating hepatocellular carcinoma compared to sorafenib."
page_243.txt,Nivolumab (OPDIVO) plus ipilimumab (YERVOY),Non-small cell lung cancer (NSCLC),n=361 (treatment arm) and n=358 (control arm),14.1 months,10.7 months,30.84%,6.8 months,5 months,26%,"{'ORR': {'Treatment Arm': '38%', 'Control Arm': '25%'}, 'DOR': {'Treatment Arm': '10 months', 'Control Arm': '5.1 months'}}","The combination of nivolumab plus ipilimumab and chemotherapy showed a statistically significant benefit in overall survival and progression-free survival for patients with metastatic or recurrent NSCLC compared to chemotherapy alone. Adverse reactions were manageable, and the treatment regimen was well-tolerated. The study demonstrated promising efficacy outcomes, with a notable improvement in both overall survival and progression-free survival.","In the CHECKMATE-9LA study, patients with metastatic or recurrent NSCLC who received nivolumab plus ipilimumab and chemotherapy had a significantly longer overall survival (OS) compared to those who received chemotherapy alone (14.1 vs. 10.7 months). Progression-free survival (PFS) was also longer in the nivolumab plus ipilimumab group (6.8 vs. 5 months). The overall response rate (ORR) was higher in the nivolumab plus ipilimumab group (38% vs. 25%), with a longer median response duration (10 vs. 5.1 months). These results suggest that the combination of nivolumab plus ipilimumab with chemotherapy may be a more effective treatment option for patients with NSCLC."
page_244.txt,Brigatinib,Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC),275,Not provided,Not provided,Not provided,"24 months (95% CI: 18.5, NE)","11 months (95% CI: 9.2, 12.9)","HR 0.49; 95% CI: 0.35, 0.68; p<.0001","{'Confirmed ORR': '74% (95% CI: 66, 81)'}","Brigatinib was approved for ALK-positive metastatic NSCLC. In a trial of 275 patients, brigatinib showed a significant improvement in progression-free survival compared to crizotinib. The confirmed overall response rate was also higher with brigatinib. Common adverse reactions included diarrhea, fatigue, and nausea.","In the ALTA 1L study, patients with ALK-positive NSCLC who received brigatinib had a significantly longer median progression-free survival (24 months) compared to those who received crizotinib (11 months). The confirmed overall response rate was higher in the brigatinib group (74%) compared to the crizotinib group (62%). Overall survival data was not provided in the summary. Brigatinib demonstrated superior efficacy in terms of PFS and ORR compared to crizotinib in this study."
page_245.txt,Olaparib (LYNPARZA),Metastatic castration-resistant prostate cancer (mCRPC),"256 patients in olaparib arm, 131 patients in control arm",19.1 months,14.7 months,"HR 0.69; 95% CI: 0.50, 0.97, p=0.0175",7.4 months,3.6 months,"HR 0.34; 95% CI: 0.25, 0.47; p<0.0001","{'ORR': '33% vs 2% (p<0.0001)', 'DOR': 'Not specified'}","Olaparib showed significant improvement in radiological progression-free survival (rPFS) and overall survival (OS) compared to investigator's choice in patients with mCRPC carrying HRR gene mutations. Additionally, olaparib demonstrated a higher objective response rate (ORR) compared to the control arm. Common adverse reactions included anemia, nausea, fatigue, and thrombocytopenia.","In the PROfound study, olaparib showed significant efficacy compared to investigator's choice in patients with HRR gene mutations. In Cohort A, olaparib demonstrated a longer radiological progression-free survival (rPFS) of 7.4 months vs. 3.6 months, improved overall survival (OS) of 19.1 months vs. 14.7 months, and a higher objective response rate (ORR) of 33% vs. 2%. In combined Cohorts A+B, olaparib also showed a longer rPFS of 5.8 months vs. 3.5 months. These results suggest that olaparib is a more effective treatment option for patients with HRR gene mutations compared to enzalutamide or abiraterone acetate."
page_246.txt,Atezolizumab (TECENTRIQ),Metastatic non-small cell lung cancer (NSCLC),Not specified,20.2 months,13.1 months,"HR 0.59; 95% CI: 0.40, 0.89; p=0.0106",8.1 months,5.0 months,"HR 0.63; 95%CI: 0.45, 0.88",{'Overall Response Rate (ORR)': '38% vs. 29%'},Atezolizumab demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared to platinum-based chemotherapy in patients with high PD-L1 tumor expression in metastatic NSCLC. The confirmed overall response rate (ORR) was higher in the atezolizumab arm. The most common adverse reaction was fatigue/asthenia.,"In the IMpower110 study, atezolizumab showed a significant improvement in overall survival (OS) compared to platinum-based chemotherapy in patients with high PD-L1 tumor expression. The median OS was 20.2 months with atezolizumab versus 13.1 months with chemotherapy. Progression-free survival (PFS) was also longer with atezolizumab (8.1 months) compared to chemotherapy (5.0 months). The overall response rate (ORR) was higher with atezolizumab (38%) than with chemotherapy (29%). These results suggest that atezolizumab is a more effective treatment option for patients with stage IV NSCLC and high PD-L1 expression who have not received prior chemotherapy for metastatic disease."
page_247.txt,ripretinib (QINLOCK),gastrointestinal stromal tumor (GIST),129,15.1 months,6.6 months,56.06%,6.3 months,1.0 month,530%,"{'Overall Response Rate (ORR)': '9%', 'Duration of Response (DOR)': 'Not provided'}","The study evaluated the efficacy of ripretinib in patients with advanced GIST who had prior treatment with multiple kinase inhibitors. Ripretinib demonstrated a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to placebo. The median PFS was 6.3 months with ripretinib and 1.0 month with placebo. The median OS was 15.1 months with ripretinib and 6.6 months with placebo. Ripretinib also showed an overall response rate of 9%. Common adverse reactions included alopecia, fatigue, and nausea.","In the INVICTUS study, patients with GIST previously treated with imatinib, sunitinib, and regorafenib were given ripretinib or placebo. Ripretinib showed a significant improvement in PFS (HR 0.15) with a median of 6.3 months compared to 1.0 month for placebo. ORR was 9% for ripretinib and 0% for placebo. Median OS was 15.1 months for ripretinib and 6.6 months for placebo, with a HR of 0.36. Ripretinib demonstrated efficacy in improving PFS and OS in this patient population."
page_248.txt,Rucaparib (RUBRACA),Metastatic castration-resistant prostate cancer (mCRPC) with deleterious BRCA mutation,115,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '44%', 'DOR': 'Median not evaluable; range 1.7-24+ months'}","Rucaparib received accelerated approval for mCRPC with BRCA mutation based on TRITON2 trial results showing a 44% objective response rate. The median duration of response was not evaluable, with a range of 1.7-24+ months. Common adverse reactions included fatigue, nausea, anemia, and others. Continued approval may be contingent upon confirmatory trials.","In the TRITON2 study, rucaparib showed promising efficacy in patients with BRCA-mutated mCRPC. The objective response rate (ORR) was 44%, with a median duration of response (DOR) that was not evaluable. The range for DOR was 1.7-24+ months, and 56% of patients with confirmed objective responses had a DOR of ≥6 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study included 115 patients who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy, with rucaparib given orally twice daily. These results suggest that rucaparib may be a promising treatment option for this patient population."
page_249.txt,Nivolumab plus Ipilimumab,Metastatic non-small cell lung cancer,793,17.1 months,14.9 months,13.40%,5.1 months,5.6 months,8.90%,"{'ORR': '36%', 'DOR': '23.2 months'}","The combination of nivolumab plus ipilimumab showed a statistically significant improvement in overall survival and progression-free survival compared to platinum-doublet chemotherapy in patients with metastatic non-small cell lung cancer expressing PD-L1(≥1%). The treatment arm demonstrated a 13.4% improvement in overall survival and an 8.9% improvement in progression-free survival, with an overall response rate of 36% and a median response duration of 23.2 months.","In the CHECKMATE-227 study, patients with PD-L1 tumor expression ≥1% who received nivolumab plus ipilimumab had a statistically significant improvement in overall survival compared to those on platinum-doublet chemotherapy (17.1 vs. 14.9 months). Progression-free survival was slightly longer in the nivolumab plus ipilimumab group (5.1 vs. 5.6 months). The overall response rate was higher in the nivolumab plus ipilimumab group (36% vs. 30%), with a longer median response duration (23.2 vs. 6.2 months). These results suggest that the combination of nivolumab plus ipilimumab may be a more effective treatment option for patients with metastatic or recurrent NSCLC and no prior anticancer therapy."
page_25.txt,Atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza),Non-small cell lung cancer (NSCLC),371,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"{'ORR': '9% in treatment arm, 8% in control arm', 'DOR': 'Not specified'}","Atezolizumab and hyaluronidase-tqjs were approved for subcutaneous injection in adult patients with NSCLC. The study included 371 patients and showed comparable efficacy between subcutaneous and intravenous formulations in terms of ORR, PFS, and OS. Common adverse reactions included fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.",Efficacy and
page_250.txt,Pomalidomide,AIDS-related Kaposi sarcoma,28,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'HIV-positive patients': {'ORR': '67%', 'Median Response Duration': '12.5 months'}, 'HIV-negative patients': {'ORR': '80%', 'Median Response Duration': '10.5 months'}}, 'Adverse Reactions': ['Decreased absolute neutrophil count or white blood cells', 'Elevated creatinine or glucose', 'Rash', 'Constipation', 'Fatigue', 'Decreased hemoglobin, platelets, phosphate, albumin, or calcium', 'Increased ALT', 'Nausea', 'Diarrhea']}","Pomalidomide was investigated in a clinical trial for treating AIDS-related Kaposi sarcoma. The study showed an overall response rate of 67% in HIV-positive patients and 80% in HIV-negative patients, with median response durations of 12.5 months and 10.5 months respectively. Common adverse reactions were reported. The drug is recommended at a dose of 5 mg once daily until disease progression or unacceptable toxicity.","In Study 12-C-0047, a clinical trial by the National Cancer Institute, 28 patients received pomalidomide for Kaposi sarcoma. The overall response rate (ORR) was 67% for HIV-positive patients and 80% for HIV-negative patients. The median response duration was 12.5 months for HIV-positive and 10.5 months for HIV-negative patients. Overall Survival (OS) and Progression-Free Survival (PFS) data were not provided in the summary. The study showed promising response outcomes with pomalidomide treatment in both HIV-positive and HIV-negative patients with Kaposi sarcoma."
page_251.txt,Olaparib with Bevacizumab,"High-grade epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer",537 (olaparib with bevacizumab) and 269 (placebo plus bevacizumab),Data not mature,Data not mature,Data not mature,37.2 months,17.7 months,HR 0.33; 95% CI: 0.25-0.45,"{'Adverse Reactions': ['Nausea', 'Fatigue', 'Anemia', 'Lymphopenia', 'Vomiting', 'Diarrhea', 'Neutropenia', 'Leukopenia', 'Urinary tract infection', 'Headache']}","The study investigated the efficacy of olaparib with bevacizumab in patients with high-grade epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer following first-line platinum-based chemotherapy and bevacizumab. The combination showed a significant improvement in progression-free survival compared to placebo plus bevacizumab. Overall survival data were not mature. Common adverse reactions included nausea, fatigue, anemia, and others.","In the PAOLA-1 study, the combination of olaparib and bevacizumab showed significant efficacy in patients with advanced high-grade epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer after first-line platinum-based chemotherapy and bevacizumab. The median progression-free survival (PFS) was 37.2 months in the olaparib with bevacizumab group compared to 17.7 months in the placebo plus bevacizumab group. The hazard ratio for PFS was 0.33, indicating a significant improvement. Overall survival (OS) data were not mature at the time of analysis. The study also assessed response outcomes, but specific details were not provided in the summary. The combination therapy demonstrated promising results in terms of PFS, highlighting its potential as a treatment option for these patients."
page_252.txt,Selpercatinib (RETEVMO),"{'NSCLC': 'RET fusion-positive non-small cell lung cancer', 'MTC': 'RET-mutant medullary thyroid cancer', 'Thyroid Cancer': 'RET fusion-positive thyroid cancer'}","{'NSCLC': 105, 'MTC': 143, 'Thyroid Cancer': 27}","{'NSCLC': 'Not provided', 'MTC': 'Not provided', 'Thyroid Cancer': 'Not provided'}","{'NSCLC': 'Not provided', 'MTC': 'Not provided', 'Thyroid Cancer': 'Not provided'}","{'NSCLC': 'Not provided', 'MTC': 'Not provided', 'Thyroid Cancer': 'Not provided'}","{'NSCLC': 'Not provided', 'MTC': 'Not provided', 'Thyroid Cancer': 'Not provided'}","{'NSCLC': 'Not provided', 'MTC': 'Not provided', 'Thyroid Cancer': 'Not provided'}","{'NSCLC': 'Not provided', 'MTC': 'Not provided', 'Thyroid Cancer': 'Not provided'}","{'NSCLC': {'ORR': '64%', 'DOR': '81% lasting 6 months or longer'}, 'MTC': {'ORR': '69% (previously treated), 73% (not previously treated)', 'DOR': '76% lasting 6 months or longer (previously treated), 61% lasting 6 months or longer (not previously treated)'}, 'Thyroid Cancer': {'ORR': '79% (previously treated), 100% (not previously treated)', 'DOR': '87% lasting 6 months or longer (previously treated), 75% lasting 6 months or longer (not previously treated)'}}","Selpercatinib showed promising efficacy in patients with RET fusion-positive NSCLC, RET-mutant MTC, and RET fusion-positive thyroid cancer, with high overall response rates and durable responses lasting 6 months or longer in a significant percentage of patients.","In the multicenter clinical trial (LIBRETTO-001) investigating efficacy in patients with RET alterations, the overall response rate (ORR) for RET-fusion-positive NSCLC was 64% in previously treated patients and 85% in treatment-naive patients. For RET-mutant MTC, the ORR was 69% in previously treated patients and 73% in treatment-naive patients. In RET fusion-positive thyroid cancer, the ORR was 79% in previously treated patients and 100% in treatment-naive patients who had only received radioactive iodine. The majority of responding patients in all groups had responses lasting 6 months or longer. Overall survival and progression-free survival data were not provided in the summary."
page_253.txt,Capmatinib (TABRECTA),Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation,97,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': {'Treatment-naïve patients': '68%', 'Previously treated patients': '41%'}, 'Response Duration': {'Treatment-naïve patients': '12.6 months', 'Previously treated patients': '9.7 months'}, 'Adverse Reactions': ['Peripheral edema', 'Nausea', 'Fatigue', 'Vomiting', 'Dyspnea', 'Decreased appetite'], 'Safety Concerns': ['Interstitial lung disease', 'Hepatotoxicity', 'Photosensitivity', 'Embryo-fetal toxicity']}","Capmatinib (TABRECTA) was granted accelerated approval for metastatic NSCLC with MET exon 14 skipping mutation. Efficacy was demonstrated in a trial with 97 patients showing ORR of 68% in treatment-naïve and 41% in previously treated patients. Common adverse reactions include peripheral edema, nausea, and fatigue. Safety concerns include interstitial lung disease and hepatotoxicity. Continued approval may be contingent upon confirmatory trials.","The GEOMETRY mono-1 trial showed promising efficacy of capmatinib in patients with metastatic NSCLC and MET exon 14 skipping. In treatment-naïve patients, the overall response rate (ORR) was 68% with a response duration of 12.6 months. Among previously treated patients, the ORR was 41% with a response duration of 9.7 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study demonstrated significant responses in both treatment-naïve and previously treated patients, indicating the potential of capmatinib as a treatment option for this patient population."
page_254.txt,Daratumumab and hyaluronidase-fihj,Multiple Myeloma,263 (daratumumab and hyaluronidase-fihj) and 259 (intravenous daratumumab),Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Monotherapy': '41.1%', 'D-VMP': '88.1%', 'D-Rd': '90.8%'}, 'DOR': {}}","Daratumumab and hyaluronidase-fihj showed non-inferiority to intravenous daratumumab in terms of overall response rate and pharmacokinetic endpoints. In combination with VMP and Rd, it demonstrated high ORR percentages. Common adverse reactions included upper respiratory tract infection, constipation, and fatigue.","In the COLUMBA trial, daratumumab and hyaluronidase-fihj showed non-inferiority to intravenous daratumumab in terms of overall response rate (ORR) and pharmacokinetic endpoints. The ORR was 41.1% for daratumumab and hyaluronidase-fihj and 37.1% for intravenous daratumumab. In the PLEIADES trial, daratumumab and hyaluronidase-fihj in combination with VMP (D-VMP) had an ORR of 88.1% in newly diagnosed multiple myeloma patients ineligible for transplant. In the same trial, daratumumab and hyaluronidase-fihj in combination with Rd (D-Rd) had an ORR of 90.8% in patients who had received at least one prior line of therapy. Overall, daratumumab and hyaluronidase-fihj showed promising response outcomes in both monotherapy and combination therapy settings."
page_255.txt,niraparib (ZEJULA),"advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer",733,Not provided,Not provided,Not provided,"21.9 months (homologous recombination deficient population), 13.8 months (overall population)","10.4 months (homologous recombination deficient population), 8.2 months (overall population)","HR 0.43 (homologous recombination deficient population), HR 0.62 (overall population)","{'Adverse Reactions': ['thrombocytopenia', 'anemia', 'nausea', 'fatigue', 'neutropenia', 'constipation', 'musculoskeletal pain', 'leukopenia', 'headache', 'insomnia', 'vomiting', 'dyspnea', 'decreased appetite', 'dizziness', 'cough', 'hypertension', 'AST/ALT elevation', 'acute kidney injury'], 'Recommended Dose': {'Less than 77 kg or platelet count <150,000/μL': '200 mg once daily', 'Greater than or equal to 77 kg and platelet count >=150,000/μL': '300 mg once daily'}}","Niraparib (ZEJULA) was approved for maintenance treatment of advanced ovarian, fallopian tube, or peritoneal cancer in patients responding to first-line platinum-based chemotherapy. The PRIMA trial showed significant improvement in progression-free survival with niraparib compared to placebo in both homologous recombination deficient and overall populations. Common adverse reactions included thrombocytopenia, anemia, and nausea. Recommended dosing is based on body weight or platelet count.","In the PRIMA study, niraparib showed a significant improvement in progression-free survival (PFS) compared to placebo in both the homologous recombination deficient and overall population. In the homologous recombination deficient group, patients on niraparib had a median PFS of 21.9 months compared to 10.4 months on placebo. In the overall population, the median PFS was 13.8 months with niraparib versus 8.2 months with placebo. The study did not require an FDA-approved companion diagnostic for treatment initiation with niraparib. Overall survival (OS) data and response outcomes were not specifically mentioned in the summary provided."
page_256.txt,Pembrolizumab (KEYTRUDA),Advanced or metastatic melanoma,101,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '39% (95% CI: 24, 55)'}",The FDA granted accelerated approval to a new dosing regimen of pembrolizumab for advanced or metastatic melanoma based on pharmacokinetic modeling and exposure-response analyses. The ORR in the first 44 patients enrolled was 39%. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials.,"efficacy information, and recommended dosing regimens,
view the full prescribing information for KEYTRUDA
.
This new dosing regimen is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to"
page_257.txt,sacituzumab govitecan-hziy (TRODELVY),metastatic triple-negative breast cancer,108,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '33.3%', 'Response Duration': 'Median 7.7 months'}","The study demonstrated efficacy of sacituzumab govitecan-hziy in adult patients with metastatic triple-negative breast cancer who had received at least two prior therapies for metastatic disease. The primary efficacy outcome measures included an overall response rate of 33.3% and a median response duration of 7.7 months. Common adverse reactions were reported, and the recommended dose and administration schedule were provided for healthcare professionals.","In the IMMU-132-01 study for metastatic triple negative breast cancer, patients receiving sacituzumab govitecan-hziy showed an overall response rate (ORR) of 33.3% and a median response duration of 7.7 months. The study enrolled 108 patients who had received at least two prior treatments for metastatic disease. Progression-free survival (PFS) and overall survival (OS) data were not provided in the summary. The treatment was administered intravenously every 21 days until disease progression or intolerance. The results suggest that sacituzumab govitecan-hziy may be an effective treatment option for patients with metastatic triple negative breast cancer."
page_258.txt,Ibrutinib (IMBRUVICA),Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),529,Not provided,Not provided,Not provided,Not provided,Not provided,66%,"{'Main Efficacy Outcome Measure': 'Progression-Free Survival (PFS)', 'Common Adverse Reactions': ['Thrombocytopenia', 'Diarrhea', 'Fatigue', 'Musculoskeletal pain', 'Neutropenia', 'Rash', 'Anemia', 'Bruising', 'Nausea'], 'Recommended Dosage': '420 mg of Ibrutinib daily with rituximab administered in cycles'}","The FDA approved the combination of Ibrutinib with rituximab for the initial treatment of adult patients with CLL or SLL based on the E1912 trial, which showed a significant 66% improvement in progression-free survival compared to the standard FCR regimen. The most common adverse reactions include thrombocytopenia, diarrhea, and fatigue.","efficacy outcome measure was progression-free survival (PFS). The trial demonstrated a statistically significant improvement in PFS for patients receiving ibrutinib plus rituximab compared with those receiving FCR (HR 0.34; 95% CI: 0.22, 0.52; p<0.0001). Median PFS was not reached in either arm after a median follow-up duration of 37 months.
The most common"
page_259.txt,Pemigatinib (PEMAZYRE),Cholangiocarcinoma,107,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '36%', 'Duration of Response (DOR)': 'Median DOR of 9.1 months, with responses lasting ≥ 6 months in 63% of responding patients and ≥ 12 months in 18% of patients'}","Pemigatinib was granted accelerated approval for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. The FIGHT-202 trial showed an overall response rate of 36% and a median duration of response of 9.1 months, with some patients experiencing responses lasting over 12 months. Common adverse reactions included hyperphosphatemia, alopecia, diarrhea, and nail toxicity.","In the FIGHT-202 study, pemigatinib showed promising efficacy in patients with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement. The overall response rate (ORR) was 36%, with 3 complete responses. The median duration of response (DOR) was 9.1 months, with 63% of responding patients having responses lasting ≥ 6 months and 18% having responses lasting ≥ 12 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study demonstrated significant clinical benefit in this patient population, highlighting the potential of pemigatinib as a treatment option for advanced cholangiocarcinoma."
page_26.txt,Lazertinib in combination with amivantamab-vmjw,Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations,1074,Data not provided,Data not provided,Data not provided,"23.7 months (95% CI: 19.1, 27.7)","16.6 months (95% CI: 14.8, 18.5)",Data not provided,"{'ORR': 'Data not provided', 'DOR': 'Data not provided'}","The study evaluated the efficacy of lazertinib in combination with amivantamab-vmjw for the first-line treatment of locally advanced or metastatic NSCLC with specific mutations. The combination showed a statistically significant improvement in progression-free survival compared to the control arm. Overall survival results were immature at the time of analysis. Common adverse reactions included rash, nail toxicity, and infusion-related reactions. Venous thromboembolic events were observed as a serious safety signal. The study was conducted under Project Orbis for expedited review.",Efficacy and
page_260.txt,TUKYSA,HER2-positive breast cancer,612,21.9 months,17.4 months,25.30%,7.8 months,5.6 months,39.30%,"{'ORR': '40.6%', 'DOR': 'Not specified'}","TUKYSA in combination with trastuzumab and capecitabine showed significant improvement in overall survival (25.3%) and progression-free survival (39.3%) in patients with advanced HER2-positive breast cancer. The treatment also demonstrated a higher objective response rate of 40.6% compared to the control arm. Common adverse reactions included diarrhea, palmar-plantar erythrodysesthesia, and hepatotoxicity.","In the HER2CLIMB trial, tucatinib in combination with trastuzumab and capecitabine showed improved outcomes in patients with HER2-positive metastatic breast cancer who had prior treatment with specific therapies. The tucatinib arm demonstrated a longer median progression-free survival (PFS) of 7.8 months compared to 5.6 months in the control arm. Overall survival (OS) was also longer in the tucatinib arm at 21.9 months versus 17.4 months in the control arm. Patients with baseline brain metastases had a longer PFS on the tucatinib arm. The confirmed objective response rate (ORR) was higher in the tucatinib arm at 40.6% compared to 22.8% in the control arm. These results suggest that tucatinib may be a beneficial treatment option for this patient population."
page_261.txt,JELMYTO,Low-grade upper tract urothelial cancer (LG-UTUC),71,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'CR': '58% achieved complete response at 3 months', 'CR Durability': '19 patients remained in complete response at 12 months', 'Adverse Reactions': ['Ureteric obstruction', 'Flank pain', 'Urinary tract infection', 'Hematuria', 'Renal dysfunction', 'Fatigue', 'Nausea', 'Abdominal pain', 'Dysuria', 'Vomiting']}","JELMYTO was approved for LG-UTUC based on the OLYMPUS trial with 71 patients. 58% achieved complete response at 3 months, with 19 patients remaining in complete response at 12 months. Common adverse reactions included ureteric obstruction, flank pain, and urinary tract infection.","The study on JELMYTO for low-grade non-invasive UTUC showed promising results. 58% of patients achieved a complete response (CR) three months after treatment initiation, with 19 patients remaining in CR at 12 months. The median response duration had not been reached, indicating a potentially long-lasting response. Progression-Free Survival (PFS) and Overall Survival (OS) data were not provided in the summary. The study focused on CR and CR durability as the major efficacy outcomes, with patients receiving maintenance therapy if they achieved a CR. Response outcomes were assessed at 3, 6, 9, and 12 months following CR determination, with some patients experiencing recurrences. Further analysis of PFS and OS would provide a more comprehensive understanding of the treatment's effectiveness."
page_262.txt,Selumetinib (KOSELUGO),"Neurofibromatosis type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas (PN)",50,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '66%', 'Duration of Response (DOR)': '82% of responders had sustained responses lasting at least 12 months'}","Selumetinib was approved for pediatric patients with NF1 and inoperable PN. The primary efficacy outcome measure showed an overall response rate of 66%, with all patients having a partial response. The drug demonstrated sustained responses lasting at least 12 months in 82% of responders.","The study investigated the efficacy of selumetinib in pediatric patients with NF1 and a measurable target PN. The overall response rate (ORR) was 66%, with all patients showing a partial response. 82% of responders had sustained responses lasting at least 12 months. The progression-free survival (PFS) and overall survival (OS) data were not specifically mentioned in the summary provided. An independent central review showed an ORR of 44%. The study demonstrated promising results in terms of tumor volume reduction and sustained responses in pediatric patients with NF1 and target PN. Further analysis of PFS and OS outcomes would provide a more comprehensive understanding of the treatment's effectiveness in this patient population."
page_263.txt,Encorafenib (BRAFTOVI),Metastatic colorectal cancer (CRC) with a BRAF V600E mutation,441,8.4 months,5.4 months,36.84%,4.2 months,1.5 months,64.00%,"{'Overall Response Rate (ORR)': '20% vs. 2%', 'Duration of Response (DOR)': '6.1 months vs. not reached'}","Encorafenib in combination with cetuximab showed significant improvement in overall survival (OS) and progression-free survival (PFS) compared to the control arm in patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation. The treatment arm also demonstrated higher overall response rate (ORR) and longer duration of response (DOR). Common adverse reactions included fatigue, nausea, diarrhea, and dermatitis acneiform.","In the BEACON CRC trial, patients with BRAF V600E mutation-positive metastatic CRC who received encorafenib plus cetuximab had significantly improved outcomes compared to those on the control arm. The median overall survival was 8.4 months vs. 5.4 months, with a hazard ratio (HR) of 0.60. Progression-free survival was also longer in the encorafenib group at 4.2 months vs. 1.5 months (HR 0.40). The overall response rate was 20% vs. 2%, and the median duration of response was 6.1 months vs. not reached. These results demonstrate the efficacy of encorafenib plus cetuximab in improving survival and response outcomes in patients with BRAF V600E mutation-positive metastatic CRC."
page_264.txt,luspatercept-aamt (REBLOZYL),Myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T),229,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,{'RBC-TI Rate': '37.9% for luspatercept-aamt vs. 13.2% for placebo'},"The study evaluated the efficacy of luspatercept-aamt in patients with low- to intermediate-risk myelodysplastic syndromes who required red blood cell transfusions. Results showed a significantly higher proportion of patients achieving red blood cell transfusion independence with luspatercept-aamt compared to placebo. Common adverse reactions to the drug include fatigue, headache, and musculoskeletal pain.","The MEDALIST trial showed that luspatercept-aamt significantly increased the proportion of patients with IPSS-R very low, low, or intermediate-risk myelodysplastic syndromes who were RBC-transfusion independent compared to placebo. Of the patients who received luspatercept-aamt, 37.9% were RBC-TI for at least 8 weeks, while only 13.2% of patients who received placebo achieved this outcome. The treatment difference was 24.6% (p<0.0001). Overall survival (OS) and progression-free survival (PFS) data were not provided in the study summary."
page_265.txt,Durvalumab,Extensive-stage small cell lung cancer (ES-SCLC),Not specified,13.0 months,10.3 months,26.20%,5.1 months,5.4 months,5.60%,"{'ORR': '68%', 'DOR': 'Not specified'}","Durvalumab in combination with chemotherapy showed a significant improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy alone in patients with extensive-stage small cell lung cancer (ES-SCLC). The treatment arm demonstrated a 26.2% improvement in OS and a 5.6% improvement in PFS. Additionally, the objective response rate (ORR) was 68% in the durvalumab plus chemotherapy arm.","In the CASPIAN study, the combination of durvalumab plus chemotherapy in previously untreated ES-SCLC patients showed improved overall survival (OS) with a median of 13.0 months compared to 10.3 months with chemotherapy alone. Progression-free survival (PFS) was also better with a median of 5.1 months in the durvalumab plus chemotherapy arm versus 5.4 months in the chemotherapy alone arm. The objective response rate (ORR) was higher at 68% in the durvalumab plus chemotherapy arm compared to 58% in the chemotherapy alone arm. These results suggest that the combination therapy may be more effective in improving survival outcomes for patients with ES-SCLC."
page_266.txt,Nivolumab and Ipilimumab,Hepatocellular Carcinoma (HCC),49,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '33%', 'Duration of Response (DOR)': '4.6 to 30.5+ months', 'Complete Responses': 4, 'Partial Responses': 12, 'Responses lasting at least 24 months': '31%'}","The combination of nivolumab and ipilimumab showed an overall response rate of 33% in patients with hepatocellular carcinoma who had previously been treated with sorafenib. The duration of response ranged from 4.6 to over 30.5 months, with 31% of responses lasting at least 24 months. Common adverse reactions included fatigue, diarrhea, rash, and nausea. Further confirmatory trials are required for continued approval.","In Cohort 4 of CHECKMATE-040, a study on patients with HCC who had progressed on sorafenib, the combination of nivolumab and ipilimumab showed promising results. The overall response rate (ORR) was 33%, with 4 complete responses and 12 partial responses. The duration of response ranged from 4.6 to over 30.5 months, with 31% lasting at least 24 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary."
page_267.txt,Isatuximab-irfc,Multiple Myeloma,307,Not provided,Not provided,Not provided,11.53 months,6.47 months,40%,"{'Adverse Reactions': ['Neutropenia', 'Infusion-related reactions', 'Pneumonia', 'Upper respiratory tract infection', 'Diarrhea']}","Isatuximab-irfc in combination with pomalidomide and dexamethasone showed a 40% reduction in the risk of disease progression or death in patients with relapsed and refractory multiple myeloma who had received at least two prior therapies. The most common adverse reactions were neutropenia, infusion-related reactions, pneumonia, upper respiratory tract infection, and diarrhea.","The study showed that patients treated with Isa-Pd had a 40% reduction in the risk of disease progression or death compared to those treated with Pd alone. The median progression-free survival (PFS) for Isa-Pd was 11.53 months, while it was 6.47 months for Pd alone. Overall survival (OS) data was not provided. Response outcomes such as overall response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not mentioned in the study results."
page_268.txt,Neratinib,HER2-positive breast cancer,621,21 months,18.7 months,12.30%,5.6 months,5.5 months,1.80%,"{'ORR': {'Treatment': '32.8%', 'Control': '26.7%'}, 'DOR': {'Treatment': '8.5 months', 'Control': '5.6 months'}}","Neratinib in combination with capecitabine showed a 12.3% improvement in overall survival compared to lapatinib plus capecitabine in patients with HER2-positive breast cancer. The progression-free survival was slightly better with neratinib, with a 1.8% improvement. Additionally, the objective response rate was higher and the response duration was longer in the neratinib group.","In the NALA study, neratinib with capecitabine showed a longer median progression-free survival (PFS) of 5.6 months compared to lapatinib with capecitabine at 5.5 months. The PFS rate at 12 months was also higher with neratinib-capecitabine combination. However, there was no significant difference in overall survival (OS) between the two groups. The objective response rate (ORR) was higher with neratinib-capecitabine at 32.8% compared to 26.7% with lapatinib-capecitabine. The median response duration was also longer with neratinib-capecitabine at 8.5 months compared to 5.6 months with lapatinib-capecitabine. Overall, neratinib with capecitabine showed better PFS and response outcomes in patients with metastatic HER2-positive breast cancer compared to lapatinib with capecitabine."
page_269.txt,Tazemetostat (TAZVERIK),Metastatic or locally advanced epithelioid sarcoma,62,Not provided,Not applicable,Not applicable,Not provided,Not applicable,Not applicable,"{'Overall Response Rate (ORR)': '15%', 'Complete Responses': '1.6%', 'Partial Responses': '13%', 'Duration of Response': '67% lasting 6 months or longer'}","Tazemetostat was granted accelerated approval for adults and pediatric patients with metastatic or locally advanced epithelioid sarcoma. The study showed an overall response rate of 15%, with 67% of responders having responses lasting 6 months or longer. Common adverse reactions included pain, fatigue, nausea, decreased appetite, vomiting, and constipation.","In a study of patients with epithelioid sarcoma, tazemetostat showed an overall response rate (ORR) of 15%, with 1.6% achieving complete responses and 13% achieving partial responses. The duration of response was 6 months or longer in 67% of responders. The study focused on patients with INI1 loss and an Eastern Cooperative Oncology Group performance status of 0-2. Progression-free survival (PFS) and overall survival (OS) data were not provided in the summary."
page_27.txt,Durvalumab (Imfinzi),Non-small cell lung cancer (NSCLC),802,Not formally tested for statistical significance,Not formally tested for statistical significance,Not applicable,Not provided,Not provided,Not applicable,"{'Event-free Survival (EFS)': 'Hazard ratio 0.68 (95% CI: 0.53, 0.88); p-value=0.0039', 'Pathological Complete Response (pCR)': 'Durvalumab arm: 17% (95% CI: 13, 21); Placebo arm: 4.3% (95% CI: 2.5, 7)'}","Durvalumab with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery, showed promising results in patients with resectable NSCLC. EFS and pCR rates were favorable in the durvalumab arm compared to placebo, with no clear detriment in overall survival observed. Common adverse reactions included anemia, nausea, constipation, fatigue, musculoskeletal pain, and rash.",Efficacy and
page_270.txt,Avapritinib (AYVAKIT),Gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation,43,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Overall': '84%', 'PDGFRA D842V mutations': '89%'}, 'DOR': 'Median response duration not reached'}","Avapritinib was approved for unresectable or metastatic GIST with PDGFRA exon 18 mutation, showing high overall response rates of 84% and 89% for different mutation subgroups. The median response duration was not reached, with a significant proportion of patients experiencing responses lasting 6 months or longer. Common adverse reactions included edema, nausea, fatigue, and others. The recommended dose is 300 mg orally once daily. FDA granted priority review and Breakthrough Therapy designation for this treatment.","The NAVIGATOR study (NCT02508532) evaluated the efficacy of avapritinib in 43 patients with GIST harboring a PDGFRA exon 18 mutation, including 38 patients with PDGFRA D842V mutations. The overall response rate (ORR) was 84% for exon 18 mutations and 89% for D842V mutations, with a combination of complete (7% and 8%) and partial responses (77% and 82%). The median response duration was not reached, with 61% of patients with exon 18 mutations having a response lasting 6 months or longer. Overall survival (OS) and progression-free survival (PFS) data were not provided. Avapritinib showed promising efficacy in patients with these specific mutations, with a high ORR and durable responses observed."
page_271.txt,Pembrolizumab (KEYTRUDA),"Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)",148,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Complete Response Rate': '41%', 'Median Response Duration': '16.2 months', 'Complete Response Lasting ≥12 months': '46%'}","Pembrolizumab was approved for the treatment of BCG-unresponsive, high-risk NMIBC with CIS. In a trial of 148 patients, the complete response rate was 41% with a median response duration of 16.2 months. 46% of responding patients had a complete response lasting at least 12 months. Common adverse reactions included fatigue, diarrhea, rash, and musculoskeletal pain.","In the KEYNOTE-057 study, pembrolizumab showed promising efficacy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who were unresponsive to BCG therapy. The complete response rate in patients with BCG-unresponsive NMIBC with carcinoma in situ (CIS) was 41%, with a median response duration of 16.2 months. 46% of responding patients had a complete response lasting at least 12 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study focused on complete response rates and duration of response as key outcomes, showing positive results in this patient population."
page_28.txt,Axatilimab-csfr (Niktimvo),Chronic graft-versus-host disease (cGVHD),79,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '75%', 'Median Time to First Response': '1.5 months', 'Median Duration of Response': '1.9 months', 'Percentage of Patients with no death or new systemic therapy initiation for at least 12 months since response': '60%'}","Axatilimab-csfr (Niktimvo) was approved for the treatment of cGVHD after failure of at least two prior lines of systemic therapy. In a trial with 79 patients, the overall response rate was 75%. The median time to first response was 1.5 months, and the median duration of response was 1.9 months. 60% of patients had no death or new systemic therapy initiation for at least 12 months since response.",Efficacy and
page_29.txt,Voranigo,Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation,331,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Major Efficacy Outcome Measure': 'Progression-Free Survival (PFS)', 'Additional Efficacy Outcome Measure': 'Time to next intervention'}","The FDA approved Voranigo for adult and pediatric patients with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. The efficacy was evaluated in 331 patients enrolled in a randomized trial, showing significant improvement in progression-free survival and time to next intervention. Common adverse reactions included fatigue, headache, COVID-19 infection, musculoskeletal pain, diarrhea, nausea, and seizure. Voranigo received priority review, fast track designation, breakthrough designation, and orphan drug designation.",Efficacy and
page_3.txt,Acalabrutinib (Calquence),Mantle Cell Lymphoma (MCL),598,Not provided,Not provided,Not provided,66.4 months,49.6 months,33.87%,"{'Serious Adverse Reactions': '69% with acalabrutinib plus BR, fatal reactions in 12%', 'Recommended Dose': '100 mg orally every 12 hours', 'Collaboration': 'FDA collaborated with international partners for review'}","Acalabrutinib in combination with bendamustine and rituximab showed a statistically significant improvement in progression-free survival for untreated mantle cell lymphoma patients ineligible for stem cell transplantation. Serious adverse reactions were reported, and the drug received traditional approval for this indication in 2025.",Efficacy and
page_30.txt,afamitresgene autoleucel (TECELRA),synovial sarcoma,44,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '43.2%', 'Duration of Response (DOR)': 'Median DOR of 6 months', 'Time to Response': 'Median time of 4.9 weeks', 'Duration of Response >6 months': '45.6%', 'Duration of Response >12 months': '39.0%'}","Afamitresgene autoleucel showed an overall response rate of 43.2% in patients with synovial sarcoma, with a median duration of response of 6 months. The treatment demonstrated promising efficacy in this patient population.","In the SPEARHEAD-1 study, 44 patients with inoperable or metastatic synovial sarcoma received afamitresgene autoleucel after lymphodepleting chemotherapy. The overall response rate (ORR) was 43.2%, with a median duration of response (DOR) of 6 months. 45.6% of responsive patients had a DOR of at least 6 months, and 39.0% had a DOR of at least 12 months. The median time to response was 4.9 weeks. The study also noted a Boxed Warning for serious or fatal cytokine release syndrome (CRS) as a potential side effect. Overall survival (OS) and progression-free survival (PFS) outcomes were not specifically mentioned in the summary."
page_31.txt,"Dostarlimab-gxly (Jemperli, GSK)",Endometrial cancer (EC),494,44.6 months,28.2 months,37.60%,11.8 months,7.9 months,49.40%,{},"The study evaluated the efficacy of Dostarlimab-gxly in combination with carboplatin and paclitaxel followed by monotherapy in patients with primary advanced or recurrent endometrial cancer. Significant improvements were observed in overall survival (OS) and progression-free survival (PFS) compared to the placebo arm, with a 37.6% improvement in OS and a 49.4% improvement in PFS in the overall population.",Efficacy and
page_32.txt,Darzalex Faspro,Multiple Myeloma,709,Not provided,Not provided,Not provided,Not reached,Not reached,60%,"{'Adverse Reactions': ['Peripheral neuropathy', 'Fatigue', 'Edema', 'Pyrexia', 'Upper respiratory infection', 'Constipation', 'Diarrhea', 'Musculoskeletal pain', 'Insomnia', 'Rash']}","Darzalex Faspro in combination with bortezomib, lenalidomide, and dexamethasone showed a 60% reduction in the risk of disease progression or death compared to VRd alone in patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant. Common adverse reactions included peripheral neuropathy, fatigue, and edema.",Efficacy and
page_33.txt,Epcoritamab-bysp (Epkinly),Follicular lymphoma (FL),127,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '82%', 'DOR': 'Not reached (NR) with 12-month Kaplan-Meier estimate of 68.4%'}",Epcoritamab-bysp received accelerated approval for adult patients with relapsed or refractory follicular lymphoma. The study included 127 patients with promising overall response rate of 82% and duration of response not reached at 14.8 months. Adverse events included cytokine release syndrome and serious infections. A Phase 3 trial is ongoing to further evaluate the clinical benefit of epcoritamab-bysp.,Efficacy and
page_34.txt,Adagrasib (Krazati),Locally advanced or metastatic colorectal cancer (CRC) with KRAS G12C mutation,94,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '34%', 'Duration of Response (DOR)': 'Median 5.8 months, 31% with DOR of at least 6 months'}","Adagrasib (Krazati) in combination with cetuximab showed a 34% overall response rate in patients with KRAS G12C-mutated CRC. The median duration of response was 5.8 months, with 31% of responders having a duration of response of at least 6 months. Common adverse reactions included rash, nausea, diarrhea, and fatigue.",Efficacy and
page_35.txt,Pembrolizumab (Keytruda),Endometrial Carcinoma,810,Not provided,Not provided,Not provided,"Median PFS not reached in dMMR cohort, 11.1 months in pMMR cohort","6.5 months in dMMR cohort, 8.5 months in pMMR cohort","HR 0.30 in dMMR cohort, HR 0.60 in pMMR cohort","{'ORR': 'Not provided', 'DOR': 'Not provided'}","Pembrolizumab in combination with chemotherapy showed significant improvement in progression-free survival for patients with advanced or recurrent endometrial carcinoma, particularly in the dMMR cohort. Adverse reactions were generally manageable, with a higher incidence of rash observed. The study was part of Project Orbis, a collaborative initiative for concurrent review of oncology drugs among international partners.","In the KEYNOTE-868/NRG-GY018 study, patients with advanced or recurrent endometrial carcinoma were divided into dMMR and pMMR cohorts. In the dMMR cohort, pembrolizumab with chemotherapy showed significantly longer median PFS compared to placebo with chemotherapy (NR vs. 6.5 months). In the pMMR cohort, pembrolizumab with chemotherapy also had a longer median PFS compared to placebo with chemotherapy (11.1 vs. 8.5 months). Overall survival data was not provided. The study demonstrated that pembrolizumab in combination with chemotherapy improved PFS in both dMMR and pMMR patients, highlighting its potential as a treatment option for advanced or recurrent endometrial carcinoma."
page_36.txt,"blinatumomab (Blincyto, Amgen Inc.)",CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph-negative BCP ALL),"{'Study E1910': 224, 'Study 20120215': 111}","{'Study E1910': '3-year OS: 84.8%, 5-year OS: 82.4%', 'Study 20120215': '5-year OS: 78.4%'}","{'Study E1910': '3-year OS: 69%, 5-year OS: 62.5%', 'Study 20120215': '5-year OS: 41.4%'}","{'Study E1910': '3-year OS: 22.8%, 5-year OS: 19.9%', 'Study 20120215': '5-year OS: 37%'}","{'Study E1910': 'Not provided', 'Study 20120215': 'Not provided'}","{'Study E1910': 'Not provided', 'Study 20120215': 'Not provided'}","{'Study E1910': 'Not provided', 'Study 20120215': 'Not provided'}","{'Study E1910': {'Adverse Reactions': ['neutropenia', 'thrombocytopenia', 'anemia', 'leukopenia', 'headache', 'infection', 'nausea', 'lymphopenia', 'diarrhea', 'musculoskeletal pain', 'tremor']}, 'Study 20120215': {'Adverse Reactions': ['pyrexia', 'nausea', 'headache', 'rash', 'hypogammaglobulinemia', 'anemia']}}","Blinatumomab showed significant improvement in overall survival rates for patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia compared to intensive chemotherapy alone. The drug demonstrated a 22.8% to 37% improvement in 3 to 5-year overall survival rates across different studies, with manageable adverse reactions reported.",Efficacy and
page_37.txt,Durvalumab (Imfinzi),Endometrial cancer,95 patients with dMMR tumors,Not available,Not available,Not available,PFS not reached in durvalumab arm,7 months in placebo arm,42%,"{'ORR': 'Not available', 'DOR': 'Not available'}","Durvalumab in combination with carboplatin plus paclitaxel showed a 42% improvement in progression-free survival compared to carboplatin and paclitaxel alone in patients with dMMR endometrial cancer. Overall survival data was immature at the time of the PFS analysis. Common adverse reactions included peripheral neuropathy, musculoskeletal pain, nausea, and fatigue.",Efficacy and
page_38.txt,Repotrectinib (AUGTYRO),Solid tumors with NTRK gene fusion,88,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR) - TKI-naïve group': '58%', 'Overall Response Rate (ORR) - TKI-pretreated group': '50%', 'Duration of Response (DOR) - TKI-naïve group': 'NE', 'Duration of Response (DOR) - TKI-pretreated group': '9.9 months'}","Repotrectinib (AUGTYRO) received accelerated approval for solid tumors with NTRK gene fusion in adult and pediatric patients. Efficacy was demonstrated in a trial with 88 patients showing promising overall response rates and duration of response. Common adverse reactions included dizziness, dysgeusia, and peripheral neuropathy. The recommended dose is 160 mg orally once daily. The drug was granted priority review and expedited programs by the FDA.",Efficacy and
page_39.txt,Selpercatinib (Retevmo),RET fusion-positive thyroid cancer,65,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Previously Treated Patients': '85%', 'Systemic Therapy Naïve Patients': '96%', 'Pediatric and Young Adult Patients': '60%'}, 'DOR': {'Previously Treated Patients': '26.7 months', 'Systemic Therapy Naïve Patients': 'Not evaluable', 'Pediatric and Young Adult Patients': '≥12 months'}}","Selpercatinib (Retevmo) received traditional approval for RET fusion-positive thyroid cancer in patients 2 years and older. Efficacy was evaluated in a multicenter trial showing high ORR and DOR rates. Common adverse reactions included edema, diarrhea, and fatigue. The drug received breakthrough and orphan drug designations.",Efficacy and
page_4.txt,Nivolumab and hyaluronidase-nvhy (Opdivo Qvantig),Clear cell renal cell carcinoma,495,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '24% in treatment arm, 18% in control arm'}","The FDA approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in patients with clear cell renal cell carcinoma. The CHECKMATE-67T trial showed a similar safety profile between subcutaneous and intravenous administration. The primary objective was to assess nivolumab exposure, with an overall response rate of 24% in the treatment arm and 18% in the control arm.",Efficacy and
page_40.txt,Imetelstat (Rytelo),Myelodysplastic syndromes (MDS),178,Median follow up time of 19.5 months,Median follow up time of 17.5 months,39.8% achieved ≥ 8-week RBC-TI in treatment group vs. 15% in control group,Not specified,Not specified,Not specified,"{'Adverse Reactions': ['Decreased platelets', 'Decreased white blood cells', 'Decreased neutrophils', 'Increased liver enzymes', 'Fatigue', 'Prolonged partial thromboplastin time', 'Arthralgia/myalgia', 'COVID-19 infections', 'Headache'], 'Dosage': '7.1 mg/kg administered as an intravenous infusion over 2 hours every 4 weeks'}","Imetelstat (Rytelo) was approved for adults with low- to intermediate-1 risk MDS with transfusion-dependent anemia. In a trial of 178 patients, the treatment group showed a significantly higher rate of achieving ≥ 8-week RBC-TI compared to the placebo group. Common adverse reactions included decreased blood cell counts, liver enzyme abnormalities, fatigue, and headache. The recommended dosage is 7.1 mg/kg every 4 weeks.","In the IMerge study, imetelstat showed significant efficacy in patients with MDS compared to placebo. The imetelstat group had higher rates of ≥ 8-week and ≥ 24-week RBC transfusion independence (RBC-TI) at 39.8% and 28% respectively, compared to 15% and 3.3% in the placebo group. Overall Survival (OS) and Progression-Free Survival (PFS) data were not provided in the summary. Response outcomes such as Overall Response Rate (ORR), Duration of Response (DOR), Complete Response (CR), and Partial Response (PR) were not mentioned in the study results. The study focused on RBC transfusion independence as a measure of efficacy in MDS patients receiving imetelstat."
page_41.txt,lisocabtagene maraleucel (Breyanzi),mantle cell lymphoma (MCL),68,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '85.3%', 'CRR': '67.6%', 'DOR': '13.3 months'}","The FDA approved lisocabtagene maraleucel for adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy. The drug demonstrated an overall response rate of 85.3% and a complete response rate of 67.6%. The median duration of response was 13.3 months. Common adverse reactions included cytokine release syndrome, fatigue, musculoskeletal pain, and encephalopathy. The recommended dose is 90 to 110 × 10^6 CAR-positive viable T cells with a 1:1 ratio of CD4 and CD8 components.",Efficacy and
page_42.txt,Selpercatinib (Retevmo),Solid tumors with RET gene fusion,25,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Confirmed Overall Response Rate (ORR)': '48%', 'Duration of Response (DOR)': 'Not reached, 92% responders at 12 months', 'Common Adverse Reactions': ['Musculoskeletal pain', 'Diarrhea', 'Headache', 'Nausea', 'Vomiting', 'Coronavirus infection', 'Abdominal pain', 'Fatigue', 'Pyrexia', 'Hemorrhage'], 'Common Grade 3 or 4 Laboratory Abnormalities': ['Decreased calcium', 'Decreased hemoglobin', 'Decreased neutrophils']}","Selpercatinib (Retevmo) was granted accelerated approval for pediatric patients with solid tumors with RET gene fusion. In a trial with 25 patients, the confirmed overall response rate was 48%, with durable responses observed in patients with RET-mutant MTC and RET fusion-positive thyroid cancer. Common adverse reactions included musculoskeletal pain, diarrhea, and headache. The recommended dose varies based on age. The study was conducted under a pediatric Written Request and received priority review and orphan drug designation.","The study evaluated the efficacy of selpercatinib in pediatric and young adult patients with RET-activated solid tumors. The confirmed overall response rate (ORR) was 48%, with a median duration of response (DOR) not reached and 92% of responders remaining in response at 12 months. Durable responses were seen in patients with RET-mutant MTC (ORR 43%) and RET fusion-positive thyroid cancer (ORR 60%). Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study demonstrated promising outcomes in terms of response rates and duration of response in this patient population."
page_43.txt,Tarlatamab-dlle (Imdelltra),Extensive stage small cell lung cancer (ES-SCLC),99,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '40%', 'Duration of Response (DOR)': '9.7 months', 'Platinum-resistant SCLC ORR': '52%', 'Platinum-sensitive SCLC ORR': '31%'}","Tarlatamab-dlle (Imdelltra) received accelerated approval for ES-SCLC with disease progression after platinum-based chemotherapy. The study included 99 patients and showed an overall response rate of 40% with a median duration of response of 9.7 months. The drug comes with a Boxed Warning for cytokine release syndrome and neurologic toxicity. FDA granted accelerated approval based on response rate and duration of response, with continued approval contingent upon verification of clinical benefit.",Efficacy and
page_44.txt,lisocabtagene maraleucel (Breyanzi),follicular lymphoma (FL),94,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '95.7%', 'Duration of Response (DOR)': 'Median not reached'}","The FDA granted accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy. The Phase 2 trial showed a high overall response rate of 95.7% with a median duration of response not reached after a median follow-up of 16.8 months. Common adverse reactions included cytokine release syndrome, headache, musculoskeletal pain, fatigue, constipation, and fever.",Efficacy and
page_45.txt,Tivdak (tisotumab vedotin-tftv),Recurrent or metastatic cervical cancer,502,11.5 months,9.5 months,21.05%,4.2 months,2.9 months,44.83%,{'ORR': '17.8%'},"Tivdak (tisotumab vedotin-tftv) was granted traditional approval for recurrent or metastatic cervical cancer. In a trial of 502 patients, Tivdak showed a significant improvement in overall survival (OS) with a median OS of 11.5 months compared to 9.5 months in the control arm. Progression-free survival (PFS) was also improved with a median PFS of 4.2 months in the treatment arm versus 2.9 months in the control arm. The confirmed objective response rate (ORR) was 17.8%. Adverse reactions were manageable with the recommended dose of 2 mg/kg every 3 weeks.",Efficacy and
page_46.txt,Tovorafenib (Ojemda),"Pediatric low-grade glioma (LGG) with BRAF fusion or rearrangement, or BRAF V600 mutation",76,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '51%', 'Duration of Response (DoR)': 'Median 13.8 months'}","Tovorafenib (Ojemda) received accelerated approval for pediatric LGG with BRAF alterations based on an ORR of 51% and a median DoR of 13.8 months in a trial of 76 patients. Common adverse reactions included rash, hair color changes, and fatigue. Continued approval may require verification in confirmatory trials.",Efficacy and
page_47.txt,Lutetium Lu 177 dotatate (Lutathera),SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs),9 pediatric patients in NETTER-P,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': 'Not provided', 'DOR': 'Not provided'}","Lutetium Lu 177 dotatate (Lutathera) was approved by the FDA for pediatric patients 12 years and older with SSTR-positive GEP-NETs. The approval was based on data from the NETTER-P study, showing efficacy and safety in adolescent patients with GEP-NETs. The recommended dose is 7.4 GBq every 8 weeks for a total of 4 doses. The adverse reaction profile in pediatric patients was similar to that in adults. Further assessment of long-term safety is required post-marketing.",Efficacy and
page_48.txt,Nogapendekin alfa inbakicept-pmln (Anktiva),Non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors,77,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'CR Rate': '62%', 'Duration of Complete Response (DOR)': {'≥ 12 months': '58%', '≥ 24 months': '40%'}, 'Common Adverse Reactions': ['Increased creatinine', 'Dysuria', 'Hematuria', 'Urinary frequency', 'Micturition urgency', 'Urinary tract infection', 'Increased potassium', 'Musculoskeletal pain', 'Chills', 'Pyrexia']}","Nogapendekin alfa inbakicept-pmln (Anktiva) was approved for BCG-unresponsive NMIBC with CIS with or without papillary tumors. Efficacy was evaluated in a trial of 77 patients showing a CR rate of 62%. Adverse reactions included increased creatinine, dysuria, and urinary tract infections. The recommended dose and administration schedule were provided for induction and maintenance therapy.",Efficacy and
page_49.txt,Alectinib (Alecensa),Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC),257,Median DFS not reached in alectinib arm,44.4 months in chemotherapy arm,"HR 0.24 [95% CI: 0.13, 0.45]; p<0.0001",Not provided,Not provided,Not provided,"{'Adverse Reactions': ['Hepatotoxicity', 'Constipation', 'Myalgia', 'COVID-19', 'Fatigue', 'Rash', 'Cough']}","Alectinib was approved for adjuvant treatment in ALK-positive NSCLC patients post-tumor resection. In a randomized trial, alectinib showed significant improvement in disease-free survival compared to chemotherapy. Common adverse reactions included hepatotoxicity, constipation, myalgia, and fatigue. The recommended dose is 600 mg orally twice daily for 2 years or until disease recurrence or unacceptable toxicity.",Efficacy and
page_5.txt,Encorafenib (Braftovi),Metastatic colorectal cancer (mCRC) with a BRAF V600E mutation,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"{'ORR': '61% in encorafenib+cetuximab+mFOLFOX6 arm, 40% in control arm', 'DOR': '13.9 months in encorafenib+cetuximab+mFOLFOX6 arm, 11.1 months in control arm'}",Encorafenib in combination with cetuximab and mFOLFOX6 showed a higher objective response rate (ORR) and longer median duration of response (DOR) compared to the control arm in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The study is ongoing to evaluate progression-free survival and overall survival for further evidence.,Efficacy and
page_50.txt,fam-trastuzumab deruxtecan-nxki (Enhertu),HER2-positive solid tumors,192,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'DESTINY-PanTumor02': {'ORR': '51.4%', 'DOR': '19.4 months'}, 'DESTINY-Lung01': {'ORR': '52.9%', 'DOR': '6.9 months'}, 'DESTINY-CRC02': {'ORR': '46.9%', 'DOR': '5.5 months'}}}","Enhertu was granted accelerated approval for adult patients with unresectable or metastatic HER2-positive solid tumors. Efficacy was evaluated in 192 patients across three trials, showing promising objective response rates and duration of response. Common adverse reactions were reported, and the drug's prescribing information includes warnings for interstitial lung disease and embryo-fetal toxicity. The recommended dosage is 5.4 mg/kg every 3 weeks. The approval was based on ORR and DOR, with continued approval contingent on further clinical benefit confirmation.","In three multicenter trials involving 192 adult patients with previously treated HER2-positive solid tumors, the confirmed objective response rates (ORR) were 51.4% in DESTINY-PanTumor02, 52.9% in DESTINY-Lung01, and 46.9% in DESTINY-CRC02. The median duration of response (DOR) was 19.4 months in DESTINY-PanTumor02, 6.9 months in DESTINY-Lung01, and 5.5 months in DESTINY-CRC02. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The trials excluded patients with certain medical conditions and treatment was administered until disease progression, death, withdrawal of consent, or unacceptable toxicity. The outcomes were assessed by independent central review based on RECIST v1.1 criteria."
page_51.txt,Mirvetuximab soravtansine-gynx (Elahere),"Platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer",453,16.5 months,12.7 months,30.70%,5.6 months,4.0 months,40%,"{'ORR': '42%', 'DOR': 'Not provided'}","Mirvetuximab soravtansine-gynx showed significant improvement in overall survival (30.7%) and progression-free survival (40%) compared to chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The drug also demonstrated a higher overall response rate of 42%.","In Study 0416 (MIRASOL), mirvetuximab soravtansine-gynx showed improved overall survival (OS) with a median of 16.5 months compared to 12.7 months in the chemotherapy arm. Progression-free survival (PFS) was also better with a median of 5.6 months for mirvetuximab soravtansine-gynx versus 4.0 months for chemotherapy. The confirmed overall response rate (ORR) was higher at 42% for mirvetuximab soravtansine-gynx compared to 16% for chemotherapy. The study met the post-marketing requirement for the previous accelerated approval of mirvetuximab soravtansine-gynx. Adverse effects included ocular toxicity, pneumonitis, peripheral neuropathy, and embryo-fetal toxicity."
page_52.txt,Fluorouracil injection,,,,,,,,,{},"The FDA approved safety labeling changes for fluorouracil injection products due to additional safety information regarding the risk of serious adverse reactions in patients with dihydropyrimidine dehydrogenase deficiency. The revisions aim to provide information about these risks and align with changes approved for another fluoropyrimidine drug, Xeloda (capecitabine) tablets. Healthcare professionals are advised to report any suspected adverse events to the FDA and can seek assistance for investigational oncology products through OCE's Project Facilitate.",N/A
page_53.txt,Ponatinib (Iclusig),Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL),245,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'MRD-negative CR rate at the end of induction': {'Ponatinib arm': '30%', 'Imatinib arm': '12%', 'Risk difference': '0.18', 'p-value': '0.0004'}, 'Common adverse reactions': ['Hepatic dysfunction', 'Arthralgia', 'Rash and related conditions', 'Headache', 'Pyrexia', 'Abdominal pain', 'Constipation', 'Fatigue', 'Nausea', 'Oral mucositis', 'Hypertension', 'Pancreatitis/elevated lipase', 'Peripheral neuropathy', 'Hemorrhage', 'Febrile neutropenia', 'Fluid retention and edema', 'Vomiting', 'Paresthesia', 'Cardiac arrhythmias']}","Ponatinib in combination with chemotherapy showed a higher MRD-negative CR rate at the end of induction compared to imatinib in adult patients with newly diagnosed Ph+ ALL. Common adverse reactions included hepatic dysfunction, arthralgia, rash, headache, and others. Ponatinib was granted accelerated approval by the FDA for this indication.","In the PhALLCON study, ponatinib showed a higher MRD-negative complete remission (CR) rate at the end of induction compared to imatinib in newly diagnosed Ph+ ALL patients. The MRD-negative CR rate was 30% with ponatinib and 12% with imatinib. Overall Survival (OS) and Progression-Free Survival (PFS) data were not provided in the summary. The study also did not report on other response outcomes such as Overall Response Rate (ORR), Duration of Response (DOR), or Partial Response (PR). Ponatinib was administered at a dose of 30 mg orally once daily, which was reduced to 15 mg once daily after achieving MRD-negative CR. The study included 245 adult patients and utilized a chemotherapy regimen with vincristine, dexamethasone, methotrexate, cytarabine, vincristine, and prednisone."
page_54.txt,Zanubrutinib (Brukinsa),Follicular Lymphoma (FL),217,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': 'Overall Response Rate (ORR): ZO arm - 69%, Obinutuzumab arm - 46%', 'DOR': 'Duration of Response (DOR): ZO arm - Median not reached, Obinutuzumab arm - 14.0 months'}","Zanubrutinib in combination with obinutuzumab showed a higher overall response rate (ORR) and longer duration of response (DOR) compared to obinutuzumab alone in patients with relapsed or refractory follicular lymphoma. Common adverse reactions included decreased neutrophil and platelet counts, upper respiratory tract infection, hemorrhage, and musculoskeletal pain. Serious adverse reactions occurred in 35% of patients. The recommended dosage is 160 mg orally twice daily or 320 mg orally once daily until disease progression or unacceptable toxicity.","In this oncology study, the ZO arm showed a higher overall response rate (ORR) of 69% compared to 46% in the obinutuzumab arm. The duration of response (DOR) was longer in the ZO arm, with a median DOR not reached compared to 14.0 months in the obinutuzumab arm. The estimated DOR rate at 18 months was 69% in the ZO arm. These results suggest that zanubrutinib (ZO) may be more effective in terms of response outcomes compared to obinutuzumab in this study. Further follow-up is needed to assess overall survival (OS) and progression-free survival (PFS) outcomes."
page_55.txt,Nivolumab (Opdivo),Urothelial Carcinoma,608,21.7 months,18.9 months,15.30%,7.9 months,7.6 months,3.90%,"{'Adverse Reactions': ['nausea', 'fatigue', 'musculoskeletal pain', 'constipation', 'decreased appetite', 'rash', 'vomiting', 'peripheral neuropathy', 'urinary tract infection', 'diarrhea', 'edema', 'hypothyroidism', 'pruritis'], 'Recommended Dose': {'Combination Therapy': '360 mg every 3 weeks', 'Single Agent': '240 mg every 2 weeks or 480 mg every 4 weeks'}}","Nivolumab in combination with cisplatin and gemcitabine showed significant improvement in overall survival (OS) and progression-free survival (PFS) compared to cisplatin and gemcitabine alone in patients with unresectable or metastatic urothelial carcinoma. The treatment demonstrated a 15.3% improvement in OS and a 3.9% improvement in PFS. Common adverse reactions included nausea, fatigue, and musculoskeletal pain.","In the CHECKMATE-901 study, nivolumab in combination with cisplatin and gemcitabine followed by nivolumab showed statistically significant benefits in overall survival (OS) and progression-free survival (PFS) compared to cisplatin and gemcitabine alone for patients with previously untreated unresectable or metastatic urothelial carcinoma. The median OS was 21.7 months with nivolumab combination versus 18.9 months with cisplatin and gemcitabine alone, and the median PFS was 7.9 months versus 7.6 months, respectively. The hazard ratios were 0.78 for OS and 0.72 for PFS, indicating a significant improvement in survival outcomes with nivolumab combination therapy. Response outcomes were not specifically mentioned in the summary provided."
page_56.txt,Inotuzumab ozogamicin (Besponsa),CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL),53,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Complete Remission (CR)': '42% achieved CR', 'Duration of CR': 'Median 8.2 months', 'MRD Negativity Rate': '95.5% based on flow cytometry, 86.4% based on RQ-PCR', 'Common Adverse Reactions': ['Thrombocytopenia', 'Pyrexia', 'Anemia', 'Vomiting', 'Infection', 'Hemorrhage', 'Neutropenia', 'Nausea', 'Leukopenia', 'Febrile neutropenia', 'Increased transaminases', 'Abdominal pain', 'Headache']}","In a study of 53 pediatric patients with relapsed or refractory CD22-positive B-cell precursor ALL, inotuzumab ozogamicin showed a 42% complete remission rate with a median duration of 8.2 months. The MRD negativity rate was high. Common adverse reactions included thrombocytopenia, pyrexia, and anemia.","In a study of 53 pediatric patients with relapsed or refractory CD22-positive B-cell precursor ALL, treatment with the study drug resulted in a 42% complete remission rate. The median duration of complete remission was 8.2 months. The majority of patients who achieved complete remission also had minimal residual disease negativity, with rates of 95.5% based on flow cytometry and 86.4% based on RQ-PCR. Overall survival and progression-free survival data were not provided in the summary. The study demonstrated promising efficacy outcomes in terms of response rates and minimal residual disease status in this patient population."
page_57.txt,Amivantamab-vmjw (Rybrevant),Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations,308,Data immature,Data immature,Data immature,11.4 months,6.7 months,69.40%,"{'Adverse Reactions': ['Rash', 'Nail toxicity', 'Stomatitis', 'Infusion-related reaction', 'Fatigue', 'Edema', 'Constipation', 'Decreased appetite', 'Nausea', 'COVID-19', 'Diarrhea', 'Vomiting']}","Amivantamab-vmjw with carboplatin and pemetrexed showed a significant improvement in progression-free survival (PFS) compared to carboplatin and pemetrexed in patients with NSCLC with EGFR exon 20 insertion mutations. Overall survival (OS) data is immature, but no trend towards detriment was observed. Common adverse reactions included rash, nail toxicity, and stomatitis.","In the PAPILLON study, patients with EGFR exon 20 insertion mutations who received amivantamab-vmjw with carboplatin and pemetrexed had a statistically significant improvement in progression-free survival (PFS) compared to those who received carboplatin and pemetrexed. The median PFS was 11.4 months with the combination treatment, compared to 6.7 months with carboplatin and pemetrexed. Overall survival (OS) results were not yet mature, but no negative trend was observed. Response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not specifically mentioned in the summary provided."
page_58.txt,Osimertinib (Tagrisso),Non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations,557,Data not mature,Data not mature,Data not available,"25.5 months (95% CI: 24.7, NE)","16.7 months (95% CI: 14.1, 21.3)",Approximately 52%,"{'Adverse Reactions': ['Leukopenia', 'Thrombocytopenia', 'Neutropenia', 'Lymphopenia', 'Rash', 'Diarrhea', 'Stomatitis', 'Nail toxicity', 'Dry skin', 'Increased blood creatinine']}","Osimertinib in combination with platinum-based chemotherapy showed a significant improvement in progression-free survival (PFS) compared to osimertinib monotherapy in patients with EGFR-mutated NSCLC. Overall survival (OS) data is still immature, but no negative trend was observed. Common adverse reactions included leukopenia, thrombocytopenia, and rash. Osimertinib was granted priority review and other expedited designations by the FDA.","In the FLAURA 2 study, osimertinib plus platinum-based chemotherapy showed a significant improvement in progression-free survival (PFS) compared to osimertinib monotherapy in patients with EGFR exon 19 deletion or exon 21 L858R mutation-positive la/mNSCLC. The median PFS was 25.5 months with combination therapy versus 16.7 months with monotherapy. Overall survival (OS) results were still immature, but no negative trend was observed. Response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not specifically mentioned in the summary provided."
page_59.txt,Lifileucel (Amtagvi),Unresectable or metastatic melanoma,89,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '31.5%', 'DOR': 'Not reached'}","Lifileucel received accelerated approval for adult patients with unresectable or metastatic melanoma previously treated with specific therapies. The trial showed an objective response rate of 31.5% with a median duration of response not reached. Adverse reactions included chills, pyrexia, fatigue, and others. The prescribing information includes a Boxed Warning for severe adverse events. Lifileucel dose ranges and FDA designations for expedited review were also highlighted.","A study evaluated lifileucel in patients with unresectable or metastatic melanoma who had previously received systemic therapy. Lifileucel showed an objective response rate (ORR) of 31.5% and a median duration of response (DoR) that was not reached. Overall survival (OS) and progression-free survival (PFS) data were not provided. The study included a lymphodepleting regimen followed by lifileucel administration and IL-2 support. Adverse events included treatment-related mortality, severe cytopenia, infection, and organ impairment. The study demonstrated promising response outcomes with lifileucel in this patient population, but caution is warranted due to the potential for severe adverse events."
page_6.txt,Remestemcel-L-rknd (Ryoncil),Steroid-refractory acute graft versus host disease (SR-aGVHD),54,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR) at Day 28': '70%', 'Complete Response Rate (CR)': '30%', 'Partial Response Rate (PR)': '41%', 'Median Duration of Response': '54 days'}","Remestemcel-L-rknd (Ryoncil) was approved for SR-aGVHD in pediatric patients. The study included 54 patients with Grade B to D SR-aGVHD, showing an overall response rate of 70% at Day 28. The most common adverse reactions were viral and bacterial infections. The recommended dose is 2 X 10^6 MSC/kg body weight per infusion given twice a week for 4 weeks.",Efficacy and
page_60.txt,Tepotinib (Tepmetko),Metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations,313,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Treatment-naïve patients': '57% with 40% having DOR ≥12 months', 'Previously treated patients': '45% with 36% having DOR ≥12 months'}, 'DOR': 'Duration of response was assessed'}","FDA approved tepotinib (Tepmetko) for adult patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping alterations. Efficacy was demonstrated in 313 patients with promising overall response rates and duration of response. Common adverse reactions included edema, nausea, fatigue, and musculoskeletal pain. Tepotinib showed significant efficacy in both treatment-naïve and previously treated patients.","In a study of 313 patients with metastatic NSCLC and MET exon skipping alterations, treatment with tepotinib 450 mg once daily showed efficacy in terms of ORR and DOR. Among treatment-naïve patients, the ORR was 57% with 40% of responders having a DOR ≥12 months. Among previously treated patients, the ORR was 45% with 36% of responders having a DOR ≥12 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary."
page_61.txt,Irinotecan liposome (Onivyde),Metastatic pancreatic adenocarcinoma,770,11.1 months,9.2 months,20.70%,7.4 months,5.6 months,32.10%,"{'ORR': {'NALIRIFOX arm': '41.8%', 'Gem+NabP arm': '36.2%'}}","The study evaluated the efficacy of irinotecan liposome in combination with oxaliplatin, fluorouracil, and leucovorin as a first-line treatment for metastatic pancreatic adenocarcinoma. Results showed a significant improvement in overall survival (OS) and progression-free survival (PFS) in the NALIRIFOX arm compared to the Gem+NabP arm, with a 20.7% improvement in OS and a 32.1% improvement in PFS.","In the NAPOLI 3 study, comparing NALIRIFOX to Gem+NabP in metastatic pancreatic adenocarcinoma, NALIRIFOX showed a statistically significant improvement in overall survival (OS) and progression-free survival (PFS). The median OS was 11.1 months with NALIRIFOX compared to 9.2 months with Gem+NabP, and the median PFS was 7.4 months with NALIRIFOX compared to 5.6 months with Gem+NabP. The objective response rate (ORR) was also higher with NALIRIFOX at 41.8% compared to 36.2% with Gem+NabP. These results suggest that NALIRIFOX may be a more effective treatment option for patients with metastatic pancreatic adenocarcinoma who have not received prior chemotherapy in the metastatic setting."
page_62.txt,erdafitinib (Balversa),urothelial carcinoma,266,12.1 months,7.8 months,55.10%,5.6 months,2.7 months,51.90%,"{'ORR': '35.3%', 'DOR': 'Not specified'}","Erdafitinib showed significant improvements in overall survival, progression-free survival, and objective response rate compared to chemotherapy in patients with urothelial carcinoma harboring selected FGFR3 alterations. The median overall survival was 12.1 months with erdafitinib versus 7.8 months with chemotherapy, demonstrating a 55.1% improvement. Median progression-free survival was 5.6 months with erdafitinib versus 2.7 months with chemotherapy, showing a 51.9% improvement. The confirmed objective response rate was 35.3% with erdafitinib. Adverse reactions were manageable with the recommended dosing schedule.","In Study BLC3001 Cohort 1, erdafitinib showed significant improvements in overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) compared to chemotherapy in patients with metastatic urothelial carcinoma (mUC) harboring selected FGFR3 alterations. Median OS was 12.1 months with erdafitinib versus 7.8 months with chemotherapy, median PFS was 5.6 months versus 2.7 months, and ORR was 35.3% versus 8.5%, respectively. These results indicate that erdafitinib is more effective in treating mUC with FGFR3 alterations after prior systemic treatments, including PD-1 or PD-L1 inhibitors."
page_63.txt,Pembrolizumab (Keytruda),Cervical cancer,1060,Data not mature at the time of analysis,Data not mature at the time of analysis,Data not available,PFS hazard ratio (HR) estimate: 0.59,PFS hazard ratio (HR) estimate: 0.91,21% of patients in treatment arm vs. 31% in control arm experienced PFS event,"{'Adverse Reactions': ['Nausea', 'Diarrhea', 'Vomiting', 'Urinary tract infection', 'Fatigue', 'Hypothyroidism', 'Constipation', 'Decreased appetite', 'Weight loss', 'Abdominal pain', 'Pyrexia', 'Hyperthyroidism', 'Dysuria', 'Rash', 'Pelvic pain'], 'Recommended Dosing Regimen': '200 mg IV every 3 weeks or 400 mg IV every 6 weeks until disease progression or for up to 24 months'}","Pembrolizumab with chemoradiotherapy showed a statistically significant improvement in PFS for patients with cervical cancer, particularly in those with FIGO 2014 Stage III-IVA disease. OS data were not mature at the time of analysis. Common adverse reactions included nausea, diarrhea, and fatigue. Recommended dosing regimen is 200 mg IV every 3 weeks or 400 mg IV every 6 weeks.","In the KEYNOTE-A18 study, pembrolizumab showed a statistically significant improvement in progression-free survival (PFS) in patients with cervical cancer who had not received definitive surgery, radiation, or systemic therapy. In the subgroup analysis, patients with FIGO 2014 Stage III-IVA disease had a PFS hazard ratio of 0.59, with 21% of pembrolizumab-treated patients experiencing a PFS event compared to 31% in the placebo arm. However, in patients with FIGO 2014 Stage IB2-IIB disease, the PFS improvement was not significant. Overall survival (OS) data were not mature at the time of PFS analysis. The study demonstrated promising results for PFS in patients with advanced cervical cancer, particularly in those with FIGO 2014 Stage III-IVA disease."
page_64.txt,Enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda),Locally advanced or metastatic urothelial cancer (la/mUC),886,31.5 months,16.1 months,47%,12.5 months,6.3 months,45%,{},"The study evaluated the efficacy of enfortumab vedotin-ejfv with pembrolizumab in patients with locally advanced or metastatic urothelial cancer. Significant improvements in overall survival (OS) and progression-free survival (PFS) were demonstrated compared to platinum-based chemotherapy, with a 47% improvement in OS and a 45% improvement in PFS. Common adverse reactions were reported, and the FDA approved the application ahead of schedule under Project Orbis.","In the EV-302/KN-A39 study, enfortumab vedotin-ejfv with pembrolizumab showed significant improvements in overall survival (OS) and progression-free survival (PFS) compared to platinum-based chemotherapy in patients with la/mUC. The median OS was 31.5 months with enfortumab vedotin-ejfv with pembrolizumab versus 16.1 months with platinum-based chemotherapy. The median PFS was 12.5 months with enfortumab vedotin-ejfv with pembrolizumab versus 6.3 months with platinum-based chemotherapy. The Hazard ratios were 0.47 for OS and 0.45 for PFS, both statistically significant. Response outcomes were not specified in the provided text."
page_65.txt,Belzutifan (Welireg),Renal Cell Carcinoma (RCC),746,Data immature,Data immature,Data immature,5.6 months,5.6 months,Hazard ratio of 0.75,"{'Adverse Reactions': ['Decreased hemoglobin', 'Fatigue', 'Musculoskeletal pain', 'Increased creatinine', 'Decreased lymphocytes', 'Increased alanine aminotransferase', 'Decreased sodium', 'Increased potassium', 'Increased aspartate aminotransferase']}","Belzutifan showed a statistically significant improvement in progression-free survival compared to everolimus in patients with advanced RCC. Overall survival results were immature at the time of analysis. Belzutifan demonstrated improved tolerability based on patient-reported outcomes. Common adverse reactions included decreased hemoglobin, fatigue, and musculoskeletal pain.","In the LITESPARK-005 study, belzutifan showed a statistically significant improvement in progression-free survival (PFS) compared to everolimus in patients with advanced clear cell RCC. The hazard ratio for PFS was 0.75, with similar median PFS estimates of 5.6 months in both treatment arms. Overall survival (OS) results were immature, but no trend towards a detriment was observed. Belzutifan also demonstrated improved tolerability compared to everolimus based on patient-reported symptom and functional outcomes. Response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not specifically mentioned in the study results."
page_66.txt,Eflornithine (IWILFIN),High-risk neuroblastoma (HRNB),360,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'EFS Hazard Ratio': {'Primary Analysis': {'EFS HR': 0.48, '95% CI': '0.27, 0.85'}, 'Supplementary Analyses': {'EFS HR Range': '0.43 - 0.59'}}, 'OS Hazard Ratio': {'Primary Analysis': {'OS HR': 0.32, '95% CI': '0.15, 0.70'}, 'Supplementary Analyses': {'OS HR Range': '0.29 - 0.45'}}, 'Adverse Reactions': ['Otitis media', 'Diarrhea', 'Cough', 'Sinusitis', 'Pneumonia', 'Upper respiratory tract infection', 'Conjunctivitis', 'Vomiting', 'Pyrexia', 'Allergic rhinitis', 'Decreased neutrophils', 'Increased ALT', 'Increased AST', 'Hearing loss', 'Skin infection', 'Urinary tract infection']}","Eflornithine (IWILFIN) was approved by the FDA for reducing the risk of relapse in patients with high-risk neuroblastoma who have shown a partial response to prior therapy. The study compared outcomes between the investigational arm and a control arm from a previous trial, showing significant improvements in event-free survival and overall survival. Common adverse reactions were reported. The drug received priority review, breakthrough designation, and orphan drug designation.","Study 3b compared the efficacy of eflornithine in HRNB patients to a historical benchmark from Study ANBL0032. The primary analysis showed a significant improvement in event-free survival (EFS) with a hazard ratio (HR) of 0.48 and overall survival (OS) with a HR of 0.32. Additional analyses confirmed these findings, with EFS HR ranging from 0.43 to 0.59 and OS HR ranging from 0.29 to 0.45. Response outcomes were not specifically mentioned in the summary provided. Overall, eflornithine showed promising results in improving survival outcomes in HRNB patients compared to the historical control arm."
page_67.txt,"Pirtobrutinib (Jaypirca, Eli Lilly and Company)",Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL),108,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '72%', 'Duration of Response (DOR)': '12.2 months'}","Pirtobrutinib was granted accelerated approval for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. Efficacy was evaluated in a trial with 108 patients showing an overall response rate of 72% and a median duration of response of 12.2 months.","In the BRUIN study, pirtobrutinib showed promising efficacy in patients with CLL or SLL who had received prior treatment with BTK and BCL-2 inhibitors. The overall response rate (ORR) was 72%, with a median duration of response (DOR) of 12.2 months. All responses were partial responses. The study included 108 patients who had received a median of 5 prior lines of therapy. The majority of patients discontinued the last BTK inhibitor due to refractory or progressive disease. Pirtobrutinib was well-tolerated when administered orally at 200 mg once daily. These results suggest that pirtobrutinib may be a valuable treatment option for patients with CLL or SLL who have previously received multiple lines of therapy."
page_68.txt,Nirogacestat (OGSIVEO),Desmoid tumors,142,Not provided,Not provided,Not provided,Not reached,15.1 months,Not provided,"{'ORR': {'Treatment Arm': '41%', 'Control Arm': '8%'}, 'DOR': 'Not provided'}","Nirogacestat was approved for adult patients with progressing desmoid tumors. In a trial of 142 patients, nirogacestat showed improved progression-free survival compared to placebo, with an objective response rate of 41% in the treatment arm. Common adverse reactions included diarrhea, ovarian toxicity, and rash.","In the DeFi study, nirogacestat showed significant efficacy in patients with progressing desmoid tumors not amenable to surgery. The median progression-free survival (PFS) was not reached in the nirogacestat arm compared to 15.1 months in the placebo arm, with a hazard ratio of 0.29. The objective response rate (ORR) was 41% in the nirogacestat arm and 8% in the placebo arm. These results were supported by improvements in patient-reported worst pain in the nirogacestat arm. Overall, nirogacestat demonstrated superior PFS and ORR compared to placebo in this patient population."
page_69.txt,Enzalutamide,Non-metastatic castration-sensitive prostate cancer with biochemical recurrence,1068,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"{'Metastasis-free survival (MFS)': {'Enzalutamide + Leuprolide vs. Placebo + Leuprolide': 'HR 0.42; 95% CI: 0.30, 0.61; p-value<0.0001', 'Enzalutamide Monotherapy vs. Placebo + Leuprolide': 'HR 0.63; 95% CI: 0.46, 0.87; p-value = 0.0049'}, 'Overall Survival (OS)': {'Data': 'Immature with 12% deaths in the overall population'}, 'Adverse Reactions': {'Enzalutamide + Leuprolide': ['Hot flush', 'Musculoskeletal pain', 'Fatigue', 'Fall', 'Hemorrhage'], 'Enzalutamide Monotherapy': ['Fatigue', 'Gynecomastia', 'Musculoskeletal pain', 'Breast tenderness', 'Hot flush', 'Hemorrhage']}}","FDA approved enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence. Efficacy was demonstrated in a trial of 1068 patients showing a significant improvement in metastasis-free survival for enzalutamide compared to placebo. Overall survival data were immature at the time of analysis. Common adverse reactions included hot flush, musculoskeletal pain, fatigue, and hemorrhage.","The EMBARK study showed that enzalutamide plus leuprolide significantly improved metastasis-free survival (MFS) compared to placebo plus leuprolide in patients with nmCSPC with high-risk BCR. Enzalutamide monotherapy also demonstrated a significant improvement in MFS compared to placebo plus leuprolide. Overall survival (OS) data were immature at the time of the study, with 12% deaths in the overall population. The study did not report specific data on progression-free survival (PFS) or response outcomes (ORR, DOR, CR, PR)."
page_7.txt,Ensacove,Anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC),290,Not statistically significant,Not statistically significant,N/A,25.8 months,12.7 months,102%,{},"Ensartinib (Ensacove) showed a significant improvement in progression-free survival (PFS) compared to crizotinib in patients with ALK-positive NSCLC. However, there was no statistically significant difference in overall survival (OS). The most common adverse reactions were rash, musculoskeletal pain, constipation, cough, pruritis, nausea, edema, pyrexia, and fatigue.",Efficacy and
page_70.txt,Capivasertib (Truqap),"Locally advanced or metastatic HR-positive, HER2-negative breast cancer with PIK3CA/AKT1/PTEN-alterations",708,Not provided,Not provided,Not provided,"7.3 months (95% CI: 5.5, 9.0)","3.1 months (95% CI: 2.0, 3.7)","Hazard Ratio [HR] 0.50 [95% CI: 0.38, 0.65] p-value< 0.0001","{'Adverse Reactions': ['Diarrhea', 'Cutaneous adverse reactions', 'Increased random glucose', 'Decreased lymphocytes', 'Decreased hemoglobin', 'Increased fasting glucose', 'Nausea', 'Fatigue', 'Decreased leukocytes', 'Increased triglycerides', 'Decreased neutrophils', 'Increased creatinine', 'Vomiting', 'Stomatitis']}","Capivasertib (Truqap) in combination with fulvestrant showed a significant improvement in progression-free survival (PFS) in patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer with PIK3CA/AKT1/PTEN-alterations. The median PFS was 7.3 months with capivasertib-fulvestrant compared to 3.1 months with placebo-fulvestrant. Common adverse reactions included diarrhea, cutaneous adverse reactions, and increased glucose levels.","In the CAPItello-291 study, patients with HR-positive, HER2-negative breast cancer and PIK3CA/AKT1/PTEN-alterations who received capivasertib and fulvestrant had a significantly longer median progression-free survival (PFS) of 7.3 months compared to 3.1 months in the placebo-fulvestrant group. The hazard ratio (HR) was 0.50, indicating a significant benefit. In patients without these alterations, the HR was 0.79, suggesting a smaller benefit. Overall survival data was not provided. The study demonstrated promising efficacy outcomes in terms of PFS for patients with specific genetic alterations in their tumors."
page_71.txt,Pembrolizumab (Keytruda),Locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma,1579,12.9 months,11.5 months,12.17%,6.9 months,5.6 months,23.21%,"{'Overall Response Rate (ORR)': '51%', 'Duration of Response (DOR)': '8 months'}","Pembrolizumab in combination with chemotherapy showed significant improvements in overall survival, progression-free survival, and overall response rate compared to placebo in patients with HER2-negative advanced gastric or GEJ adenocarcinoma. Adverse reactions leading to permanent discontinuation were observed in 15% of patients, with infections and diarrhea being the most common causes.","In the KEYNOTE-859 study, pembrolizumab combined with chemotherapy showed a significant improvement in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to placebo in patients with HER2-negative advanced gastric or GEJ adenocarcinoma. Median OS was 12.9 months with pembrolizumab versus 11.5 months with placebo, median PFS was 6.9 months versus 5.6 months, and ORR was 51% versus 42%. The duration of response (DOR) was also longer with pembrolizumab. Patients with tumors expressing PD-L1 CPS ≥ 1 and CPS ≥ 10 showed a significant improvement in OS, PFS, and ORR with pembrolizumab treatment."
page_72.txt,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"In a study of ROS1-positive patients, those who were TKI-naïve had a higher overall response rate (ORR) of 79% compared to 38% in patients who had received prior ROS1 TKI treatment. The median duration of response (DOR) was also longer in the TKI-naïve group at 34.1 months compared to 14.8 months in the prior treatment group. Responses were seen in intracranial lesions and in patients with resistance mutations. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study suggests that ROS1 TKI-naïve patients may have better response outcomes compared to those who have received prior treatment with a ROS1 inhibitor."
page_73.txt,Fruquintinib (Fruzaqla),Metastatic Colorectal Cancer (mCRC),"691 in FRESCO-2, 416 in FRESCO","7.4 months in FRESCO-2, 9.3 months in FRESCO","4.8 months in FRESCO-2, 6.6 months in FRESCO","34% in FRESCO-2, 29% in FRESCO",Not provided,Not provided,Not provided,"{'Adverse Reactions': ['Hypertension', 'Palmar-plantar erythrodysesthesia', 'Proteinuria', 'Dysphonia', 'Abdominal pain', 'Diarrhea', 'Asthenia']}","Fruquintinib was approved for adult patients with mCRC who had prior chemotherapy and biological therapies. In two trials, it showed significant improvement in overall survival compared to placebo, with common adverse reactions being hypertension and diarrhea.","In the FRESCO-2 and FRESCO oncology studies, fruquintinib showed significant improvement in overall survival (OS) compared to placebo in patients with metastatic colorectal cancer. In FRESCO-2, the median OS was 7.4 months with fruquintinib versus 4.8 months with placebo, while in FRESCO, it was 9.3 months versus 6.6 months, respectively. Progression-free survival (PFS) and response outcomes were not explicitly mentioned in the summary provided. The results suggest that fruquintinib could be a beneficial treatment option for patients with mCRC who have progressed on previous therapies."
page_74.txt,Pembrolizumab (Keytruda),HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma,698,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '74% in pembrolizumab arm, 52% in placebo arm', 'DOR': '10.6 months in pembrolizumab arm, 9.5 months in placebo arm'}","Pembrolizumab in combination with trastuzumab and chemotherapy showed promising results in the treatment of HER2-positive gastric or GEJ adenocarcinoma, with a significantly higher objective response rate compared to placebo. The safety profile was consistent with known profiles of the individual treatments. Further analysis is needed to determine overall and progression-free survival outcomes.","KEYNOTE-811 study evaluated pembrolizumab in HER2-positive gastric or GEJ adenocarcinoma patients. Pembrolizumab plus chemotherapy showed a higher objective response rate (ORR) of 74% compared to 52% with placebo plus chemotherapy. The median duration of response (DOR) was 10.6 months with pembrolizumab and 9.5 months with placebo. In a subgroup analysis of patients with PD-L1 CPS <1, the hazard ratios for overall survival (OS) and progression-free survival (PFS) were 1.41 and 1.03, respectively. These results suggest that pembrolizumab in combination with chemotherapy improves response outcomes in this patient population."
page_75.txt,Pembrolizumab (Keytruda),Biliary tract cancer (BTC),1069,12.7 months,10.9 months,16.50%,not provided,not provided,not provided,{},Pembrolizumab in combination with gemcitabine and cisplatin showed a statistically significant improvement in overall survival for patients with locally advanced unresectable or metastatic biliary tract cancer compared to placebo plus chemotherapy.,"In the KEYNOTE-966 study, pembrolizumab plus chemotherapy showed a significant improvement in overall survival (OS) compared to placebo plus chemotherapy in patients with locally advanced unresectable or metastatic biliary tract cancer (BTC). The median OS was 12.7 months with pembrolizumab plus chemotherapy and 10.9 months with placebo plus chemotherapy. Progression-free survival (PFS) data was not provided. Response outcomes were not specifically mentioned in the summary provided."
page_76.txt,toripalimab-tpzi,nasopharyngeal carcinoma (NPC),289,"Not reached (95% CI: 38.7 months, not estimable)","33.7 months (95% CI: 27.0, 44.2)","HR 0.63 [95% CI: 0.45, 0.89], p-value=0.0083",11.7 months,8.0 months,"HR 0.52 [95% CI: 0.36, 0.74], p-value=0.0003","{'ORR': '21% (95% CI: 15, 28)', 'DOR': '14.9 months (95% CI: 10.3, not estimable)'}","Toripalimab-tpzi in combination with cisplatin and gemcitabine showed significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to placebo in patients with metastatic or recurrent nasopharyngeal carcinoma. As a single agent, toripalimab-tpzi demonstrated a 21% overall response rate (ORR) and a median duration of response (DOR) of 14.9 months in patients with unresectable or metastatic NPC who had received prior platinum-based chemotherapy.","In the JUPITER-02 study, toripalimab-tpzi with cisplatin and gemcitabine showed a significant improvement in progression-free survival (PFS) with a median PFS of 11.7 months compared to 8.0 months for the placebo-containing regimen. Overall survival (OS) also improved significantly with toripalimab-tpzi, with a median OS not reached versus 33.7 months for the placebo group. In the POLARIS-02 study, toripalimab-tpzi as a single agent resulted in a 21% overall response rate (ORR) and a median duration of response (DOR) of 14.9 months in patients with unresectable or metastatic NPC who had received prior platinum-based chemotherapy. These results suggest that toripalimab-tpzi may be an effective treatment option for patients with advanced NPC."
page_77.txt,Ivosidenib (Tibsovo),Myelodysplastic syndromes (MDS) with IDH1 mutation,18,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Complete Remission Rate': '38.9%', 'Time-to-CR': '1.9 months', 'CR Duration': 'Not estimable', 'Transfusion Independence Rate': '67% for RBC and platelet transfusions'}","Ivosidenib (Tibsovo) was approved for adult patients with relapsed or refractory MDS with IDH1 mutation. The trial demonstrated a complete remission rate of 38.9% and a transfusion independence rate of 67% for RBC and platelet transfusions. Common adverse reactions included GI toxicities, arthralgia, fatigue, and QTc prolongation.","Overall survival (OS) and progression-free survival (PFS) data were not provided in the study. The study focused on response outcomes, specifically complete remission (CR) and partial remission (PR) rates. All observed responses were CRs, with a CR rate of 38.9%. The median time-to-CR was 1.9 months, and the median CR duration was not estimable. Additionally, a high conversion rate from transfusion dependence to independence was observed, with 67% of patients dependent on transfusions becoming independent. Among patients already independent of transfusions at baseline, 78% remained transfusion independent. These findings suggest promising efficacy in terms of response outcomes for patients with myelodysplastic syndromes."
page_78.txt,Entrectinib (Rozlytrek),Solid tumors with NTRK gene fusion,33 pediatric patients,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': 'Overall response rate of 70%', 'DOR': 'Median duration of response was 25.4 months'}","Entrectinib (Rozlytrek) received accelerated approval for pediatric patients with solid tumors having NTRK gene fusion. Efficacy was demonstrated in 33 patients with a 70% overall response rate and a median duration of response of 25.4 months. Common adverse reactions included pyrexia, constipation, and vomiting. Continued approval may be contingent upon further clinical benefit confirmation.","In a study of 33 pediatric patients with NTRK-positive tumors receiving entrectinib, the overall response rate (ORR) was 70%, with a median duration of response (DOR) of 25.4 months. The most common cancers were primary central nervous system tumors and infantile fibrosarcoma. The study showed promising efficacy outcomes in terms of response rates and duration of response, indicating the potential benefit of entrectinib in this patient population."
page_79.txt,"Pembrolizumab (Keytruda, Merck)",Non-small cell lung cancer (NSCLC),797,Not reached (95% CI: not estimable [NE]),"52.4 months (95% CI: 45.7, NE)","Hazard ratio [HR] 0.72 (95% CI: 0.56, 0.93); p-value=0.0103","Not reached (95% CI: 34.1 months, NE)","17 months (95% CI: 14.3, 22.0)","HR 0.58 (95% CI: 0.46, 0.72); p-value=<0.0001","{'Adverse Reactions': ['Nausea', 'Fatigue', 'Neutropenia', 'Anemia', 'Constipation', 'Decreased appetite', 'White blood cell count decreased', 'Musculoskeletal pain', 'Rash', 'Cough', 'Vomiting', 'Diarrhea', 'Dyspnea'], 'Surgery Impact': {'Unable to Receive Surgery (%)': {'Pembrolizumab Arm': 6, 'Placebo Arm': 4.3}, 'Delays in Surgery (%)': {'Pembrolizumab Arm': 3.1, 'Placebo Arm': 2.5}}}","Pembrolizumab in combination with platinum-containing chemotherapy showed improved overall survival and progression-free survival in patients with resectable non-small cell lung cancer. Adverse reactions were reported, with a slightly higher impact on surgery in the pembrolizumab arm compared to placebo.","The KEYNOTE-671 study showed that pembrolizumab, in combination with platinum-based chemotherapy, improved overall survival (OS) compared to placebo in patients with previously untreated and resectable Stage II, IIIA, or IIIB NSCLC. The median OS was not reached in the pembrolizumab arm, while it was 52.4 months in the placebo arm. Progression-free survival (PFS) was also significantly longer in the pembrolizumab group. The study demonstrated a higher response rate and longer duration of response (DOR) with pembrolizumab. Overall, pembrolizumab showed a favorable efficacy profile in this patient population."
page_8.txt,cosibelimab-ipdl (Unloxcyt),metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC),109,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'mCSCC': '47%', 'laCSCC': '48%'}, 'DOR': {'mCSCC': 'Not reached', 'laCSCC': '17.7 months'}}","The FDA approved cosibelimab-ipdl for adults with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation. The efficacy was evaluated in a trial with 109 patients, showing an objective response rate of 47% for mCSCC and 48% for laCSCC, with a median duration of response not reached for mCSCC and 17.7 months for laCSCC.",Efficacy and
page_80.txt,Nivolumab (Opdivo),Stage IIB/C melanoma,790,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Recurrence-Free Survival (RFS)': {'Hazard Ratio': 0.42, 'p-value': '<0.0001'}, 'Common Adverse Reactions': ['Fatigue', 'Musculoskeletal pain', 'Rash', 'Diarrhea', 'Pruritis']}","Nivolumab was approved for adjuvant treatment of completely resected Stage IIB/C melanoma in patients 12 years and older. The CHECKMATE-76K trial showed a significant improvement in recurrence-free survival with nivolumab compared to placebo. Common adverse reactions included fatigue, musculoskeletal pain, rash, diarrhea, and pruritis.","In the CHECKMATE-76K study, patients with Stage IIB/C melanoma were randomized to receive nivolumab or placebo. The study showed a significant improvement in recurrence-free survival (RFS) with nivolumab compared to placebo, with a hazard ratio of 0.42 (p-value <0.0001). Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. Response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not mentioned in the study results. The study excluded patients with certain types of melanoma, autoimmune diseases, and prior melanoma therapy except surgery. The findings suggest that nivolumab may be an effective treatment option for patients with Stage IIB/C melanoma."
page_81.txt,Encorafenib (Braftovi) with Binimetinib (Mektovi),Metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation,98,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Treatment-naïve patients': '75%', 'Previously treated patients': '46%'}, 'DOR': {'Treatment-naïve patients': 'NE', 'Previously treated patients': '16.7 months'}}","Encorafenib with binimetinib was approved for adult patients with metastatic NSCLC with a BRAF V600E mutation. Efficacy was demonstrated in 98 patients with significant objective response rates and duration of response. Common adverse reactions were reported, and recommended doses were provided for healthcare professionals.","In a study of 98 patients with metastatic NSCLC and BRAF V600E mutation, treatment with encorafenib and binimetinib showed promising results. Among treatment-naïve patients, the objective response rate (ORR) was 75% with a median duration of response (DoR) that was not estimable. Among previously treated patients, the ORR was 46% with a median DoR of 16.7 months. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The study did not allow prior BRAF or MEK inhibitors. These findings suggest that the combination of encorafenib and binimetinib may be effective in patients with metastatic NSCLC and BRAF V600E mutation, particularly in treatment-naïve patients."
page_82.txt,Bosulif,Chronic phase (CP) Ph+ chronic myelogenous leukemia (CML),28 patients with R/I CP Ph+ CML and 21 patients with ND CP Ph+ CML,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Major Cytogenetic Response (MCyR)': '76.2% for ND CP Ph+ CML and 82.1% for R/I CP Ph+ CML', 'Complete Cytogenetic Response (CCyR)': '71.4% for ND CP Ph+ CML and 78.6% for R/I CP Ph+ CML', 'Major Molecular Response (MMR)': '28.6% for ND CP Ph+ CML and 50% for R/I CP Ph+ CML', 'Median Duration of Follow-up': '14.2 months for ND CP Ph+ CML and 23.2 months for R/I CP Ph+ CML'}","Bosulif was approved for pediatric patients with CP Ph+ CML. Efficacy was evaluated in the BCHILD trial, showing significant cytogenetic and molecular responses in both newly diagnosed and resistant/intolerant patients. Common adverse reactions included gastrointestinal symptoms and laboratory abnormalities. Recommended dosages were provided based on disease status. The study demonstrated promising outcomes in pediatric CML patients.","Efficacy was evaluated in the BCHILD trial (NCT04258943), a multicenter, nonrandomized, open-label trial conducted to identify a recommended bosutinib dose in pediatric patients with ND CP Ph+ CML and R/I CP Ph+ CML, to estimate the"
page_83.txt,"Temozolomide (Temodar, Merck)",Anaplastic astrocytoma and glioblastoma,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,Not specified,"{'ORR': 'Not specified', 'DOR': 'Not specified'}","The FDA approved updated labeling for temozolomide (Temodar, Merck) for the adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma and the treatment of adults with refractory anaplastic astrocytoma. Additional labeling revisions were made for the treatment of adults with newly diagnosed glioblastoma. The Project Renewal initiative aims to update labeling information for older oncology drugs to ensure clinical relevance and scientific accuracy.",N/A
page_84.txt,HEPZATO KIT (melphalan for Injection/Hepatic Delivery System),Uveal melanoma with unresectable hepatic metastases,91,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '36.3%', 'DOR': '14 months'}",The FDA approved HEPZATO KIT for adult patients with uveal melanoma with unresectable hepatic metastases. The FOCUS study showed an objective response rate of 36.3% and a median duration of response of 14 months.,"The FOCUS study evaluated the efficacy of melphalan (HEPZATO) in 91 patients with uveal melanoma and unresectable hepatic metastases. The study showed an objective response rate (ORR) of 36.3% and a median duration of response (DoR) of 14 months. Melphalan was administered via the Hepatic Delivery System every 6 to 8 weeks for up to 6 infusions. The recommended dose was 3 mg/kg based on ideal body weight. The study also highlighted severe peri-procedural complications such as hemorrhage, hepatocellular injury, and thromboembolic events, leading to a Boxed Warning in the prescribing information. Due to these risks, HEPZATO KIT is only available through a restricted program under a Risk Evaluation and Mitigation Strategy."
page_85.txt,Elrexfio (elranatamab-bcmm),Multiple Myeloma,97,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '57.7%', 'DOR': 'Median not reached, 6-month rate 90.4%, 9-month rate 82.3%'}","Elrexfio (elranatamab-bcmm) received accelerated approval for relapsed or refractory multiple myeloma in patients who have received at least four prior lines of therapy. The study demonstrated an objective response rate of 57.7% and a durable response with a median duration not reached. Adverse events included cytokine release syndrome and neurologic toxicity, leading to a Risk Evaluation and Mitigation Strategy. Common adverse reactions included CRS, fatigue, and injection site reactions.","In the MagnetisMM-3 study, elranatamab-bcmm showed promising efficacy in patients with relapsed/refractory multiple myeloma. The objective response rate (ORR) was 57.7% in patients who had not received prior BCMA-directed therapy, with a median duration of response (DOR) not reached at a median follow-up of 11.1 months. The DOR rates at 6 and 9 months were 90.4% and 82.3%, respectively. However, the study also highlighted significant risks, with 58% of patients experiencing cytokine release syndrome (CRS) and 59% experiencing neurologic toxicity. Grade 3 CRS occurred in 0.5% of patients, and Grade 3 or 4 neurologic toxicity occurred in 7%. Due to these risks, elranatamab-bcmm is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)."
page_86.txt,Akeega (niraparib and abiraterone acetate),Castration-resistant prostate cancer with deleterious or suspected deleterious BRCA mutations,423,30.4 months,28.6 months,6.29%,16.6 months,10.9 months,52.29%,"{'Adverse Reactions': ['Decreased hemoglobin', 'Decreased lymphocytes', 'Musculoskeletal pain', 'Fatigue', 'Constipation', 'Hypertension', 'Nausea'], 'Required Blood Transfusion': '27% of patients, including 11% requiring multiple transfusions'}","The study evaluated the efficacy of Akeega in patients with BRCA-mutated castration-resistant prostate cancer. The treatment arm showed a statistically significant improvement in both overall survival (OS) and progression-free survival (PFS) compared to the control arm. Adverse reactions were common, with a notable percentage of patients requiring blood transfusions. Akeega demonstrated promising results in improving outcomes for patients with the specified cancer type and genetic mutation.","In the MAGNITUDE study, patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) were randomized to receive niraparib and abiraterone acetate or placebo and abiraterone acetate. In patients with BRCA mutations, there was a significant improvement in radiographic progression-free survival (rPFS) with niraparib and abiraterone acetate compared to placebo. Overall survival (OS) also showed a trend favoring the investigational arm in BRCA-mutated patients. However, in patients without BRCA mutations, no benefit was observed. The study demonstrated that the improvement in outcomes was primarily seen in patients with BRCA mutations, highlighting the importance of genetic profiling in guiding treatment decisions for mCRPC."
page_87.txt,talquetamab-tgvs (Talvey),relapsed or refractory multiple myeloma,187,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Overall Response Rate (ORR)': '73% for 0.4 mg/kg weekly, 73.6% for 0.8 mg/kg biweekly', 'Duration of Response (DOR)': '9.5 months for 0.4 mg/kg weekly, not estimable for 0.8 mg/kg biweekly', 'Adverse Reactions': ['CRS', 'dysgeusia', 'nail disorder', 'musculoskeletal pain', 'skin disorder', 'rash', 'fatigue', 'decreased weight', 'dry mouth', 'pyrexia', 'xerosis', 'dysphagia', 'upper respiratory tract infection', 'diarrhea']}","Talquetamab-tgvs showed promising results in patients with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The drug demonstrated a high overall response rate and a durable duration of response, with manageable adverse reactions. However, the treatment is associated with serious risks of cytokine release syndrome and neurologic toxicity, requiring administration under a restricted program.","In the MonumenTAL-1 study, talquetamab-tgvs showed promising efficacy in heavily pretreated multiple myeloma patients. The overall response rate (ORR) was 73% for both dosing regimens, with a median duration of response (DOR) of 9.5 months for the 0.4 mg/kg weekly group and not estimable for the 0.8 mg/kg biweekly group. Approximately 85% of responders maintained their response for at least 9 months. However, the study also highlighted serious risks of cytokine release syndrome (CRS) and neurologic toxicity, leading to a Boxed Warning on the prescribing information. Talquetamab-tgvs is only available through a restricted program due to these safety concerns."
page_88.txt,pralsetinib (Gavreto),metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC),237,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': {'Treatment-naïve patients': '78%', 'Previously treated patients': '63%'}, 'DOR': {'Treatment-naïve patients': '13.4 months', 'Previously treated patients': '38.8 months'}, 'Adverse Reactions': ['Musculoskeletal pain', 'Constipation', 'Hypertension', 'Diarrhea', 'Fatigue', 'Edema', 'Pyrexia', 'Cough']}","Pralsetinib was granted regular approval for metastatic RET fusion-positive NSCLC based on efficacy demonstrated in 237 patients. The primary efficacy measures included high ORR in treatment-naïve and previously treated patients, with a median DOR of 13.4 and 38.8 months respectively. Common adverse reactions included musculoskeletal pain, constipation, and hypertension. Pralsetinib is recommended at a dose of 400 mg orally once daily.","In a study of 237 patients with RET fusion-positive NSCLC, pralsetinib showed efficacy in both treatment-naïve and previously treated patients. The overall response rate (ORR) was 78% in treatment-naïve patients and 63% in previously treated patients. The median duration of response (DOR) was 13.4 months in treatment-naïve patients and 38.8 months in previously treated patients. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The results suggest that pralsetinib may be a promising treatment option for patients with locally advanced or metastatic RET fusion-positive NSCLC."
page_89.txt,Trifluridine and Tipiracil with Bevacizumab,Metastatic Colorectal Cancer (mCRC),492,10.8 months,7.5 months,44%,5.6 months,2.4 months,133%,{},"The study evaluated the combination of Trifluridine and Tipiracil with Bevacizumab in patients with metastatic colorectal cancer who had received prior chemotherapy regimens. The trial demonstrated a significant improvement in overall survival and progression-free survival compared to single-agent Trifluridine. Common adverse reactions included neutropenia, anemia, and fatigue. The recommended dosing regimen was provided for healthcare professionals.","In the SUNLIGHT study, LONSURF plus bevacizumab showed a significant improvement in overall survival (OS) compared to LONSURF alone in patients with mCRC. The median OS was 10.8 months with LONSURF plus bevacizumab versus 7.5 months with LONSURF alone. Progression-free survival (PFS) was also longer with LONSURF plus bevacizumab (5.6 months) compared to LONSURF alone (2.4 months). The hazard ratios for OS and PFS favored the combination therapy. The study demonstrated a statistically significant benefit in terms of both OS and PFS with the addition of bevacizumab to LONSURF. Additional response outcomes such as ORR, DOR, CR, and PR were not specifically mentioned in the summary provided."
page_9.txt,Durvalumab (Imfinzi),Limited-stage small cell lung cancer (LS-SCLC),730,55.9 months,33.4 months,67.10%,16.6 months,9.2 months,80.40%,"{'Adverse Reactions': ['Pneumonitis or radiation pneumonitis', 'Fatigue']}","Durvalumab demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) compared to placebo in patients with limited-stage small cell lung cancer (LS-SCLC) whose disease had not progressed following concurrent platinum-based chemotherapy and radiation therapy. The median OS was 55.9 months with durvalumab compared to 33.4 months with placebo, and the median PFS was 16.6 months with durvalumab compared to 9.2 months with placebo. Common adverse reactions included pneumonitis or radiation pneumonitis and fatigue.",Efficacy and
page_90.txt,dostarlimab-gxly (Jemperli),endometrial cancer (EC) that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H),122,Not provided,Not provided,Not provided,30.3 months,7.7 months,74.03%,"{'ORR': 'Not provided', 'DOR': 'Not provided'}","The study evaluated the efficacy of dostarlimab-gxly in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. A significant improvement in progression-free survival was observed with dostarlimab-gxly compared to placebo. Common adverse reactions included immune-mediated reactions and the recommended dosing regimen involves combination therapy followed by monotherapy. The FDA approved this application under Project Orbis, granting it priority review and breakthrough designation.","In the RUBY study, which focused on patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer, dostarlimab-gxly with chemotherapy showed a significant improvement in progression-free survival (PFS) compared to placebo with chemotherapy. The median PFS was 30.3 months with dostarlimab-gxly versus 7.7 months with placebo. Overall survival (OS) data was not provided in the summary. Response outcomes such as objective response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not mentioned in the summary. The study used a double-blind, placebo-controlled design and included 122 patients in the dMMR/MSI-H subgroup. The primary efficacy outcome measure was investigator-assessed PFS using RECIST v 1.1 criteria."
page_91.txt,Quizartinib (Vanflyta),Acute Myeloid Leukemia (AML) with FLT3 internal tandem duplication (ITD)-positive,539,Improved overall survival (OS) with hazard ratio (HR) of 0.78,Not specified,Not specified,Not specified,Not specified,Not specified,"{'CR Rate (Complete Response)': {'Quizartinib Arm': '55%', 'Placebo Arm': '55%'}, 'Median Duration of CR': {'Quizartinib Arm': '38.6 months', 'Placebo Arm': '12.4 months'}}","Quizartinib in combination with chemotherapy showed a statistically significant improvement in overall survival for adult patients with newly diagnosed FLT3-ITD positive AML. The CR rate was 55% in both the quizartinib and placebo arms, with a longer median duration of CR observed in the quizartinib arm. Quizartinib is not indicated for maintenance monotherapy following allogeneic HSCT.","In the QuANTUM-First study, quizartinib showed a statistically significant improvement in overall survival (OS) compared to placebo in newly diagnosed FLT3-ITD positive AML patients. The hazard ratio (HR) for OS was 0.78 with a 2-sided p-value of 0.0324. The complete response (CR) rate in the quizartinib arm was 55% with a median duration of 38.6 months, while the CR rate in the placebo arm was also 55% with a shorter median duration of 12.4 months. Quizartinib was not indicated for maintenance monotherapy post-HSCT. The study also highlighted potential cardiac risks associated with quizartinib, leading to its availability through a restricted program."
page_92.txt,Talzenna (talazoparib) with enzalutamide,Metastatic castration-resistant prostate cancer (mCRPC) with HRR gene mutations,399,Not provided,13.8 months,Not provided,Not provided,Not provided,Not provided,"{'Radiographic Progression-Free Survival (rPFS)': 'HR 0.45; 95% CI: 0.33, 0.61; p<0.0001', 'Common Adverse Reactions': ['Decreased hemoglobin', 'Decreased neutrophils', 'Fatigue', 'Nausea', 'Fractures', 'Dizziness'], 'Blood Transfusion Requirement': '39%', 'Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) Diagnosis': '2 patients'}","Talzenna with enzalutamide showed a statistically significant improvement in radiographic progression-free survival compared to placebo with enzalutamide in patients with HRR gene-mutated mCRPC. Common adverse reactions included decreased blood cell counts, fatigue, nausea, fractures, and dizziness. A significant percentage of patients required blood transfusions, and two patients were diagnosed with MDS/AML.","In the TALAPRO-2 study, enzalutamide plus talazoparib showed a significant improvement in radiographic progression-free survival (rPFS) compared to enzalutamide plus placebo in patients with HRR gene-mutated mCRPC. The median rPFS was not reached with enzalutamide plus talazoparib, while it was 13.8 months with enzalutamide plus placebo. The hazard ratio for rPFS was 0.45, indicating a strong benefit with the combination therapy. Patients with BRCA mutations had a particularly favorable outcome with a hazard ratio of 0.20. Overall survival data were not provided in this summary. Response outcomes such as ORR, DOR, CR, and PR were not specifically mentioned in the study results."
page_93.txt,Glofitamab-gxbm,Diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) arising from follicular lymphoma,132,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '56%', 'DOR': '18.4 months', '9-month Kaplan-Meier estimate for DOR': '68.5%'}","Glofitamab-gxbm received accelerated approval for relapsed or refractory DLBCL or LBCL arising from follicular lymphoma. The trial included 132 patients with a 56% objective response rate and a median duration of response of 18.4 months. Common adverse reactions included cytokine release syndrome, musculoskeletal pain, rash, and fatigue. Glofitamab-gxbm administration requires careful monitoring due to potential severe reactions.","The study focused on patients with relapsed or refractory DLBCL and LBCL arising from follicular lymphoma who had received at least two prior lines of therapy. The main outcomes were an objective response rate (ORR) of 56%, with 43% achieving complete responses. The median duration of response (DOR) was 18.4 months, with a 9-month Kaplan-Meier estimate of 68.5%. The median time to response was 42 days. The study also highlighted warnings for serious or fatal cytokine release syndrome (CRS), neurologic toxicity, serious infections, and tumor flare. Overall, the results showed promising efficacy in terms of response outcomes and survival for patients with relapsed or refractory LBCL."
page_94.txt,Olaparib with abiraterone,Metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutation,796,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Major Efficacy Outcome Measure': 'Investigator-assessed radiological progression-free survival (rPFS)', 'Common Adverse Reactions': ['Anemia', 'Fatigue', 'Nausea', 'Diarrhea', 'Decreased appetite', 'Lymphopenia', 'Dizziness', 'Abdominal pain']}","The study evaluated the efficacy of olaparib with abiraterone in patients with BRCA-mutated metastatic castration-resistant prostate cancer. Significant improvement in radiological progression-free survival was observed in the treatment arm compared to the control arm. Common adverse reactions included anemia, fatigue, and nausea. The study demonstrated promising results in patients with BRCA mutations, warranting further investigation.","The PROpel trial evaluated olaparib with abiraterone versus placebo with abiraterone in 796 mCRPC patients. Olaparib combination showed a significant improvement in radiological progression-free survival (rPFS) compared to placebo. In patients with BRCA mutations (11% of population), olaparib combination had a median rPFS that was not reached versus 8 months with placebo. Overall survival (OS) was also improved in the BRCA mutation subgroup. In patients without BRCA mutations (89% of population), the rPFS and OS were also improved with olaparib combination, but to a lesser extent. The study suggests that the benefit of olaparib with abiraterone is primarily seen in patients with BRCA mutations."
page_95.txt,Epcoritamab-bysp (Epkinly),"Diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma",148,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': 'Overall response rate of 61% with 38% complete responses', 'DOR': 'Median duration of response was 15.6 months'}",Epcoritamab-bysp (Epkinly) received accelerated approval for relapsed or refractory DLBCL. The main efficacy outcome measure showed an overall response rate of 61% with a median duration of response of 15.6 months. Adverse reactions included cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. The recommended regimen involves subcutaneous administration in 28-day cycles.,"In a study of 148 patients with relapsed or refractory DLBCL, the overall response rate (ORR) was 61%, with 38% achieving complete responses. The median duration of response (DOR) was 15.6 months. Serious side effects included cytokine release syndrome (CRS) in 51% of patients, immune effector cell-associated neurotoxicity syndrome (ICANS) in 6%, and serious infections in 15%. Grades of CRS ranged from 1 to 3, and ICANS grades ranged from 1 to 5. Epcoritamab-bysp should be administered by a qualified healthcare professional due to the risk of severe reactions. Patients should be hospitalized for 24 hours after the Cycle 1 Day 15 dosage."
page_96.txt,Polivy (polatuzumab vedotin-piiq),Diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL),879,Not significant improvement observed,Not significant improvement observed,Not significant improvement observed,Statistically significant improvement,Not provided,"Hazard ratio of 0.73 (95% CI: 0.57, 0.95; p = 0.0177)","{'Modified Event-Free Survival': 'HR 0.75; 95% CI: 0.58, 0.96; p=0.0244', 'Adverse Reactions': {'Common Reactions': ['Peripheral neuropathy', 'Nausea', 'Fatigue', 'Diarrhea', 'Constipation', 'Alopecia', 'Mucositis'], 'Grade 3-4 Abnormalities': ['Lymphopenia', 'Neutropenia', 'Hyperuricemia', 'Anemia'], 'Peripheral Neuropathy': 'Developed or worsened in 53% of patients, resolution in 58% after 4 months', 'Serious Adverse Reactions': ['Febrile neutropenia', 'Pneumonia']}}","Polivy in combination with R-CHP showed a statistically significant improvement in progression-free survival for previously untreated DLBCL and HGBL patients with an IPI score of 2-5. No significant difference in overall survival was observed. Common adverse reactions included peripheral neuropathy, nausea, fatigue, and diarrhea.","Efficacy was based on investigator-assessed progression-free survival (PFS). PFS was statistically significantly longer in the pola + R-CHP arm, with a hazard ratio (HR) of 0.73 (95% CI: 0.57, 0.95; p = 0.0177). This arm also had a statistically significant improvement in modified event-free survival (HR 0.75; 95% CI: 0.58, 0.96; p=0.0244). No significant difference in complete response rate or overall survival (HR 0.94; 95% CI: 0.67, 1.33 on final analysis) was observed.
The most common"
page_97.txt,Omisirge,Hematologic malignancies,125,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'Time to neutrophil recovery': '12 days for omidubicel-onlv vs. 22 days in UCB arm', 'Incidence of BMT CTN Grade 2/3 bacterial or Grade 3 fungal infections': '39% in omidubicel-onlv arm vs. 60% in UCB arm', 'Adverse reactions': {'Infusion reactions': '47%', 'Acute GVHD': '58%', 'Chronic GvHD': '35%', 'Graft failure': '3%'}, 'Common Grade 3-5 adverse reactions': {'Pain': '33%', 'Mucosal inflammation': '31%', 'Hypertension': '25%', 'Gastrointestinal toxicity': '19%'}}",Omisirge was approved for use in hematologic malignancies to reduce time to neutrophil recovery and infection incidence in patients undergoing umbilical cord blood transplantation. Study P0501 showed favorable outcomes in terms of neutrophil recovery time and infection rates compared to unmanipulated cord blood transplantation.,"Study P0501 evaluated the efficacy of omidubicel-only transplantation versus unmanipulated cord blood (UCB) unit transplantation in patients with hematologic malignancies. Overall survival (OS) and progression-free survival (PFS) were not specifically mentioned in the summary provided. However, the study focused on time to neutrophil recovery and the incidence of infections post-transplantation. Omidubicel-only transplantation showed a median time to neutrophil recovery of 12 days compared to 22 days in the UCB arm. The incidence of Grade 2/3 bacterial or Grade 3 fungal infections through Day 100 post-transplantation was lower in the omidubicel-only group. Adverse events included infusion reactions, acute and chronic graft versus host disease (GvHD), and graft failure. Response outcomes such as overall response rate (ORR), duration of response (DOR), complete response (CR), and partial response (PR) were not mentioned in the summary."
page_98.txt,Enfortumab vedotin-ejfv (Padcev) with pembrolizumab (Keytruda),Locally advanced or metastatic urothelial carcinoma,121,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '68% (95% CI: 59, 76)', 'DOR': {'Dose Escalation Cohort + Cohort A': '22 months (range: 1+ to 46+)', 'Cohort K': 'Not reached (range: 1 to 24+)'}}","The study evaluated the combination of enfortumab vedotin-ejfv with pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. The confirmed objective response rate was 68%, with a median duration of response of 22 months. Common adverse reactions included laboratory abnormalities and the recommended dosing regimen involves intravenous infusions on specific days until disease progression or unacceptable toxicity.","In the EV-103/KEYNOTE-869 study, 121 patients with locally advanced or metastatic disease who had not received prior systemic therapy were treated with enfortumab vedotin-ejfv plus pembrolizumab. The study showed an objective response rate (ORR) of 68%, with 12% achieving complete responses. The median duration of response (DoR) for the dose escalation cohort + Cohort A was 22 months, while for Cohort K it was not reached. Overall survival (OS) and progression-free survival (PFS) data were not provided in the summary. The combination therapy demonstrated promising efficacy outcomes in terms of ORR and DoR in this patient population."
page_99.txt,retifanlimab-dlwr (Zynyz),Metastatic or recurrent locally advanced Merkel cell carcinoma (MCC),65,Not provided,Not provided,Not provided,Not provided,Not provided,Not provided,"{'ORR': '52% (95% CI: 40, 65)', 'DOR ≥ 6 months': '76%', 'DOR ≥ 12 months': '62%'}","The study evaluated the efficacy of retifanlimab-dlwr in adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. The drug showed an objective response rate of 52%, with a complete response rate of 18%. A significant proportion of patients had a duration of response of 6 months or more, indicating promising results in this patient population.","The study evaluated 65 patients with metastatic or recurrent locally advanced Merkel cell carcinoma who had not received prior systemic therapy. The objective response rate (ORR) was 52%, with a complete response rate of 18%. The duration of response (DOR) was ≥6 months for 76% of patients and ≥12 months for 62% of patients. Overall survival (OS) and progression-free survival (PFS) outcomes were not specifically mentioned in the summary."